var title_f42_47_43760="Apparatus for CVVHD";
var content_f42_47_43760=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F51946&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F51946&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 474px\">",
"   <div class=\"ttl\">",
"    Schematic of CVVHD with post-filter infusion of replacement fluid",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 454px; height: 357px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFlAcYDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiis/SNa03WVmbSr63vFhcxyGGQNtb0OPoaANCiiigAooooAKKKjaaJZ44WlQTSAsiFgGYDGSB3AyM/UUASUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVja/4itNFmtbZ47m71C7J+z2dpHvlkAxubGQFUZGWYgDIGckA7Nec+K7qbSdd8WXUDhb2XRIWtZ+rQ4eVSB6fM6t6E9elAG5J42s4oG8zS9dW8GQtl/Z8hlc+xAKfjux715t4S+F+ueHNPsdRnliuL1bCOwurBdSntEeNXZ0kaZCcypu24xsxnGK9c8OeHdO8PWxi02Eq7hfOldy7zMP4nYkkscnJPrWje2lvfWktreQxz20qlJIpFDK6nqCD1FAHkGuvd6N8tzocJlPKxf8JtNE7D2Em0frVrSFXVrh7W10m6jv4lDzWdx4nu4541PRtvIZD2dSVPY16Fp/hbQdORlstG0+HcMMVt1yw9CcZNcLaWFtpHiazhswEh0/xC9paoOkMFxYiV4V9E8xshegAUDAAAAKKpqJijn/4RmX7M959jDf8ACXXW7d5hjzjGMZHTOcU/UJEsr9tPOi6hd6iih3tLHxFeTyRqfus+AAgODjJycHHSuhi/5F6z/wCw9/7dGqGtR3CD4haJbz3unalqETapY3cOQZIxbwxNskwQGV02kcMquhHUGgDn77U0s4Jml8Ma950a5+zr4hn81j6AF+tU9M8LeI01WDxUHtxqcVyLmLTZdVNzJFbqjIbFZHJUFt5cuG27vlIIAYepeH/DvhqbRLC4s9B02OCe3jkUG2RjgqCMkjJPPU8mrT+EPDbsWbQNJJPU/Y4/8KAKa+MYmj3Louusw+8i2e5lPocH+Wa0dB8Q2GttcxWhmjurbb59rcwtDNEGztJVgDg4OGGQcHB4OKV34H8N3CYGkW1tIPuzWg+zyIexV0wQR2INc14Jupr3X/D1xdyi4vF0vUraa5KgPMsV3BHGzY4yQGP1ZsYoA9JooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACvLvHSzXWqeJ7aEhbqe30uxt2YZCCW4kBOO4zkkf7Neo15v4wdYfHEEjg7A+mbyB6zzhSfxIFALU6JtI8TFiV8URKCeB/ZqHH/j1J/Y/if/AKGqL/wWJ/8AFVKdWOT81H9rH+9Ue0Rp7KRENM8VR8p4ksZCO02l8H/vmUVwmhX1zqd/eNeG2N3H42+zvJaqVSTyrNFzgkkHamCMnkGvQU1Yb1LNwCM15n8OoXHiVbeQDd/wlOt3knH3iBtUn8JR+FNSTJlBx3Owi/5F6z/7D3/t0at+KbqOx8Vw3c6l4bfQtQlkUdWVXtyRVSL/AJF6z/7D3/t0ab8QFL6teoOM+GdSAPYZaGqJJPC9l4zs/C+kW4u9B3Q2kSbWt5eMKBgkP6YGa0s+NdpQx+HNx6S75+P+AY5/76pul6wJNJ0+RW+WS1hcc+qA1Z/tY/3qj2iNPZSMPxdrXi/w14T1rVrhPD0qWFpLcCQPMhYqpIXYQeSRgfN1NQfDKySLVphsZW0/SLCy+fqJGDzS/n5kef8AdrP+Mdy2pfDbU7FMs91c2VsB/v3UYP6V1nhUKnirxigAB+2W5H0+yQgD9D+dUnciUXF2Z1NFFFMQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBjeM9Tl0Xwnq+pW3l+fa2skqGQEqGCnBIHUA8muR8L614suFEdtANTspY1ubW/wBTT7K08ZAyD5SsoJJyuQp29RkZrsfFln/aHhfVrTvNaSoPqVOP1rD+FGpJc/DHw3eXEixrLZoV8xgML/CPyxQBX1fxT4js3jtv7AijupFLBkkku1QZA3FY0zjJ6ZGaf4E1nUNS1i9hl1OLVrFLeOVpxa/ZmgnLuph8vJIwEzhvmXuTnjtYpElUNE6up7qcivPfhUrf2/48d8ZOsuq8dVA7/iT+GKAPRKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAryX4pSG2TxrLNw6adp91A3oIriQ/o2Pzr1qvLPi1p51A+IrQ/KbrwvcmJs4y0Ugb+brQxp2ZVuNV/wBIk+bqxNR/2qf71efRa0ZoIZWb5njRj9SoJp39rf7X614/tj3/AKsd9/av+1Tfh7Ks/i63nVjtfUtWAHYttt8/qprg/wC1v9r9a6/4XOH/ALDuwML/AMJDqULt6l4nYf8AoIrqwtTmk15HFjqXJBPzO0i/5F6z/wCw9/7dGp/GsefEmmhRlrrTNQtSPXKxuB/45UEX/IvWf/Ye/wDbo1p+IF87xz4ZiA+5BezZ/wCAon/s9dx5h5z4e1fPhzRzvz/oUI/JAKkv9fmtURoLO5vCTgrA0YK+53sv6V57oGpeVodhFvB8uLy+P9liP6Ve/tb/AGv1ryHWsz31hrou+L/FV4+k2anRb+L/AImtjJmWS32tsnD7RiU8nGB29xXpPh3X9VXxb4sf/hFNZkV57fEUclkGiIgT75NwASeCME8Y6HivF/Eepo2lwtK3yRahYzMc9AtwmT+tfR3h2LZ4s8WPnPmXFu30/wBHQf0rvw0+eDfmeZjafs5peQn/AAkeqf8AQl+IP+/1h/8AJNH/AAkeqf8AQl+IP+/1h/8AJNdLRXQcZk6Pqt5fzvHdaBqemKq7hJdyWzKxz0HlSuc/UAe9eC+HNe1H/hZV3B4iv76LwqPFOoRQTLO21rsFPKglOfliC8qvQknOQDj6QooAKKKKACiiigAooooAKKKKACiiigCO52/Z5d7BF2HLHsMda+Y/hdpPgqTwjDc3+nzpqaXE8Ly+exyofIwjZVRgjgAfrX0jr6h9C1FDkhraQHHX7pr4u0PVpZdHt5+FNyWnZV6BmY5H4YxXdgMKsTNxeyRy4uv7CKa6nssvh74czHN5pt1cDuDdtGD65WPaDW98BpbS1vfFWiWKBLbTbiNIMMWBhfe8fLEkkKwU5JPy9a8IbU5ypCP83bPrXof7OmvW+na34ifWpVtRqMsSJO+RCZEBTZv6AnnAbBOOM1vj8FDD01JdzLCYqVaTTPpGiiivKO8KKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACuD+I0BudV0+2jz5s+m6lEMDsYk/rtrvK5nxVZaquraXrWi29vezWSTQy2csnlGWOTZkxvyA4KLw3BBIyOtAHx/p2rxtpdnIbiFVaFOsgHYCtBLmZ0DJ8ynkMvIP417nBpfgTT7l2ltNQ8KXbMzeVdWwRBnrsYq8RHJ4VjjPauY1fwf4Qa5trjSvh5caja6jdLbLqGo6lLYRzSsMq2w5bYcYDbBk42ggg15jy7tL8P8Agntxzhfah+P/AADy8agDIYxPBvHVfNXI/WvV/hHK8ngLTr8cxP4u3QOPuyIcRFlPcZL8+xp5HhzT9O0C01L4W6KYdXums7GC0aOaRZkYqTKzovynBO7JOOor0rSPD+oXN5pf2+y0/RtD0pvNs9KsW37pQCFZ2CqoVQzEIo+8QSeMV0YfCewk5XucmMx/1mChy21vvf8AQhjGPD9oPTX/AP26NaetZf4geG1jGXS1vZHx2T90P/QitZcX/IvWf/Ye/wDbo1p+J1v9O8Q6ZrtjYTajbQwTWd3b25HnIjlGWRFJAfDRgFcg4bIyRg9Z558k6ddSixjOCoLScHqP3jcVY+1y+tekeOvBvhWS9vtdttV8TeFoZ3868ifQ55rfzGPLBTGdrMTzg4NULPwT4O+0x2d14t8V6vqMz+XFb6dp7W53hN5Q/utqts+bDMDt5ryJ4Co5Npqx9BTzWioJSi7/AC/zPO9amml0a+RT8whMi/7yYcfqtfVfge/W98TatcHj+0tP0/U4s8Eo8boRj2Kc+m4V5b/wq/wo2Y72b4jWsbDayyQtIJFPVSY4m6jI7V6j4cjW98UafPpGl3VlomkabJp8c13C8LTb2hKoiOA5VBCcswHLDGfmI7MLQlRTUne552PxVPEuLgmrdzuaKKK6zgCiiigAooooAKKKKACsHx7ql5ongvW9T0yETXtpaSSxKRkbgOpHcDrj2reoPPWgDyX4beIRP4n0/Tptf13VLy60sXzyTi3azmzsJaPZ86FWYrtIHQ+xPrVcpp9npOi+NxZWOiaXYte2TXEdzbWyRSSMkgEisQBkYeMj8fw6ugAooooARgGUhgCDwQe9eKal+z/pkl1M+k63eafA7lxCIw4TPYcj/H1Jr2yiqhOVN3g2n5EyjGatJXPmLwZ8JG8U2upbtdvLCexv3tJjHlvLIVG8sBgMsu4qX5B6ivb/AAR4F0zwt4fm0pVju4Z+JhLENjqBgLtOcjqSSSSWYk84EPw5LDU/HEbclNfk59jbW7D/ANCxXaVVStUqfHJv1dxRpwh8KSOQ/sHVPDvz+E51uLEddIvpT5aj/pjLy0f+6dydgF61p6F4msdXuJLMrNZarEMy2F2vlzIPUDJDr/tIWX3rcrM17QtO123ji1K38xom3wyoxSWFv70brhkPuCKzLNOiuQ8/xB4Zz9sWXxBo69J4UH22Ef7aDAmHuuG/2WPNaNz4w8PWljY3l3q9nb216SLd5pPL8wg4IAbByDwR1B4NAG9RRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVl+KNGtvEPh7UdJvoYpre8haJllXcuSODj2OCO4I4rUooA8v+E39mHTLXw9f6baRXelSST2MTxqwjAcq5jJ5DxuWRscjKno4z6hXA+NPBk11qP8Aa+iDNyW8ya2ExhZpQu1Z4JefKmCgKcgpIoCuMAEVNK8cajp95Fp2u2dxdTnONtv5N4VA5byMlZgACSYGc/7AoAuRf8i9Z/8AYe/9ujXe15qNVsV8B2WrpcpNp7aws8c0AMvmq10dvlqoLOxJACgZycYqaf4iytcy29rpcX2hCVNs1151ypzjDRQLJsPszDFAHa67pNhrulXGm6vbrc2M4AliYkBgCCOQQeoBrzjwoya78U7rVdPnujpiI9wkQYfZ2XYkEU4GMlpPLuNrA4McSnGHBL7yz8U+LYmh1CxItHP/AB73f+jWeP8AprGrGaceqEoh6Gu58KaBF4e014BcS3d1cSG4urqUANPKQF3YHCgKqqqjhVVQOlAG1RRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHLeO/wDQ10fW1HOmX0bSkf8APGXMMmfYCQP/AMAFdTVLW9Oh1fR77Tbn/UXkDwPjrtZSp/nVDwRqM2qeFdOuLs5vVjMF17Txkxyj/vtWoA3KKKKACiimyIskbI4yrAqRnsaAOQ8EkJ4q8eRhl2nVopAMgk5sLXJ/T9K7GvDfAvhHTdO17wXdwSXjuZtQwkk2VHlb0ToAThSRz175r3KgAooooAK89+MOla14l0eLw/o+lPLHcTQSyX7TxpFAElDEMpbeThR91T1r0KigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACs3xFpdnq+kzW2owCWIDzFOcNG68q6MOVdTyGGCDyK0qbKgkjdCcBgRmgDxq/8DyT/DQXV34r8QXEHlLqTWjC1SJ5s+YQdkIcKWJJAYZyea9fsLS2sbOK2sbaG2to1ASKFAiKPQAcCvJopfFlx4fsNIkvdAGnXV5Jom5LWbzVSPzB5nL4LERHjGMnrXsIGAB6UAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFYOr+MvDOjXElvqviHSbO4jxvhmu40kXPTKk5/SgDerl/DedP8WeI9KIxFK8eqQD/ZlBSQD6SRMx/wCugqsvxO8FM0YHiTT8ynbGDJjf6keoHqOBXOa78RfB0XinQNVs/EemzqrTWFyYJw4EUihw3Gc4kjjHtvPvQB6pRXGr8UPBJdVbxLp0ZY4Blk8sfm2BV+Lx34RlZVj8U6CzNyANQhJP4bqAOjopFZXUMpDKRkEHIIpaAPJPBNtqn/CbadbXt1p8mmWL6w9osEDrPlLmOMiVixU/60n5QOgr1uvOvCtnfW/xO1W0uhbi30+2nu4ZEJ3TLf3JcAj+EobR1687geK9FoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDyrT720Y6HaLdW7Xa+J7omASqZB/wAfGcrnPcfnXqteY6L4bW3+Md9P5GlAQQvqIuI7ULcyG5JTYz46L5Lc5ydwHY16dQAUUUUAFFFFABRRRQAUUUUAFFFc14v8UHR5bbTdLtTqXiG9BNpYq20bRwZZW/giXIyx74ABJAoAveJvEel+GdPW71i5EKSSLDDGql5Z5WOFjjjXLO57KoJrlktvF/jFTNd3Vx4O0ZlzDa23lyajLycNK7Bo4hjadiBm5OXHIrS8KeDzY3za54juhrHieXO67dcR2qkY8m2T/lnGB1P3m5LE8AddQB8+fE7wv4y8M6AL5vibrEunPcxW1x+52zxpI2wGPy+Xbey5AAbAOPQ9N4K8T+D9D8PWEH/CLajolzHEFuLc6HOzRuOGLSBDvyRneSSQcnnNdL8XVs30LSV1Q2wsTrNj5/2nb5RTzhkNu4x9aj+w/DMMf3PhAHPpb0AeYeN/EOm6jrHiy5tbTVb+O+sNPtrdodOnVpbZJ2N3aIxUbS6EkjgMCPQY7bVPGvw/v/DP9k2eoDToQifZhDpcy/ZmQhoyEEYxtZV+Xjpjitr7F8M/+ePhD8relNr8Nf8Anl4Q/K3oAT/haPgi4UAaoJkY4GLKdwT6fcrz/wAYazY+OYGstI01bjRNQR4bO1hj8q41qZf4y3DRWkT4ZpDgsVwMjh+kg0+w0u7v/wDhGviPYaPp11ctdCxiW0kjiZgoYLu6KSucDuT61n6B4bsdDvLm40v4ow/a7uTdPPP9kmlcFifLVmztjBLEIuACx9aALul+N9X8K3nhfwnrnh2EXEiW9m09rqIm8pPliE7rsBRGf5V3EbjwORXrVeFfDjSp/FtzFOLkXFtb6mL7Wta2DzNWvIJW+zwREfKIIgqMSuVzhVzmRq91oA4nw27TfFbxqxYFYrTTYABzjAnfH/kTOPf3rtq4fwTG0nj/AOIN4pBhN7aWq4/vR2kbN/6NFdxQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHhHjnxz4q0vXPiba6XFcXFppsFk1vcI8Krp2+HczbW+Z9xz03Yx2r1/w9q1veWFlC97BLqJtYpZohIvmAsgOSo5Gc56VYm0TSp2v2n0yxkbUAq3he3Qm5CjCiTI+cAcDOcVDqnhzRdVhii1HSrK4WJQsW+FSYwOmw4yuPbFAGtRXLf8Irc2I/4p/xBqdiB0guX+2w/TEuXA9lcUfb/FenY+3aRZavEOsumT+TL/35lO3/AMimgDqabLIkMTyzOscaKWZ2OAoHUk9hXNw+N9FEyw6lNNpFwxwI9Tha2yfRXYbG/wCAsa4/4hPdeItSlijSe48PaVNAlzHawC582SRDIZDF0lWMGEhcMMyFiG2AUAXLHxj4bPxK1K5Guaf9ll0y1iS4MuIXcSzkgSfcJwy8Bu4r0qsPwsL2+8J2S+I7WJbuWHbPA0YAK5IG5OQCVwSvIBJHasnQbU+FvFX9g2uRoV9bvdWEJYkWckZUSQp6RkOrKvRcOB8u0KAdlRRRQAUUUUAFFFFABRRRQBjeL9fh8M6BcalPE9w6lY4LaP79zM7BY4k/2mYge2c9BWf4G8O3GlQXGpa5LFdeJtS2y39xGDsUj7sEWeRFGDhe55Y8saoauv8AbPxW0fT5QTZ6LZNqrL1VriRjDDn/AHVE5HuQe1dxQAUUUUAV7+ytdRtXttQtoLq2fG6KeMOjYORkHisv/hEPDX/QvaP/AOAUX/xNblcj4/8AFb+H7Uw6ekUmoG3mvHaUEx2ttEuZJnA5bGQqoCCzEDIAZlANL/hEPDX/AEL2j/8AgFF/8TR/wiHhr/oXtH/8Aov/AImuT8N6amr6pfWHiiTXX1iCKK5YSamyRmOTcFKpbsqKdyOCCCeB8zZzWrqGja34eRr7wtfXeowx/NJo+oTmYTKOohmfLo+M4DMyE4BC53AA1/8AhEPDX/QvaP8A+AUX/wATR/wiHhr/AKF7R/8AwCi/+JpI/FugnQbPWZtUtLbT7uNZYpLiQRkg/wAODzuzwV6g8daNK8S2+rXqQ6fY6nLbkEm8e1aGEYHYybS2exUEUAaWnrYWsS2WnrawxwghbeAKoQZ5AUdOat181aF4c1eD4rPqEeiXzTDxZdzFpNNeJPscmQZvtXAZRyVj5B5Pfn6Ov7ZbyxuLV3dEnjaMshwyhgRkHseaAOQ+GKkS+MGfO9/EFyTk9gsYH6AV21ePfBbR/s+sfa3TSYimjQbBp1gbXzFklkGZjvbzHH2cfNx99vrXsNABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAyWNJomjmRZI2GGVhkEehFeXt4c0nQ/H11aA3OiW+shJdOuNOna2jNwqbZYCinyyxCrIoZTuzJj7pr1Oqer6ZY6zp01hqtrDd2cwAeGZQytg5Bx6ggEHqCARQBzXj2PWo9N02PTH1We1Vyt8+mtCt642HYyb8JjftLYx2/h3Cs/whc6h4h17TLrUDDI+h2Btr2eBgY5NQkCedGhHBEYQhiONz7eqsBjeGtAh1Dxbr2k3upa9caXbqVS0k1WcxgbyNpO4MRgYwWIx1zXqdjZ22n2cNpYW8NrawqEjhhQIiKOgVRwB7CgCeiiigAooooAKKKKACiiigDitLcW3xg1+CQ5e90izuIv92OSdGA/F1/MV2tcN8S459Jl0rxjYxPK+iM4vooxlpbCTAmwB1KbUlA/6Zkd67OyuoL6zgu7OaOe1njWWKWNgyyIwyrAjqCCDmgCaiiigArlNMijuPHnihLuNZCbS0iVZFBDQES8YPVS2/NdXXmHjB7vS/F+peI9IRJNSsYLK0Nq7YW/hlldRBnoj7yCj9iSG+UkgA7vQdA0rQIZItGsILNJCC/lry2BgZPXAHAHYdKp3p03xNPLY2evyrJZOVuoNNvFSQE8bZCvzrjB6Fec+lVF8daJ80Gpy3Ok3Qyr297C0TqfY8q3sVJHoa8xW9k0KS0Og3KXX2PT7y2s9QXTXggt4FUSvJO5P79xtXCIACxLEjPAB3Xwv0DSLKTXrix0+EMmrXMUV3IvmTOqkBh5rZdsSeYOSeQa7+sHwFpf9jeC9FsGLmWK0j853OWklI3SOx7szlmPuTW9QAUUVHdTxWttLcXMixQRIZJHY4CqBkk+wFAHnnwmsrq21PxKlzcQTQ6bNFosBiiKF0hVpt7EscsTdFSBgZTPfA9Hrifg/DM3gxNUu43iudbup9WeNuqLPIXjX8I/LH4V21ABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAee+C/8Akovib6H/ANGNXoVee+C/+Si+Jvof/RjV6FQAUUUUAFFFFABRRXkPiTxx4nsvEXjw6dJpZ07wtHaTm2nt2L3KSxb3HmBxtIwcfKeo/EA9eoqppN6upaVZX0aMiXUKTqjdVDKDg+/NW6ACvOZI5Phg1xcW0Ek3gV3aaaGFCz6OScs6IOWt8kkqBmPkgFc7fRqKAIrS5gvLSG6s5op7aZFkilicMkiEZDKRwQQQQRUtcDdeFNT8LXEt/wDD1oFtmy8/h65cpaTNu3FoGAP2eQ5boDGSRlQfmrV8MeN9L12+k0yQT6Zr0IJl0q/URXCgZ+ZRnEiccOhZfegDqa848S291N8Q7OFUiNhNcWU08pkw6NF57IgTHILKCWyMY6GvR64TXYZG+LXhyJLmZLaWyubmeAKpWR4SixEkjcMfaJOhwePSgDuyAeoBrzT4mM+rNoraYbS4sbm2cSzNIR+4mlt03x4BDEqx4OBhuvaq2t+K7nSfgHq/iS6uXe6lt7mW3kY8qZpnEA+i+ZGAPQVwHwX1hvFfhj4baebuWM2rXlnerHt/ex23lyRxkkEgc25JGDgEd6APpMcdKKKKACuB+JF/ca2JvA2gqkmpapblL+4bmPT7N8o8rersNyonc8nCqas674wludUuPD/guKLUtejGLiZsm007tmdx1friJTvOOdo+atfwf4ag8NafJGJ5b3ULqQz31/PjzbqY9XbHAA4CqOFUADpQBs2sEdrbRW8K7YokCIPQAYFS0VFdXENrA891NHDCgy0kjBVUe5PAoAlorhfEPxc8B+H5PL1HxPp/m90t3Nww+ojDY/GmaV8Yfh/qtxHBaeKtO82ThVmYw5PplwBn2oA72isvXfEOj6BaG61vU7OwgxkPcTKmfpnr+Fcynjm/1h9vg7wzqGpQ5x9vvj9gtCPVWcGRx7rGR70Ad1RXCXXijxN4dj+2eLtCsP7HU5uL7SLx5zaLkDfJE8aMUGcsylioBJGASO6RldFdGDIwyCDkEUALRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAee+C/+Si+Jvof/AEY1ehV574L/AOSi+Jvof/RjV6FQAUUUUAFFFFABXH678PPD2q6jqGqTacs2p3YRpDNcTGCZ412x+ZEHCMBgcY9e9dhRQBieFtcXWLWaOaAWep2b+ReWZbJhfGRg/wASEcq3Qj3yBt1zXijR7pruDXNB2rrVouwxs21LyHOTC5/Mq38LexYHU0DV7XXNMivbMuEYlXjkXbJC6nDRuvZlOQRQBo0UUUAFY3ifwxo3iiyS117T4buONt8TNlZIW/vRuMMjcDlSDWzRQB5+ul+NPCpJ0XUE8U6UoyLHVZRFeoPSO5A2yfSVc/7dcb4j+JWl6X42utY1mO/0Y2OiPaJBf2rrIt1LIzogKhkYMtucMrFeMZzxXt0k8MUsUcssaSTErGrMAXIBJAHc4BPHYV8z/HPSZ/FPhHx3rFrHJO0Wu2Vhap1J8geSQv1muJRj1oA9d8Gad4Y8YfCnRNKP2PWtHt7WC2dVYsnmRIoweeoIrz7wPD4Z8FQfDLUriTT9Etrnw9NeXM88ojW4uHitMkbjy55OByfSvW/ht4Xh8GeBtH0GHaTaQASsvR5T80jfixY/SuF8AKrXHwlLqjFfCTlCyglT5doMjPQ4447UAdO3xDi1BFXwpoOua7I4OyRbRrS3H1mnCLj/AHdx9qhk8PeKvE5I8V6vFpOmMedL0ORw8i/3ZbpgHI7ERqn1Nd9RQBQ0LRtN0DS4dO0Wyt7GxhGEhgQKo9Tx1J6knknk1forG8TeJ9F8MWqT69qMFmsh2xIxLSSt/djQZZ29lBNAGf8AE3xlaeAfBl/4gvYWuBbhVit1cKZpGICrk9Bk5JwcAE4PSvhz4qfGLxL8R4orXVGt7TTIn8xLO0UqjN2ZySSxH5e1egftbePb3Xb3RtBTTtR03TI4vt+y/hEMlw5Lor7DllUBXADbTlmyvANfO9ABRXongn4O+MfGWn6pd6Rp6J9gKo0N0/kvK5AbYgYYztIb5iowRzXuvhP9mjR9V+H2itrn9oaT4lJMl4yuHyPMPyFCSB8mACCOeTnpQB5N8DfivD4Q1+zi8UWFpqGmF1T7fPB513YqF2r5TnJEa90A9dvPB+69M1C01XT7e+025iurO4QSRTRMGV1PcGvJ/FXwM8Af8IPeaVbWttocT3CXI1J5C8kLZAxvkbO0rldpO3LZxu5rY+AGmTeH/AL+HrmNxLo2oXVp5x+7cL5hkSVRk4VlkU4+tAHo8saSxvHKivG4KsrDIYHqCO4rhvhsX0W/1zwbKztDo7xzacXYsfsMwJiTJJJ8tkkjH+yiV3dcP4iX+zfin4U1JRtj1G3udJmYngnAni/H91KP+BUAdxRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAee+C/wDkovib6H/0Y1ehV574L/5KL4m+h/8ARjV6FQAUUUUAFFFFABRWZe6/o9je/Y73VbC3ugnmeTLcIjhfXBOce9R/8JRoH/Qb0z/wKj/xoA165HxBZXOg6nL4k0WB5o3A/tSxiGWuEAwJox/z1Qdv4146ha1/+Eo0D/oN6Z/4FR/40DxPoJOBremZP/T0n+NAGhYXltqFlBeWMyT2s6CSOWM5VlPQg1M7KilnIVQMkk4Ar531nxFfabPqep6f/ah8LT3Vw6adpj/Z4wyusfnm6KnbE8mSwjK7C2fmJORr1hayXEfgrwv5ptpLoS6jqM2onEe7crBo8k5U4O7HegD3F/FGgJcrbvrmlLcMQoiN3GGJPQYzmsz4p+LIvBHgLV9dk2mW3hIt0P8AHM3yoPpuIz7A15SY9YmkuLC51m1t9PMqwT2mkaVDapMkiE43tvdSMYyOoPbrW0mleDP+EC8OR+MNRT+xtHnmMOn3NyZvPlV2WNWXl5SoyFjAOc4wRgUAcL8FfFfiv/hGdR8YeM7G51M2tmLLQ7u6f95PK74WGOMDLmRygMvUhVGTg4998E+Go9D8GaXo98I7qeELPcOwyJLkv5ryf9/SWHpxWRo2l3XinWNP1/XbGXT9M08eZo+kzDa6OVI+0zoOFk2kqkZzsBJOGOE7ugArhtdhis/iX4Ejt4o4bdbTULaONFCqg2QkKAOAAE6V3NcR8QSLXxL4Dvzk7NYa1P0mtpl5/ELQB29FFFAHCahrOu+KNTvdL8HSRadYWczW17rc8YlIlX78VvEeGZTgM7/KpyMMQcafhfwNovh27kv4Ipr3WZhibVL+Qz3UntvP3R/soFX2qh8Ewo+FXhsKoWQW377/AGptx8xj7l9xJ9TXb0AfBX7Vt5Ld/GrV0ljljW2hghj8zuvlhsr7Esa838K6Fe+JNfs9L021ubqaeRVZLeMu6pkBmwOwBySeB3r1/wDbJivl+LMMl4Q1s+mw/ZSFxhAz5BPc795+jCvJ/A3ie+8G+K9O17S2H2mzlD7D92RTwyH2ZSR+NAH6YWVtHZ2cFtDu8qGNY03HJwBgZPfpXnvjXw94bfUbvUfiDrs1xbz/ALuwsGunto4EAGVijiYNLIxJJb5m6AAAc9l4V8Qad4p8P2WsaNcJcWV1GHRlOSp7q3owPBHYitFreFrhLhoYzOilVkKgsoPUA9QDigDhvEt1LL4N0e6tdCnudFWRReaXf2nmSm3CsqM0bbm+RxFIQAXwDxkbSz4JR2MHha+h06OyjC6lcNILC48+2yzB18pv7uxkG3jaQRgYrX8X6l4isdW0dfD+jS6naMJ3vBHJFGQQoWJC0jDClm3EruYCPhTmqHw2juf7S8VTajFY2d/JfqLiysixjVxEv77LBSzSAqS20ZCjrg0AdzXE/FnEGjaPqPIOn6zYz8DnBmWNh+KyNXbVxHxnUN8PrtnIEaXVnI5PZRcxE0AdvRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAee+C/+Si+Jvof/RjV6FXnvgv/AJKL4m+h/wDRjV6FQAUUUUAFFFFAHBajai98Y3dk0jxQ3kqJOYgod1WAso3EZAB54rS/4QXTv+fvUf8Av8P8KrH/AJKGP+u4/wDSY12lAHKf8ILp3/P3qP8A3+H+FKvgfTlYMLvUcg5H74f4V1VFAHhGtaHp2meBNKWwtxGZNeuHldjueUtLIr7j33Kqgjp8o44rkRIdCtTaXUg/s2fT7uOzc/8ALFj5gELH0J+6ffb6Z9F8SWVxdeBLOZBGtnZalcXUrlvnLC6ZUQLjod5JbPG3GDnjlNQgiuNGlinRZIzpl7lWGeQ0hB+oIBoA1+mqXZHUXdv/AOinrufhh4a0O007+2bbSbGLVrqad5rxYR5zsZHBO/rz6DivOdIt7m0mube8uPtLx3kCpMRhmTy327v9rHBPfGe+K9c+HX/IpWv/AF0m/wDRr0AdLRRRQBneJBcHw7qgspWhujayiKRTgo+w7SPcHFeI2HxJt/iB8F/7dOxdc8O3dne30CnG0xTIzSAf3WjDn8x2r3+vm/4dfBK18G+MNQ0rVNYvJ11vRriGP7OBFC6klJonByWKrJCynI/i44oA+kAcjI6UVy3wv1KfVPAWjS3qul/DEbO7V+ouIGMMv/j8bfhXU0AcV8H0EHgv7GDlrPUtQtm9il5MP5Yrta4f4bILTVfHGnbhm316SZUH8KzwQz5/FpHruKAOD+Mfw3074k+GGsbsLDqVuGewu8cwyEDg+qNgBh7A9QK+MPhrYR6H441LRvFnhmTVEdH0u6s1i3zxSsflMJHSTcoAbpgnnnNfoXXmvjnwppaeO9E8SyRvELxv7K1EwMUMwcfuHZgQVZJFUB1IYblGcDgA3vhj4f8ADPhzwulp4LWP+zWld3dJTIXlHyuWJ53ArtI4xtxgYxXWVxX9gXHhHUDe+ENOSfTJ1Vb3SY5FjJdeBPCWwpkI4cMRvCqdwKnfqaT4oTUL+O0bR9cs5XBO66sWWNcDoXGVH589qAKXjDQfEevX8cGneJm0LRPKAm+xW6teSvlsgStkRrjbghd2c84rB8EeHbHwR4+vtOhvtSddUsopUk1G4M73s0bPvIdujIpXKjqGzjCnHpFxI0VvLJHC87opZYoyoZyB90biBk9OSB7iuFsLnVfHM2jX/wDZi6Totpdm6DXUivdyvHuQKqJlUUnOW3kleAOcgA76uT+LNt9r+GfiaPGSthLKB7opYf8AoNdLf3trp9pLd39zDa2sQ3STTOERB6kngVmzz2PifwzfLpN5a3tvdQSwLLBKsiElSMZHHfmgDR064F3p9rcjpNEsn5gH+tWK5b4WXgv/AIceGp9xZvsEMbk9Q6KEYH3DKRXU0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHnvgv/kovib6H/wBGNXoVee+C/wDkovib6H/0Y1ehUAFFFFABRRRQBxZ/5KGP+u4/9JjXaVxZ/wCShj/ruP8A0mNdpQAUUUUAeKXvizT5fBus6Isd2s1vqsllJcPDiAXBug6xbu5ZWBBxj1IJGcS4/wCQZJ/2DL7+cldBqHhbSU8FapriQSi9k1KW5kTznMTz/a9omMedvmBQADjiufuP+QZJ/wBgy+/nJQBpH/kJ3f8A192//op69P8Ah1/yKVr/ANdJv/Rr15gf+Qnd/wDX3b/+inr0/wCHX/IpWv8A10m/9GvQB0tFFFABXL+P7K5ewsdV0yCSfUdHu0vI4oxlpY+UmjA7lonfA/vBa6iigDhfDQGgfEfxDohUJaauo1yzwpxv+WK6TOcZDCKT6zH0ruq474l6XdzafZa7osBn1vQZ/tttEg+a4jwVmgHB/wBZGWA/2gh7V0eh6rZ67o9lqmlzLPY3kSzQyD+JWGRx2PqDyDxQBy2mldO+MOt2wRlXVtJtr5W/haSCR4pfx2yW/wCldvXDfEdm0nV/CviVd3lWN99hu8HA+z3WIiT7CUQN/wABNdzQAVzPxKTf4I1QhgrRIsyMTjDI6up/NRXTVxvji4/te8tPCdid9zdslxfMp/49rRXBZm9DIV8tR3yx6KaAOyHIFFFFABXFab4E+wSXsdvr+tQ2Mly9zbQQ3G0W4fl4xwQV3biPTdjtXa0UAeeeIPBei2UMuteI/EmuvBYsLmGS7vsx2kgG0SIm3aX5wu4NyflGTU3hnwwuraRZazqUV9pfiCZT5t1bn7JcTxhj5bXEa/KXKBCysDtJIGOlWvKHibx7I9wgfSvDpVYkPKy3zqGLkdD5UbAD0aRj1ANdnQB55p6yfDRzb3txNd+EriaSb7fPgyafNI5dhMVABhZmJD4GwnDfKcr6DFIk0SSxOskbgMrqchgehB7ilYBlIYAg8EHvXIXXg+XTDJdeCLwaRc8ubFwXsJ2POGh/5Z5/vRbTk5IboQDsKKwvCfiKPXradJrZ7DVbN/JvrCVgXt5MZHI4ZGHzK44YHscgbtABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHnvgv/kovib6H/wBGNXoVedXnhLxRFruo32g6xp1g1zMW817dpXaM8hGU/KCGLfMOoPI4rJ8Xaf4/0/wxqlzeeN9OhiSBhvW1Fu2TwAsgBKMc4BAJyRgUAet0V8//AAs8M/F0W895rPiWS28+NfLXUH+1HAPH7oqNhxySTk5AKgjjvP7C+JH/AEOOm/8AgtWgD0SivO/7C+JH/Q46b/4LVo/sL4kf9Djpv/gtWgDQP/JQh/13H/pMa7SvITpvi3+2Psv/AAkFl/bv28OL37GNnk/Zj+72dM55zW1/YXxI/wChx03/AMFq0AeiUV53/YXxI/6HHTf/AAWrSjQviPuGfGOm4zz/AMSxaAINT/5JLqP/AF+S/wDpaa4O5/5Bkn/YMvv5yU+5sdesfDVvd69q9vqHnatNaW4gg8kxxvOxkVscOCyAgEcYHNR3H/ILf/sF3v8AOSgDTP8AyE7v/r7t/wD0U9dWb7UtI+EkmqaM0pvbFprhYI7U3BuQJX/dFB82G/vAjb16Ag8r01W6PX/S7b/0U9aXhb4cHVdKbUl8ZeMrGW4uZpVhs9T8uCH96/yrGVK7fqDQBgfs/fHCfxlrV94f8WiK21h5ZJbLauxXTJJgx/eQdO5AOeRz9AV4vN4Us7nxdZeH/iHDbanqdwr3Wi+JbWIWd3I0RDNFIYyMSoCGUj5WVSSAQc9uNU1zWtTurDw69vbWFg32e41W9j81ppwPmSKJSoO3gM5IG7ICnBwAdjRXnen+LtTsi93fvDqnh1L5tPm1GK3Ns8EgbYZNhZhJCJPkLgqVIJwygsPRKAMrxD4h0rw5BBca5eJZWs0ghFxKCIlc9A79Ezg8tgZ4zkiuLiuo/h/rzSlgfAutzedHco26LTLuQ8hj/DBMxyG+6shIOA4x3PiHRrHxDol7pOrQLcWN5EYpY27g9x6EHBB7EA18t+CvAvjT4d+ONTsb2bU7n4eWr/6aiRC4hu7aQN/ywbIPAxJsBYDOAeKAPpfx1oX/AAkvg7WdGDiOS9tXijc9Ekx8jfg2D+FR+AvES+JvDVveSKIdQizbahak/NbXSYEsTDsQeR6qVI4IrldFlv8AwZp9vJo32jxR4GmIa1a2f7ReadE3RV6m4gXjGMyKOP3gAxT1bU7ZNd03xt4Ba11cavjSb22tpdv2qXbugdx/C8WCH3DcsbNkfIBQB2PinXLqK9g0Lw8kc2vXSeZukGY7KHODPKB2yCFXguwIGAGZb3hnw/aaBaSR27Sz3Vw/m3d5Od011JjBd2+gAAGAoAAAAAqHwf4f/sKxla6n+2axev8AaNQvSMGeXGOB/CijCqv8KgDrkk8Wa7LpENrb6dai91i+k8mzti21ScZZ3YA7Y0HLNg9gMlgCAJ4v8W6R4Tt7aTWJ2V7qQxQQxoXeRgMk4HRQBkscKvcjIqXQPEun63LNb27SQ3sKh5LS4XZKqH7rgdGQ44dSVPrXm4vdV8KfEG2tNUt4fGWvaxDI0k1qotprK0BzsSJ2MYiyP76sxX5txxWV4B1C2TxFba/eq2meEU89NLljjZbRp3cpK3z/AD2qfKB5T4jLgsDnGQD3es3xHrNr4f0W61O+3mGBeEjG55HJwqIO7MxCgdyRWirBlDKQQRkEd648Rr4k8eSNN+803w6VEadUe9dclj6mONlA9DKT1AoA0/BOmXOmeH4l1EINTuZHu7zZyBNIxdlB7hchQfRRW9RRQAUUUUAYep6D9o8SaZrdlOLa9tg0Fx8mRdWzZPlt/uthlPY7uzGtyiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiisLxH4hXS5YbGygN/rVyCbeyjbBI7ySN/BGD1Y/QAnAoAs+Idds9Bs1mvC7ySN5cFvCu+W4kPREUck/oBySACayNK0O81PUINZ8VBDdRNvs9ORt0Nl6MT/y0l9X6DooHJNnw94ee1um1XWrgX+uyrtafBEduh/5ZQqfup6n7zYyxPAHRUAFFFFABRRRQBxZ/wCShj/ruP8A0mNdpXFn/koY/wCu4/8ASY12lABRRRQB5Frk2lH4c3Nxc3lqt1ZXlzsDzgCMteEMSufvAcAnkZOOtcDdeItFFlJCuqW8swsLqExQBpXDu0mxcKD1yMfWvoiXQNHlneaXSdPeZ23tI1shZm9Sccn3q9BbwW4xBDHEP9hQP5UAeC29xf3+oTtpHhzXr3zbiNo3e0NtEdkbA5eUjAJIwcGvYPAljfad4VsbfVoYoL755JYYpPMWMs7Nt3YG7GcZx1rfooA4H4klP+Eq+HYQf6WdbbYw6+X9kn3j6dM0vh7X9O8Na1qHhjXby2sbs3Et7ZPNKFS6gldnG1jxvUllZevyhuhrm/jB4mttJ+IHgv7MYrrUrNdQnS2RtzeYbYIisoOQD5mffGB1rofh94Bt9P099R8TRpqniLUWNxeT3aiTYzD/AFaA8KAMLx6emAADH+JHjAKl9oFkLS9s76BUa6s90v8AZ0bMqySXAUEBAGZg3HIwRj5q9Ut5Yp7eKW3lWWF1DJIjBgykcEHuPeo7OytbKIxWdtBbxE5KRRhAT9BXLz6FfeHJpLzwgiyWjsXuNFd9kTk8loGPET/7P3GP90ktQB2FFZmja3Z6tppvIGeFEYxyx3CGJ4ZBjKOp6EZH1yCMgg1fhminUtDIkig4JRgaAOYh8MT6Nr633hieK1sbqUtqGmyg+S5PWaLH+rk7kD5X7gH5qwNY8HaTrfxPubpY5NN1K301JF1DTnNvcGSSRlLMy8SYWMDDhh7V6VXLXxax+I2mzNkw6jYyWn+7JE3mL+atJ/3zQBT/ALK8dacSNP8AEematDn5U1Ww8uUD3khKqT/2zFcp4t8O/EDWdQh1KG00G31K3ga2SSLVLoL5bMGYoUEbK5wOu5TgZHFerarqNppOm3OoalcR21lbRmWaaQ4VFAySa4Txh4pfWvAekx+HjNBqHi0pa6eWGJIoZFLPcEA5GyEM/sdo70AeWeDNX1OO9e/0ldSGuauTptp/av8ApYvGLYluYrtFCsIwgfaRtKRYTGQa+h9H0e10rQrbSYVMlrDCIT5uGMgxyX9S3JPqSam0nTrXSdLs9OsIhFaWkKQQoP4UVQoH5CsvxT4lj0XyLS1t31HW7sEWenRNh5SOrM3IjjXI3OeB0ALFVIBy3iWO68EPZp4MlEtxfy+VbeHpstE56u8RzmFUB3NzsA4ADMM6nw0ubC10saM0k6a9HuuNQivYxFcSzO26SbaCQylicFSygYAPFaPhbw4+nXNxq2sXC3/iK9ULcXQXCRIDkQQqfuRKe3Vj8zEk1f17QdP12COPUISZIm3wTxsUmgf+9G4+ZT9D9aANSiuP+3a34X+XWFl1rR16X9vF/pMC/wDTaJR84/24xn1Tqa6fTdQtNUsorzTrmG6tZRuSWFwysPqKALNFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHO+DfEkXjPwdba3pSSWiXiyCIXChmjZXZMsAcHlc4z0qz4b8P22hxTMskl1qFyQ93fT4Mtww6FiOgHQKMADgCue+F/gvVvBGmQaVP4gh1LSLeN1hgGn+S6u0m8sX8xsjlhjHf2ruqACsrWvEWk6HJDHq19FavMGaMPn5gMZ6D3FatZGuX+qWcsC6XozakjhjIwuUh8sjGBhuucnp6UAUP+E98L/8AQZtv/Hv8KP8AhPfC/wD0Gbb/AMe/wpv9t+Jf+hSf/wAGMNH9t+Jf+hSf/wAGMNAD08deGZHVE1i3LMcAfN/hWbp3xR8LX1wyR3k0duwka3u5YHWC7WNgkjQvjDhWYDPfPGRzWX8Q9d8SnwZqdunh97Ga9EenxXAvo2Mb3EiwhgBzkGTIx3xVDwSb+DV9Z1TSPDbXllA/9h6awu4YxFZ2hMe1cjPzTCYk9wE7KKALx8S6N/wlf9qf2jD9g+1iHzudu/7Mfl6dcV03/Ce+F/8AoM23/j3+FeUzfEfUofjG2nz+H0S3W5js8i5Uv9re3yqFs7dhU46Z3ce1ep/234l/6FJ//BjDQBT1b4oeE9MWIy6k03mbmYW1vJKYo1+/K4VTtjXIyx4Gavnx54YBwdZtv/Hv8K88+Keo6nfPFBf6Q2mtHo+r3Bb7SkvmRrbbSny9Ms6Hnj5a7qy1vxJ9it8eE3b90vJ1GH0FAFg+PfC4BJ1m24/3v8K6Gyu4L60hurSRZbeZQ8br0ZT0Nc4db8S448IuT/2EYa6Kxlmms4Zbq3+zTugLw7w+w9xuHB+ooAnqprAJ0m9CSSRMYHxJGcOp2nlT2I7VbrgtQ+IFpetqNnoWlX+sQwl7aS7tprWKHzQOUVppkLkZGSoIHTOcigDxDS/hlb+JdT0OKS91OTTYvDq6jqU4WBZfPulLj975WXJZC2X3sDjBFfR/gO4muvBGgT3UrzXElhA8kshyzsY1yxPck8mvnez/AGh/DNv8O9M0WzOtWep2djDbNI1lFLFIyRBGUjzAdpI6jB6H1FemfCb4j6XN4a8MaVrEUmj3dxYRfYmupEMN4qjafLkUkBuBlGww3Ac0Aes0UUUAeffH2wvNU+Euu2emWlxeXcnkbILeNpHbE8ZOFUEnABP0FbPw+8K/8InpM9m0mnyvLOZS9lYCzTG1QAUDNk8HnPfHauoooAKr3Fnb3FxbTzwpJLbMXhZhkoxBUke+CR+NWKjuJora3lnuJFjhiUu7scBVAyST6AUAfMH7WEvjXXNfsPDGl2LvoLItxi1PmNK24JvmAGURWYAZ4JyckjC+s/D2yj1bxRd61GN2j6JD/YGi5HDCMgXM4HT5nRYwQekJ9ayLjUtQOgT6rYEw+K/G9wtppKvw9paBW8tyOoEcXmTsOzvt7ivUPDmjWfh7QbDR9Mj8uysoVgiXjOFGMnHUnqT3JJoApeMNbuNItLSHS7ZLvWNQnFpZQyNtj37WYvIRyEREZjjk7cDkil8LeHY9FSa4uZ2v9au8Ne6hIu15mHRVHOyNckLGDhRnqxZjozaZazata6lLHuvLaKSGFyThFkKF8Dpk+WvPXr6mrlABRRRQAVzGp+Fit7Lqfhu6/snVJDul2pvt7o/9NosgE/7SkN7npXT0UAczp3iny76LTPElr/ZOqSHbFuffb3R/6Yy4AJ/2Gw3sRzXTVW1KwtNTspbPUbaG6tZRtkimQMrD3Brz34j6i/gXwTFY6PqV5HeaheR2lnNOTcvaqxBcgEFmVEVjzk8jnoKAPS6K4X4MeKJ/FPgiCbUZfN1WzlezvGK7SZEPDEYGMqVPQck13VABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAch8VHaLwrDNGu+SLVdNkWPvIRewEKPc9B9a43QNS1PS72Xw94Y1+xu7VNQuI1mm8N3kyQyPM8jRvcxzCJmUuVJ+UZGDg5rR+Pd/Jp+j6HNCSZft7C3j4w10YJRbk+u2Uo4Hqo9K73wvo1v4e8OaZo9mqrBY26QLgYztUAk+5OST3JoA8r1PS5rfw5cWMmpz293D4pjudS1KO2QqZJCskbrEzMBEHeBcEkgKSa2te1nxloFzDbT6hb37tHvEll4RvJ0Pb52juSFbjoB74rtLvw3p93aa1bTpI0Wrkm5G/v5aplf7pwo/EZrYUbVC5JwMZNAHh91d3/i+28SXOq3+mpfaXoN7brpsNjc21x+/jB8yQXG1gn7sAbVIJJ+bjFeveFrn7b4Y0i6Of39nDLz/tID/WuK+LUMcGoaHqQxG5iv7GR8fejktJX2n1G+JDj2rqvACeV4D8Npz8um2w5OT/qloA3qKKKACvnzwF4F1eWwa6Tw74C1Gy3G2t5by3YNJHE7r5oHltzIdzEk85HbFev+PLyeLR007T5Gj1PVpRY2zr96MsCXkH+5GHf6qPWtzTrODTrC2srOMRW1tEsMSDoqqMAfkKAPy71CE21/cwOFDRSMh25xkEjjPavrT4MeDbzxR8OPCE8mh+EF0xLpZp7poGN5NHFK4ZWGzaS2NpJbG0n1xXzn4+8OX1r8VNc0C1tZprw6nLDbwquXlDOTHgf7SlT+Nffnww8Mnwd4A0TQXcPLZ24ErDoZGJZ8e25jj2oAgGj6x4cJfw1OdQ00ddKvZTuQekExyV9kfK+hUVpad4o028029u52lsPsCl7yG9jMUlsACSWB4xgHDAlTjgmt2sfxjoaeJfC2qaNJM0C3sDQiVRnYSODjvg4470AUfCvjTTPE87R6bDqKKYvPikurKWFJ48gb42YAMOR+ddNXJeBrTxZYwQ2fiVtENna2ywRNYGUySMuAGbcAF+UdBnk9a62gArO8RaRba9o1zpmoGQWdwAsyo20umQWQn+6wBUjuCauxzwyyyxxSxvJCQsiqwJQkAgEdjgg89jXCfEm4m16/s/Ammu6SapGZtUnTGbbTwcPz2aU/ul4PBc/w0AHgIHxRr1740mB+wMrafocZDALaK37yfaTjMzqCDgHy44/U139RWltDZ2sNtaRJDbwoscUca7VRQMBQOwAGKloAKKKKACiiigAooooAKr3FhaXF3bXVxawS3VqWMEzxhnhLDDbGPK5HBx1FWKKAKtpp9lZz3M1nZ28E10/mTyRRKrSt/eYgfMfc1aoooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoormviRqeo6L4J1bVdHmgiu7GBrgefCZFcKCSuAy4z6549DQB0tFcpo2sa0fB+i3suntrGoXsCzyG08u2jj3DcARJJngELkbs4JwM4qT7Z4vuD+60fRrRP71xqEkj/98LFj/wAf/wAaAOnormP7P8W3GfP17S7VfS001iw/4E8pB/75FH/CL3k3/H94p16cd1jeG3X8PLjVv1oA4n49Dzbrw64II0d315kP8RglhUD8fNNenajrWl6Zn+0tSsrTHXz51j/mRXhXxr0XSdD1OG5vjeTacmn+ZdS3V5NcuF+22quQHc/wlvlGB7V2+jeKvhnZhBpdtY2khAKxwaS6vznGAseT36etAHpUEsdxDHNBIkkUih0dGBVlIyCCOoNPrkv+Fi+F0lEd1qL2LHgG/tJrUH6GVFFaSeLfDkkRkTX9IaMHG4XkZH55qXOK0bCxzHxoQvoulBVLObyRVUdybS4FdP4HYN4K8Pspyp0+3IP/AGzWuI8Y+NfDWq6x4UsrLV7S5uBrMR8kE/vldJIjsOMPgyDOCa6L4PytL8MPDQfO6GyjtyT3MY8vP/jtUB2FFFYfi3xRpnhSxtrrWJJkjubhbSEQwtKzysCVUKoJydpoAz9K/wCJ3431DUiCbPSFOnWpPRpmw07j6YjQHsVcd66ysPwSLAeGLM6Sl2tod5Bu4mjmdi7b2dWAO5m3HOBnOe9blAHjtz4cji/aXs9WuLaAS3OnPcW100uCyxp5MkQTby+ZY23buFBGOuPT5tbtIPENvo05kju7mBp4Cy4SYKcOqt3ZcgkehyM4OOc+KunXbaRZ6/o8DTax4euBqEESD5p4wpWeEcH78TOBj+ILWjrFlZeN/Ctpc6beeW0ix3+mahGuWgkxmOQA9sHBU9VLKepoA6WivPPB/wAU9H1rxFD4VvH+z+LI45Rd2qAmKOWI4ZVfowIy64ydo5weK9DoAK8b/aK+LU/w60qGx0i0lfWb+NvJupIj5FuOm7JGHf0Xt1PGAfZK8ymtNG8dHU/EPiuO0m8IWcUkFgt1/qmQf667JPTJXajdlUsD89AGb8M70eAvgnZa34ha6vNW1Rvt8seDJcXt1cEeVEq9Wdh5a47YycAHHZ/D3w7c6RaXmpa20UviTWJRdajLGPlQ4xHAh6+XEvyDnn5m/iNZXhCwufE+s23irVYpLXSrRDHoGlsmzyoyNpupQefMdeFX+BD/AHnbHoNABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFZniPQ9P8R6VLpurxSTWUv340meLcPQlCDj2zg1p0UAUdD0q00PSrfTdNSSOzt1KxJJK8pUZJxucliOeMngcDgVeoooAKKKKAPF/2gLSO41Pw3DNgpezR2uG6HF5auf8Ax1Wrs7rwF4OnklMmgaSGdiWZLZUbPqCMEH3Fcf8AtETG0uPCF+ySvBYXj3kwjXcfLj2M5IHJCoHcgc4QntT9U+J/hCwYvceLNIZWyw8ibzzj6Rg14Ob42WGqQjGm5XXRN/kb0ocyetjpP+Ff6Ai+Xa3uvWsGMeTBrV0seP8Ad8zFZcnwf8FSTCWSG+eUfxG/lz/6FXO2Hxl8E31z5EPiWGN+zXMEkCf99MAK0dS+JnhPTNv2vxXo+T2gn88/iIwcV5rzzEQfI6M0+1pGnsYvW6M74oeFfDvhbTPDGoaRYRRSw+JdPlmuXJll2K5JzI5LY4zjOK9F+EpJ8Bafk7sSXAz6gTyYI9q8e+KHjLQPE/w71C00PXbDUdTd4ZbO2hl/emRHDElDghQoYkngAHNew/CC1az+GHhmJ87jYxyHPX5xv/8AZq93KsW8VRc3Bxadtb9l3MKseV2udfXB/GHwhqHjLRNJtNLNn5tnqcN9Il1NJCsiIrgqHjBYE7hyMEckEHFd5RXpmZi+DdOudJ8NWVjew28E8IYNHb3Es8ajeSMSS/O3BGc98jpitqiigArzizY/DXWprW5CR+B9RnMtrcD5V0q5kbLQydlhkc5RuArMVOAUr0eoru2gvLSa1vIYp7aZGjlilQMkiEYKsDwQQSCDQB86+PfgxceEvGFj49+GduxexuVurnRo+CyZ/eCH2ZSwKe529lr6KtZ47q1huISTFKgkUkYOCMjiuKt/Ceu+G0EXgzW4/wCzVAEel6ujXEUI6bYpQRIigDhW3gdsDirEq/EC4Cxo3hewB4aYefcke4QhB+ZoA3PFmo6Rpfh3ULnxJdw2mkiFkuJJZCg2sMFQRzuOcALySeOa5DTtFu/GL2Umtae2leELLY1jocqbZLkpjy5Llf4UXAKweoBfkBV1dG8C20OqRav4hv7rxDrURzDcX20RWp4z5EKgJGeB8wBf1Y12FABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAGR4n8P2fiPTVtL4zRtHIJ7e4t5PLmtpVztkjb+Fhkj0IJBBBIPH6X8JdLsbqW6TVNSjupG3GSzWCz57nEMa8nue9ej0UAcBqfw5ku7ZoB4p1mWFusOoxW1/Hj0xNET+tQaN8LINJjf7B4g1PT5HOW/su3tLNP++EhwfxzXo1FAHEXHw9h1HEWveINc1axyN9ncSRRxTAdFl8qNGkGexOD3BrtlUKoVQAoGAAMAClooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAP/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Diagram of equipment used for the performance of continuous venovenous hemodialysis (CVVHD) or slow continuous hemodialysis. A: Double-lumen subclavian catheter; B: Blood pump; C: Venous bubble trap; D: Dialyser; E: Air embolus detector; F: Venous pressure monitor; G: Heparin infusion; H: Dialysate infusion pump; I: Dialysate collection bag; J: Saline infusion; K: Dialysate; L: Constricting clamp.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Tam PY-W, Huraib S, Mahan B, et al. Clin Nephrol 1988; 30:79.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_47_43760=[""].join("\n");
var outline_f42_47_43760=null;
var title_f42_47_43761="Retinoblastoma gross path";
var content_f42_47_43761=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F71468&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F71468&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Retinoblastoma gross pathology",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 307px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This surgically excised eye is almost filled by a cream-colored intraocular retinoblastoma with calcified flecks.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Rubin E, Farber JL. Pathology, 3rd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 1999. Copyright &copy; 1999 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_47_43761=[""].join("\n");
var outline_f42_47_43761=null;
var title_f42_47_43762="Trifluridine: Pediatric drug information";
var content_f42_47_43762=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Trifluridine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?17/33/17939?source=see_link\">",
"    see \"Trifluridine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?0/5/94?source=see_link\">",
"    see \"Trifluridine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F231119\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Viroptic&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F231120\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Sandoz-Trifluridine;",
"     </li>",
"     <li>",
"      Viroptic&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1050467\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiviral Agent, Ophthalmic",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1050462\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?17/33/17939?source=see_link\">",
"      see \"Trifluridine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children and Adults: Ophthalmic: Instill 1 drop into affected eye every 2 hours while awake, to a maximum of 9 drops/day, until re-epithelialization of corneal ulcer occurs; then use 1 drop every 4 hours for another 7 days; do",
"     <b>",
"      not",
"     </b>",
"     exceed 21 days of treatment",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F231107\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, ophthalmic [drops]: 1% (7.5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Viroptic&reg;: 1% (7.5 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F231093\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1050470\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ophthalmic: Avoid contact of bottle tip with skin or eye; instill drops onto the cornea of the affected eye(s); apply finger pressure to lacrimal sac during and for 1-2 minutes after instillation to decrease risk of absorption and systemic effects",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1050464\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store in refrigerator; storage at room temperature may result in a solution with altered pH which could result in ocular discomfort upon administration and/or decreased potency",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1050469\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of primary keratoconjunctivitis and recurrent epithelial keratitis caused by herpes simplex virus types I and II",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F231151\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Viroptic&reg; may be confused with Timoptic&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F231150\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     Ocular: Burning or stinging (5%), palpebral edema (3%), epithelial keratopathy, hyperemia, hypersensitivity reactions, irritation, keratitis sicca, ocular pressure increased, stromal edema, superficial punctate keratopathy",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1050474\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to trifluridine or any component",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10898837\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300175\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F231101\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F231103\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13823810\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse effects were not observed during animal reproduction studies of the ophthalmic solution.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1050466\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ophthalmologic exam (test for corneal staining with fluorescein or rose Bengal)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1050461\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Interferes with viral replication by incorporating into viral DNA in place of thymidine, inhibiting thymidylate synthetase resulting in the formation of defective proteins",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1050472\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Onset of action: Response to treatment occurs within 2-7 days; epithelial healing is complete in 1-2 weeks",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1050473\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Absorption: Ophthalmic: Systemic absorption is negligible, while corneal penetration is adequate",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1050475\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Found to be effective in 138 of 150 patients unresponsive or intolerant to idoxuridine or vidarabine",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12861 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.76.133-1E93B43961-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_47_43762=[""].join("\n");
var outline_f42_47_43762=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231119\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231120\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050467\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050462\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231107\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231093\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050470\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050464\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050469\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231151\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231150\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050474\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10898837\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300175\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231101\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231103\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13823810\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050466\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050461\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050472\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050473\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050475\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12861\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12861|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?17/33/17939?source=related_link\">",
"      Trifluridine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?0/5/94?source=related_link\">",
"      Trifluridine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_47_43763="Diazoxide: Patient drug information";
var content_f42_47_43763=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Diazoxide: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/38/13924?source=see_link\">",
"     see \"Diazoxide: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?13/11/13492?source=see_link\">",
"     see \"Diazoxide: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F159130\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Proglycem&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F159131\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Proglycem&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10012089\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691935",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat low blood sugar.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10012088\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701933",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to diazoxide or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701385",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a sulfa (sulfonamide) allergy, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10012092\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10012093\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698364",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10012095\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very low blood sugar or very high blood sugar.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699055",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shakiness, trouble moving around, or stiffness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10012091\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695887",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take on an empty stomach. Take 1 hour before or 2 hours after meals.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10012096\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10012097\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11935 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-6BEDC4A8C2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_47_43763=[""].join("\n");
var outline_f42_47_43763=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159130\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159131\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012089\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012088\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012092\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012093\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012095\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012091\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012096\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012097\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?13/38/13924?source=related_link\">",
"      Diazoxide: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?13/11/13492?source=related_link\">",
"      Diazoxide: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_47_43764="Fenoterol and ipratropium: Patient drug information";
var content_f42_47_43764=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Fenoterol and ipratropium: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/8/31876?source=see_link\">",
"     see \"Fenoterol and ipratropium: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F10159248\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Duovent&reg; UDV",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F13319003\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10206005\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691417",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to open the airways in lung diseases where spasm may cause breathing problems.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10206004\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2749870",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to ipratropium, fenoterol, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701360",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a fast heartbeat.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10206009\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697225",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have glaucoma, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697265",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood pressure, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697334",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have prostate disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have seizures, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697166",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an overactive thyroid, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697564",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your use of caffeine (for example, tea, coffee, cola) and chocolate. Use with this drug may cause nervousness, shakiness, and a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10206010\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698279",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697983",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698162",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to sleep.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10206012\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure or a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699102",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are not able to get the breathing attack under control.",
"       <b>",
"        Get help right away.",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698996",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Peak flow measurement low.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699112",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10206007\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694871",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow what your doctor has told you to do.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696292",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may breathe in this drug from your mouth with a special machine (nebulizer).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10206008\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10206013\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10206014\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15570 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-5849588C53-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_47_43764=[""].join("\n");
var outline_f42_47_43764=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10159248\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13319003\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10206005\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10206004\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10206009\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10206010\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10206012\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10206007\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10206008\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10206013\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10206014\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?31/8/31876?source=related_link\">",
"      Fenoterol and ipratropium: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_47_43765="Stockinette types";
var content_f42_47_43765=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F66332&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F66332&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Stockinette in different sizes",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 355px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Stephen Titus, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_47_43765=[""].join("\n");
var outline_f42_47_43765=null;
var title_f42_47_43766="Causes of painless scrotal swelling in children and adolescents";
var content_f42_47_43766=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Causes of painless scrotal swelling in children and adolescents",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/47/43766/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/47/43766/contributors\">",
"     Joel S Brenner, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/47/43766/contributors\">",
"     Aderonke Ojo, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/47/43766/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/47/43766/contributors\">",
"     Amy B Middleman, MD, MPH, MS Ed",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/47/43766/contributors\">",
"     Gary R Fleisher, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/47/43766/contributors\">",
"     Laurence S Baskin, MD, FAAP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/47/43766/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/47/43766/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?42/47/43766/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The spectrum of conditions that affect the scrotum and its contents ranges from incidental findings to pathologic events that require expeditious diagnosis and treatment (eg, testicular torsion, testicular cancer). The most common causes of painless scrotal swelling in children and adolescents include hydrocele and nonincarcerated inguinal hernia. Less common causes are varicocele, spermatocele, localized edema from insect bites, nephrotic syndrome (swelling is usually bilateral), and rarely, testicular cancer (",
"    <a class=\"graphic graphic_table graphicRef57879 \" href=\"mobipreview.htm?16/47/17147\">",
"     table 1",
"    </a>",
"    ). Scrotal swelling and testicular masses should be evaluated promptly.",
"   </p>",
"   <p>",
"    The clinical presentation, diagnosis, and management of hydrocele, varicocele, spermatocele will be discussed below along with the presentation and diagnosis of testicular cancer. Inguinal hernia, the evaluation of scrotal pain and swelling, and the causes of scrotal pain in children and adolescents are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/3/21561?source=see_link\">",
"     \"Overview of inguinal hernia in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/38/2663?source=see_link\">",
"     \"Evaluation of scrotal pain or swelling in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/39/32376?source=see_link\">",
"     \"Causes of scrotal pain in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HYDROCELE",
"    </span>",
"    &nbsp;&mdash;&nbsp;A hydrocele is a collection of peritoneal fluid between the parietal and visceral layers of the tunica vaginalis. Hydroceles may be communicating or noncommunicating.",
"   </p>",
"   <p>",
"    Communicating hydroceles usually develop as a result of failure of the processus vaginalis to close during development; the fluid around the testis is peritoneal fluid (",
"    <a class=\"graphic graphic_figure graphicRef70784 \" href=\"mobipreview.htm?0/16/256\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef50831 \" href=\"mobipreview.htm?17/42/18083\">",
"     picture 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43766/abstract/1\">",
"     1",
"    </a>",
"    ]. Noncommunicating hydroceles have no connection to the peritoneum; the fluid comes from the mesothelial lining of the tunica vaginalis (",
"    <a class=\"graphic graphic_figure graphicRef58679 \" href=\"mobipreview.htm?1/17/1299\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Hydroceles are common in newborns (whether related to delayed closure of a patent processus vaginalis or fluid trapped at the time of testicular descent is not known) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43766/abstract/1\">",
"     1",
"    </a>",
"    ]. The majority of hydroceles in neonates resolve spontaneously, usually by the first birthday [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43766/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In older children and adolescents, noncommunicating hydroceles may be idiopathic or may occur secondary to epididymitis, orchitis, testicular torsion, torsion of the appendix testis or appendix epididymis, trauma, or tumor. These conditions must be excluded in children and adolescents with hydrocele. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/38/2663?source=see_link\">",
"     \"Evaluation of scrotal pain or swelling in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H11\">",
"     'Testicular cancer'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Clinical presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with hydroceles present with a cystic scrotal mass. A hydrocele that communicates with the peritoneal cavity may increase in size during the day or with the valsalva maneuver. In contrast, noncommunicating hydroceles are not reducible and do not change in size or shape with crying or straining.",
"   </p>",
"   <p>",
"    Examination of patients with hydroceles should include palpation of the entire testicular surface for findings of epididymitis, orchitis, testicular torsion, torsion of the appendix testis or appendix epididymis, trauma, or tumor as the primary etiology; doppler ultrasonography may be necessary to exclude these conditions. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/38/2663?source=see_link\">",
"     \"Evaluation of scrotal pain or swelling in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H11\">",
"     'Testicular cancer'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of hydrocele can be made by physical examination and transillumination of the scrotum that demonstrates a cystic fluid collection. Communicating hydroceles are often reducible; noncommunicating hydroceles are not. Doppler ultrasonography may be necessary to evaluate the testicle and rule out a primary cause.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical repair is indicated for hydroceles in newborns that persist beyond one year of age, for communicating hydroceles, and for idiopathic hydroceles that are symptomatic or compromise the skin integrity.",
"   </p>",
"   <p>",
"    The management of hydrocele in a neonate or child younger than one year of age usually is supportive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43766/abstract/2\">",
"     2",
"    </a>",
"    ]. Hydroceles that are present in newborns, whether communicating or noncommunicating, usually resolve spontaneously by the first birthday, unless they are accompanied by an inguinal hernia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43766/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/3/21561?source=see_link\">",
"     \"Overview of inguinal hernia in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Communicating hydroceles in older patients rarely resolve and pose a risk for development of incarcerated inguinal hernia. Surgical repair of communicating hydroceles is usually undertaken on an elective basis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43766/abstract/2-4\">",
"     2-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Idiopathic hydroceles are often asymptomatic. Surgical repair may be indicated for symptomatic complaints. Reactive hydroceles usually resolve with treatment of the underlying condition. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/3/21561?source=see_link\">",
"     \"Overview of inguinal hernia in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/39/32376?source=see_link\">",
"     \"Causes of scrotal pain in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/47/41720?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and staging of testicular germ cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     INGUINAL HERNIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical presentation, diagnosis, and management of inguinal hernia in children is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/3/21561?source=see_link\">",
"     \"Overview of inguinal hernia in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     VARICOCELE",
"    </span>",
"    &nbsp;&mdash;&nbsp;A varicocele is a collection of dilated and tortuous veins in the pampiniform plexus surrounding the spermatic cord in the scrotum (",
"    <a class=\"graphic graphic_figure graphicRef73206 \" href=\"mobipreview.htm?7/57/8080\">",
"     figure 3",
"    </a>",
"    ). One etiologic theory is that varicoceles result from increased venous pressure and incompetent valves [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43766/abstract/3,5-7\">",
"     3,5-7",
"    </a>",
"    ]. Varicoceles occur more commonly on the left side (85 to 95 percent) because the left spermatic vein enters the left renal vein at a 90 degree angle, whereas the right spermatic vein drains at a more obtuse angle directly into the inferior vena cava, facilitating more continuous flow [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43766/abstract/3,5,6\">",
"     3,5,6",
"    </a>",
"    ]. Approximately 10 to 25 percent of all adolescent males and as many as one-third of all males examined at an infertility clinic have a varicocele. However, only 10 to 15 percent of males with varicoceles have fertility problems [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43766/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Clinical presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with varicoceles can be asymptomatic or present complaining of a dull ache in or fullness of the scrotum upon standing.",
"   </p>",
"   <p>",
"    The examination for varicocele initially should be performed with the patient standing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43766/abstract/8\">",
"     8",
"    </a>",
"    ]. The scrotum is inspected for any visible distention around the spermatic cord (indicative of a grade III varicocele). The scrotum, testes, and cord structures are then gently palpated; a palpable varicocele has the texture of a \"bag of worms\". Grade II varicoceles are palpable, but nonvisible. The patient should then be asked to perform the valsalva maneuver; if the varicocele is palpable only with the valsalva maneuver, it is Grade I (",
"    <a class=\"graphic graphic_table graphicRef51251 \" href=\"mobipreview.htm?2/43/2747\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Varicocele grade does not correlate well with abnormal semen analysis or infertility in adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43766/abstract/9\">",
"     9",
"    </a>",
"    ]. Studies in adolescents correlating varicocele grade and testicular size in adolescents have had conflicting results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43766/abstract/10-13\">",
"     10-13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The patient also should be examined in the supine position [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43766/abstract/8\">",
"     8",
"    </a>",
"    ]. This maneuver will help to differentiate idiopathic from secondary varicocele. Idiopathic varicocele usually is more prominent in the upright position and disappears in supine, whereas secondary varicocele usually does not get much smaller with change in position from upright to supine.",
"   </p>",
"   <p>",
"    Processes that cause inferior vena caval (IVC) obstruction must be ruled out with Doppler ultrasonography if the varicocele persists in the supine position, has acute onset, or is right-sided [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43766/abstract/5\">",
"     5",
"    </a>",
"    ]. These processes include IVC thrombus, right renal vein thrombosis with clot propagation down the IVC, and abdominal mass (eg, retroperitoneal tumors, kidney tumors, or lymphadenopathy) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43766/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no clear guidelines established for treatment of a varicocele in childhood. Most varicoceles in adolescents are managed conservatively with observation. When more aggressive treatment is necessary, varicoceles are repaired through surgical ligation or testicular vein embolization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43766/abstract/8\">",
"     8",
"    </a>",
"    ]. These procedures should be considered under the following circumstances [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43766/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Affected testicular volume is less than that of the unaffected testicle (a difference in size of &gt;10 to 15 percent or &gt;2 mL when assessed by ultrasonography); loss of testicular volume is associated with a decreased sperm count [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/47/43766/abstract/15\">",
"       15",
"      </a>",
"      ]; testicular growth arrest can be reversed with varicocele repair [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/47/43766/abstract/11,16-18\">",
"       11,16-18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      To alleviate symptoms: Pain, heaviness, swelling.",
"     </li>",
"     <li>",
"      Bilateral varicoceles.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although grade of varicocele should not be the sole indication for treatment, treatment may be warranted in adolescents with large varicoceles (grade III) and abnormal semen analysis, since varicocele repair has been associated with improved semen analysis in adolescents and young men [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43766/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one study, hormonal tests and orchidometry in 76 sexually mature (Tanner V) adolescents with varicocele were correlated with semen analysis. Twenty patients (26 percent) had abnormal semen. Unstimulated concentrations of LH and FSH were significantly greater in adolescents with abnormal than normal semen analysis (4.1 versus 3.3",
"    <span class=\"nowrap\">",
"     mU/mL",
"    </span>",
"    for LH, and 5.3 versus 3.7",
"    <span class=\"nowrap\">",
"     mU/mL",
"    </span>",
"    for FSH) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43766/abstract/19\">",
"     19",
"    </a>",
"    ]. Neither mean testicular volume nor the ratio of testicular volume on the abnormal to the normal side differed significantly between groups. These data suggest that LH and FSH concentrations may be more helpful than testicular volume in identifying patients with testicular dysfunction in adolescents with varicocele.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SPERMATOCELE (EPIDIDYMAL CYST)",
"    </span>",
"    &nbsp;&mdash;&nbsp;A spermatocele (epididymal cyst) is a painless, fluid-filled cyst of the head (caput) of the epididymis that may contain nonviable sperm (",
"    <a class=\"graphic graphic_figure graphicRef67291 \" href=\"mobipreview.htm?26/35/27199\">",
"     figure 4",
"    </a>",
"    ). A spermatocele can be palpated as distinct from the testis and typically transilluminates as a cystic mass. In contrast, testicular tumors are palpated within the testis and do not transilluminate. Ultrasonography may be helpful to confirm the diagnosis of spermatocele. Spermatoceles do not affect fertility. Treatment (eg, surgical excision) is indicated to relieve discomfort.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     TESTICULAR CANCER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Testicular cancer accounts for 20 percent of cancer diagnosed in males 15 to 35 years old, rendering it the most common solid tumor in males within this age group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43766/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. The epidemiology and risk factors for testicular cancer, which include cryptorchidism, family history of testicular cancer, cancer of the other testicle, human immunodeficiency virus (HIV) infection, intratubular germ cell neoplasia of the unclassified type (also called carcinoma in situ or testicular intraepithelial neoplasia), and race, are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/25/2457?source=see_link\">",
"     \"Epidemiology of and risk factors for testicular germ cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Clinical presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Testicular cancer usually presents as a painless mass discovered by the patient or clinician on physical examination, although rapidly growing germ cell tumors may cause acute scrotal pain secondary to hemorrhage and infarction. Other common signs are testicular enlargement or swelling. Many patients also report an aching feeling in the lower abdomen or scrotum.",
"   </p>",
"   <p>",
"    On examination, intrascrotal malignancies usually are firm, nontender masses that do not transilluminate unless accompanied by a reactive hydrocele. Some patients may have gynecomastia. The clinical presentation of testicular cancer and advanced or metastatic testicular cancer are discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/47/41720?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and staging of testicular germ cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Scrotal ultrasound is the initial diagnostic test of choice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43766/abstract/20,22\">",
"     20,22",
"    </a>",
"    ]. Although pathology is the definitive diagnostic test, scrotal ultrasound may help to distinguish intrinsic from extrinsic testicular lesions. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/47/41720?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and staging of testicular germ cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several conditions may mimic neoplasia on ultrasound, including inflammation, hematoma, infarct, fibrosis, and tubular ectasia of the rete testis. In cases in which the ultrasound is inconclusive, MRI may help differentiate benign from malignant lesions. This was illustrated in a study of 622 patients who underwent ultrasound examination to evaluate a variety of scrotal diseases, of whom 17 had a lesion suspicious for cancer but an inconclusive ultrasound [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43766/abstract/23\">",
"     23",
"    </a>",
"    ]. No lesion defined as benign by MRI proved to be malignant (negative predictive value 100 percent), although two benign inflammatory lesions were mistakenly thought to be malignant (positive predictive value 71 percent). These findings suggest ultrasound is sufficient in the vast majority of patients with suspected malignancy on examination, but MRI is a useful adjunct when the ultrasound result is equivocal.",
"   </p>",
"   <p>",
"    Boys with lesions that are consistent with cancer should be referred to a urologist for diagnostic evaluation, which may include blood tests for various tumor markers, and radical inguinal orchiectomy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/47/41720?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and staging of testicular germ cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of testicular cancer is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/7/13432?source=see_link\">",
"     \"Overview of the treatment of testicular germ cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Early detection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prevention of testicular cancer centers on improved awareness and early detection (eg, secondary prevention). Efforts to increase awareness of testicular cancer can occur in the general community (eg, Lance Armstrong Foundation [",
"    <a class=\"external\" href=\"file://www.livestrong.org/\">",
"     www.livestrong.org",
"    </a>",
"    ]), in schools, and at medical visits.",
"   </p>",
"   <p>",
"    Screening for testicular cancer is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/38/28261?source=see_link&amp;anchor=H2303359#H2303359\">",
"     \"Screening for testicular cancer\", section on 'Screening tests'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     OTHER CAUSES",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Insect bites &ndash; Localized edema from insect bites may cause scrotal swelling; such swelling may be accompanied by erythema",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      pruritus.",
"     </li>",
"     <li>",
"      Nephrotic syndrome &ndash; The nephrotic syndrome is characterized by nephrotic range proteinuria, hypoalbuminemia, edema, and hyperlipidemia. The edema is gravity dependent. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/35/37432?source=see_link\">",
"       \"Etiology, clinical manifestations, and diagnosis of nephrotic syndrome in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Other conditions producing generalized edema due to hypoproteinemia or increased hydrostatic pressure (eg, protein losing enteropathy, hepatic cirrhosis).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?17/29/17873?source=see_link\">",
"       \"Patient information: Hydrocele (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?16/52/17217?source=see_link\">",
"       \"Patient information: Varicocele (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most common causes of painless scrotal swelling in children and adolescents include hydrocele and nonincarcerated inguinal hernia. Less common causes include varicocele, spermatocele, localized edema from insect bites, nephrotic syndrome, and rarely, testicular cancer (",
"      <a class=\"graphic graphic_table graphicRef57879 \" href=\"mobipreview.htm?16/47/17147\">",
"       table 1",
"      </a>",
"      ). Scrotal swelling and testicular masses should be evaluated promptly. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A hydrocele is a collection of peritoneal fluid between the parietal and visceral layers of the tunica vaginalis (",
"      <a class=\"graphic graphic_figure graphicRef58679 \" href=\"mobipreview.htm?1/17/1299\">",
"       figure 2",
"      </a>",
"      ). Hydroceles may occur in reaction to testicular torsion, tumor, epididymitis, orchitis, or trauma; these conditions must be ruled out by palpation of the entire testicular surface",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      ultrasonography. Such reactive hydroceles usually resolve with treatment of the underlying condition. Surgical repair of hydroceles is indicated for hydroceles in newborns that persist beyond one year of age, for communicating hydroceles, and for idiopathic hydroceles which are symptomatic. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Hydrocele'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A varicocele is a collection of dilated and tortuous veins in the pampiniform plexus surrounding the spermatic cord (",
"      <a class=\"graphic graphic_figure graphicRef73206 \" href=\"mobipreview.htm?7/57/8080\">",
"       figure 3",
"      </a>",
"      ). Inferior vena caval obstruction must be excluded in patients with varicocele if the varicocele persists in the supine position, has acute onset, or is only right-sided. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Varicocele'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A spermatocele (epididymal cyst) is a painless, fluid-filled cyst of the head (caput) of the epididymis that may contain nonviable sperm (",
"      <a class=\"graphic graphic_figure graphicRef67291 \" href=\"mobipreview.htm?26/35/27199\">",
"       figure 4",
"      </a>",
"      ). Spermatoceles do not affect fertility and rarely require excision. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Spermatocele (epididymal cyst)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Testicular cancer usually presents as a painless mass in the testicle that is firm and nontender; it may be accompanied by a reactive hydrocele. Such masses must be evaluated promptly. Scrotal ultrasonography is the initial diagnostic test of choice; boys with lesions that are consistent with cancer should be referred to a urologist for additional evaluation. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Testicular cancer'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Boys with a history of cryptorchidism, previous testicular cancer, HIV infection, intratubular germ cell neoplasia of the unclassified type (also called carcinoma in situ or testicular intraepithelial neoplasia), or family history of testicular cancer are at risk of developing testicular cancer. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Testicular cancer'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Baskin LS, Kogan AB. Hydrocele/Hernia. In: Pediatric Urology Practice, Gonzales ET, Bauer SB.  (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 1999. p.649.",
"    </li>",
"    <li>",
"     Spencer Barthold J, Kass EJ. Abnormalities of the penis and scrotum. In: Clinical Pediatric Urology, 4th, Belman AB, King LR, Kramer SA.  (Eds), Martin Dunitz Ltd, London 2002. p.1093.",
"    </li>",
"    <li>",
"     Rohn RD. Male genitalia: Examination and findings. In: Comprehensive Adolescent Health Care, Friedman SB, Fisher M, Schonberg SK, et al.  (Eds), Mosby-Yearbook, St. Louis 1998. p.1078.",
"    </li>",
"    <li>",
"     Anderson MM, Neinstein LS. Scrotal disorders. In: Adolescent Health Care: A Practical Guide, Neinstein LS.  (Ed), Williams &amp; Wilkins, Baltimore 1996. p.464.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43766/abstract/5\">",
"      Pillai SB, Besner GE. Pediatric testicular problems. Pediatr Clin North Am 1998; 45:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43766/abstract/6\">",
"      Skoog SJ, Roberts KP, Goldstein M, Pryor JL. The adolescent varicocele: what's new with an old problem in young patients? Pediatrics 1997; 100:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43766/abstract/7\">",
"      Kass EJ. Adolescent varicocele. Pediatr Clin North Am 2001; 48:1559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43766/abstract/8\">",
"      Paduch DA, Skoog SJ. Current management of adolescent varicocele. Rev Urol 2001; 3:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43766/abstract/9\">",
"      Vereecken RL, Boeckx G. Does fertility improvement after varicocele treatment justify preventive treatment at puberty? Urology 1986; 28:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43766/abstract/10\">",
"      Lyon RP, Marshall S, Scott MP. Varicocele in childhood and adolescence: implication in adulthood infertility? Urology 1982; 19:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43766/abstract/11\">",
"      Paduch DA, Niedzielski J. Repair versus observation in adolescent varicocele: a prospective study. J Urol 1997; 158:1128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43766/abstract/12\">",
"      Costabile RA, Skoog S, Radowich M. Testicular volume assessment in the adolescent with a varicocele. J Urol 1992; 147:1348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43766/abstract/13\">",
"      Steeno O, Knops J, Declerck L, et al. Prevention of fertility disorders by detection and treatment of varicocele at school and college age. Andrologia 1976; 8:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43766/abstract/14\">",
"      Roy CR 2nd, Wilson T, Raife M, Horne D. Varicocele as the presenting sign of an abdominal mass. J Urol 1989; 141:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43766/abstract/15\">",
"      Haans LC, Laven JS, Mali WP, et al. Testis volumes, semen quality, and hormonal patterns in adolescents with and without a varicocele. Fertil Steril 1991; 56:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43766/abstract/16\">",
"      Kass EJ, Belman AB. Reversal of testicular growth failure by varicocele ligation. J Urol 1987; 137:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43766/abstract/17\">",
"      Laven JS, Haans LC, Mali WP, et al. Effects of varicocele treatment in adolescents: a randomized study. Fertil Steril 1992; 58:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43766/abstract/18\">",
"      Okuyama A, Nakamura M, Namiki M, et al. Surgical repair of varicocele at puberty: preventive treatment for fertility improvement. J Urol 1988; 139:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43766/abstract/19\">",
"      Guarino N, Tadini B, Bianchi M. The adolescent varicocele: the crucial role of hormonal tests in selecting patients with testicular dysfunction. J Pediatr Surg 2003; 38:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43766/abstract/20\">",
"      Iammarino NK, Scardino PT. Testicular cancer: the role of the primary care physician in prevention and early detection. Tex Med 1991; 87:66.",
"     </a>",
"    </li>",
"    <li>",
"     Surveillance, Epidemiology, and End Results (SEER) Program. Public-use Data (1973-1998), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2001, based on August 2000 submission.",
"    </li>",
"    <li>",
"     American Cancer Society. Cancer reference information, www.cancer.org/docroot/cri/content/cri_2_4_3x_Can_Testicular_Cancer_Be_Found_Early_41.asp (Accessed on November 27, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43766/abstract/23\">",
"      Muglia V, Tucci S Jr, Elias J Jr, et al. Magnetic resonance imaging of scrotal diseases: when it makes the difference. Urology 2002; 59:419.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6448 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-122.72.76.133-46BEA4AD38-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_47_43766=[""].join("\n");
var outline_f42_47_43766=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HYDROCELE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Clinical presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      INGUINAL HERNIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      VARICOCELE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Clinical presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SPERMATOCELE (EPIDIDYMAL CYST)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      TESTICULAR CANCER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Clinical presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Early detection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      OTHER CAUSES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6448\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6448|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?0/16/256\" title=\"figure 1\">",
"      Communicating hydrocele",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?1/17/1299\" title=\"figure 2\">",
"      Hydrocele",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?7/57/8080\" title=\"figure 3\">",
"      Varicocele",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?26/35/27199\" title=\"figure 4\">",
"      Spermatocele",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6448|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?17/42/18083\" title=\"picture 1\">",
"      Communicating hydrocele 2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6448|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/47/17147\" title=\"table 1\">",
"      Differential diagnosis painless scrotal mass",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/43/2747\" title=\"table 2\">",
"      Varicocele grading",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/39/32376?source=related_link\">",
"      Causes of scrotal pain in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/47/41720?source=related_link\">",
"      Clinical manifestations, diagnosis, and staging of testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/25/2457?source=related_link\">",
"      Epidemiology of and risk factors for testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/35/37432?source=related_link\">",
"      Etiology, clinical manifestations, and diagnosis of nephrotic syndrome in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/38/2663?source=related_link\">",
"      Evaluation of scrotal pain or swelling in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/3/21561?source=related_link\">",
"      Overview of inguinal hernia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/7/13432?source=related_link\">",
"      Overview of the treatment of testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?17/29/17873?source=related_link\">",
"      Patient information: Hydrocele (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?16/52/17217?source=related_link\">",
"      Patient information: Varicocele (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/38/28261?source=related_link\">",
"      Screening for testicular cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_47_43767="Subdural hematoma in adults: Prognosis and management";
var content_f42_47_43767=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Subdural hematoma in adults: Prognosis and management",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/47/43767/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/47/43767/contributors\">",
"     William McBride, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/47/43767/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/47/43767/contributors\">",
"     Jose Biller, MD, FACP, FAAN, FAHA",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/47/43767/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/47/43767/contributors\">",
"     Janet L Wilterdink, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?42/47/43767/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 5, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subdural hematoma (SDH) and epidural hematoma are characterized by bleeding into the spaces surrounding the brain.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Subdural hematomas form between the dura and the arachnoid membranes",
"     </li>",
"     <li>",
"      Epidural hematomas arise in the potential space between the dura and the skull",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The prognosis and management of SDH will be discussed here. Other aspects of SDH are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/49/6936?source=see_link\">",
"     \"Subdural hematoma in adults: Etiology, clinical features, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Epidural hematoma is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/42/19112?source=see_link\">",
"     \"Intracranial epidural hematoma in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The estimated overall mortality rate in patients requiring surgery for SDH is 40 to 60 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43767/abstract/1-6\">",
"     1-6",
"    </a>",
"    ]. In patients who present with coma prior to surgical evacuation, the mortality rate is 57 to 68 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43767/abstract/2,7,8\">",
"     2,7,8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Prognostic indicators",
"    </span>",
"    &nbsp;&mdash;&nbsp;Age and neurologic status as assessed with the Glasgow coma scale (GCS) are important prognostic indicators in patients with SDH, as illustrated by the following reports.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a series of 60 patients treated for acute SDH, the rates of overall mortality and functional recovery were 55 and 30 percent, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/47/43767/abstract/3\">",
"       3",
"      </a>",
"      ]. An initial GCS score of 3 was associated with a mortality rate of 93 percent, while no patient with GCS score &gt;7 expired [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/47/43767/abstract/3\">",
"       3",
"      </a>",
"      ]. In patients who presented with an initial GCS score of 4 to 6, mortality rates for patients &gt;65 years old compared with patients 19 to 40 years old were 82 and 50 percent, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/47/43767/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a series of 200 adult patients with acute SDH, mortality at three months was significantly higher in patients &gt;50 years old than in patients 10 to 30 years old (25 and 75 percent, respectively) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/47/43767/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The GCS grades coma severity according to three categories of responsiveness: best eye opening, best verbal, and best motor response (",
"    <a class=\"graphic graphic_table graphicRef81854 \" href=\"mobipreview.htm?28/62/29676\">",
"     table 1",
"    </a>",
"    ). The GCS is scored between 3 and 15, with higher scores indicating better performance.",
"   </p>",
"   <p>",
"    The majority of SDH cases requiring surgery are complicated by associated intracranial",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    extracranial injuries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43767/abstract/2\">",
"     2",
"    </a>",
"    ]. Concurrent brain lesions such as contusions, subarachnoid hemorrhage, and epidural hematoma are likely to have a negative impact on prognosis in patients with SDH. In this regard, a study that prospectively collected data for 33 patients with acute SDH found that brain parenchymal injury underlying an evacuated SDH was associated with a mortality of 53 percent, as compared with a mortality of 9 percent in those without such injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43767/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, several studies have identified head CT findings that correlate with poor outcome after SDH, including the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hematoma thickness [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/47/43767/abstract/4,10\">",
"       4,10",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Hematoma volume [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/47/43767/abstract/11\">",
"       11",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Presence",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      degree of midline brain shift [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/47/43767/abstract/8,10,11\">",
"       8,10,11",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Reduced patency of the basal cisterns [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/47/43767/abstract/10\">",
"       10",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, some studies have not confirmed these relationships [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43767/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute symptomatic SDH is a neurologic emergency that often requires surgical treatment to prevent irreversible brain injury and death caused by hematoma expansion, elevated intracranial pressure, and brain herniation.",
"   </p>",
"   <p>",
"    The decision between operative or nonoperative management of SDH is based upon multiple factors, including the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43767/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Glasgow coma scale (GCS) score (",
"      <a class=\"graphic graphic_table graphicRef81854 \" href=\"mobipreview.htm?28/62/29676\">",
"       table 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Head CT findings, mainly SDH clot thickness, degree of midline shift, and presence of associated brain lesion",
"     </li>",
"     <li>",
"      Neurologic examination, including pupillary signs",
"     </li>",
"     <li>",
"      Clinical stability or deterioration over time",
"     </li>",
"     <li>",
"      Acuity of SDH",
"     </li>",
"     <li>",
"      Presence and severity of comorbidities and associated trauma",
"     </li>",
"     <li>",
"      Age",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Nonoperative management of acute SDH may be appropriate for clinically stable patients with small hematomas (ie, clot thickness &lt;10 mm), even those with coma, as long as there are no clinical or CT signs of brain herniation (ie, midline shift &lt;5 mm) or elevated intracranial pressure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43767/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;The surgical evacuation of symptomatic acute SDH can be performed by different techniques, including burr hole trephination, craniotomy, and decompressive craniectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43767/abstract/2\">",
"     2",
"    </a>",
"    ]. When indicated, identification and ligation of the bleeding vessel must be undertaken.",
"   </p>",
"   <p>",
"    While there are few studies comparing different surgical methods, limited observational data suggest that craniotomy is associated with better outcomes than burr hole evacuation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43767/abstract/2\">",
"     2",
"    </a>",
"    ]. In a surgical series of 60 patients with SDH, 25 patients underwent craniotomies, 24 were treated with burr holes, eight had craniotomies with dural grafting, and three had decompressive craniectomies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43767/abstract/3\">",
"     3",
"    </a>",
"    ]. In a subgroup of severely affected patients with GCS scores of 4 to 6, patients treated with burr holes had a significantly worse outcome (with increased mortality and decreased functional recovery rates) than those treated with craniotomy.",
"   </p>",
"   <p>",
"    These results should be interpreted with great caution given methodologic limitations of this study, including small patient numbers, nonrandomized treatment allocation, and differences between treatment groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43767/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Timing of surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evidence from observational studies suggests that surgery within two to four hours after the onset of neurologic deterioration in patients with SDH is associated with a lower mortality than delayed surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43767/abstract/1,2,13-15\">",
"     1,2,13-15",
"    </a>",
"    ]. These studies reported mortality rates between 30 and 47 percent if surgery was performed within two to four hours of deterioration, generally characterized by a decreasing GCS score or emergence of new focal findings such as pupillary asymmetry or posturing. However, mortality rates were 80 to 90 percent when intervention was delayed beyond two to four hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43767/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, most studies evaluating the time between injury and surgery have reported no significant relationship with outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43767/abstract/5,8,10,11,16,17\">",
"     5,8,10,11,16,17",
"    </a>",
"    ], and some reports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43767/abstract/3,10,18\">",
"     3,10,18",
"    </a>",
"    ] found that early intervention appeared to have a worse outcome than delayed surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43767/abstract/2\">",
"     2",
"    </a>",
"    ]. However, these data are probably confounded by selection bias, since patients who had immediate surgery tended to have more severe injuries and lower initial GCS scores than those in whom intervention was delayed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43767/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Nonoperative management",
"    </span>",
"    &nbsp;&mdash;&nbsp;No randomized trials have compared surgery with conservative management for patients with SDH, but limited observational data suggest that stable patients with acute SDH who have small hematomas can be managed nonoperatively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43767/abstract/6,19,20\">",
"     6,19,20",
"    </a>",
"    ]. Hematoma enlargement and neurologic deterioration requiring surgery may occur hours to weeks after injury in such patients. Thus, close observation, intracranial pressure monitoring, and serial brain imaging is an important aspect of nonoperative management.",
"   </p>",
"   <p>",
"    Supporting evidence is found in the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a series of 23 conscious patients with acute isolated SDH who were initially managed nonoperatively, six patients deteriorated neurologically and required surgical hematoma evacuation at a mean of 15 days after injury [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/47/43767/abstract/19\">",
"       19",
"      </a>",
"      ]. Compared with those who did not have surgery, patients requiring surgery had significantly larger hematoma volume (53 versus 32 cm^3). An initial hematoma thickness &gt;10 mm was present in all six patients requiring surgery compared with none in the nonoperative group.",
"     </li>",
"     <li>",
"      In a study of 31 patients with traumatic SDH who were initially managed nonoperatively, six experienced neurologic deterioration requiring surgical hematoma evacuation within three days of injury [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/47/43767/abstract/20\">",
"       20",
"      </a>",
"      ]. In a subgroup of patients with a GCS score of &lt;15, midline shift &gt;5 mm on head CT was significantly associated with neurologic worsening, leading to surgery.",
"     </li>",
"     <li>",
"      In another series of 65 comatose patients with acute SDH, 15 patients were selected for nonoperative management because they were clinically stable or improved from the time of injury to evaluation, had hematoma thickness &lt;10 mm and midline shift &lt;5 mm on initial head CT, and had no evidence of uncompensated intracranial pressure elevation with invasive monitoring [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/47/43767/abstract/6\">",
"       6",
"      </a>",
"      ]. Two patients in the nonoperative group had delayed surgical evacuation after developing parenchymal hematomas and intracranial pressure elevation. A functional outcome was achieved in 13 of 50 patients (26 percent) initially treated with surgery and in 10 of 15 patients (67 percent) initially managed nonoperatively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients with traumatic head injury, serial follow-up head CT scans should be obtained during the first 36 hours after injury, as there is a high incidence of clot expansion during this interval [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43767/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. Hematoma expansion may be even more likely when the patient presents with diminished consciousness, a low Glasgow coma scale (GCS) score, or with additional intracranial injuries on CT scan such as mass effect, intraventricular hemorrhage, or epidural hematoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43767/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given these data, we suggest that the first follow-up head CT scan should be obtained within six to eight hours of the initial scan for patients with acute traumatic SDH who are managed nonoperatively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43767/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Deciding who needs surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;The appropriateness and timing of intervention is governed by such factors as the acuity of hemorrhage, initial presentation, neurologic decline, age of the patient, and CT characteristics of the hematoma. The approach to management of SDH may differ for acute and",
"    <span class=\"nowrap\">",
"     subacute/chronic",
"    </span>",
"    SDH.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Acute SDH",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with an acute SDH, clinical status and head CT findings can be used to select those who require emergent surgical decompression from those in whom initial medical management may be appropriate. Age may also influence the decision to perform surgery, as advanced age appears to be a poor prognostic indicator in patients with acute SDH. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Prognostic indicators'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Guidelines from an expert panel published in 2006 recommend surgical evacuation for patients with acute SDH who have clot thickness &gt;10 mm or midline shift &gt;5 mm, regardless of the Glasgow coma scale (GCS) score [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43767/abstract/2\">",
"     2",
"    </a>",
"    ]. In addition, surgery is recommended if the GCS score has decreased by &ge;2 points from the time of injury to hospital admission",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the patient presents with asymmetric or fixed and dilated pupils.",
"   </p>",
"   <p>",
"    The guidelines recommend nonoperative management in an intensive care unit with intracranial pressure monitoring for patients who present with coma (defined as a GCS score &lt;9), provided they are neurologically stable and have clot thickness &lt;10 mm, midline shift &lt;5 mm, no pupillary abnormalities, and no intracranial hypertension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43767/abstract/2\">",
"     2",
"    </a>",
"    ]. Surgery is recommend for these patients if the intracranial pressure is consistently &gt;20 mmHg.",
"   </p>",
"   <p>",
"    The guidelines further recommend that surgery be performed as soon as possible for patients with indications for surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43767/abstract/2\">",
"     2",
"    </a>",
"    ]. Craniotomy is the recommended surgical technique for patients with acute SDH and coma (defined as GCS score &lt;9).",
"   </p>",
"   <p>",
"    Similar to the guidelines, we recommend urgent (within two to four hours) surgical hematoma evacuation for patients with acute SDH and the potential for recovery who are admitted with signs attributable to brain herniation or elevated intracranial pressure, such as asymmetric or fixed and dilated pupils. In addition, we recommend urgent surgical hematoma evacuation for patients with acute SDH, with or without coma, who have evidence of neurologic deterioration since the time of injury, and we suggest urgent surgical hematoma evacuation for patients with clot thickness &ge;10 mm or midline shift &ge;5 mm on initial brain scan.",
"   </p>",
"   <p>",
"    We suggest nonoperative management for patients with acute SDH not meeting these criteria. Thus, nonoperative management is appropriate for patients, with or without coma at presentation, who are clinically stable or improving, have no signs of brain herniation, and have clot thickness &lt;10 mm and midline shift &lt;5 mm on initial head CT. Small asymptomatic SDHs can be managed conservatively without surgery, as these usually resolve spontaneously with gradual absorption over weeks.",
"   </p>",
"   <p>",
"    Patients with diminished consciousness or coma who are managed nonoperatively should be observed in an intensive care unit with intracranial pressure monitoring and serial head CT scans. For such patients, we recommend urgent surgical evacuation if there is clinical evidence of neurologic deterioration, or if intracranial pressure is persistently &gt;20 mmHg.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Chronic SDH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urgent surgical hematoma evacuation is necessary for patients with chronic SDH and the potential for recovery who develop signs attributable to brain herniation or elevated intracranial pressure, such as asymmetric or fixed and dilated pupils.",
"   </p>",
"   <p>",
"    There are no expert guidelines for the management of symptomatic chronic SDH. We recommend surgical evacuation of chronic SDH in patients with potential for recovery if there is evidence of moderate to severe cognitive impairment or progressive neurologic deterioration attributable to the chronic SDH. In addition, we suggest surgical evacuation of chronic SDH in patients with clot thickness &ge;10 mm or midline shift &ge;5 mm on brain scan.",
"   </p>",
"   <p>",
"    Although data are sparse, some authors advocate conservative management for elderly patients with chronic SDH but no evidence of increased ICP, even when the SDH is thought to be causing or contributing to cognitive impairment. In one small series, five patients older than 70 years with chronic SDH following minor head trauma were observed over approximately one month. These patients were clinically characterized by headache and decreased cognition on the Mini Mental Status Exam at the outset of the study. Serial head CT scans revealed complete disappearance or marked reduction in SDH size by 30 to 45 days, and clinical recovery was complete [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43767/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For liquefied chronic SDH that fails to resolve spontaneously, one or more burr holes can be placed to allow drainage of the hematoma. A flexible catheter (Jackson-Pratt drain) is usually placed in the subdural space for several days until the drainage subsides [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43767/abstract/24\">",
"     24",
"    </a>",
"    ]. A randomized, controlled trial found that the use of a drain after burr hole placement prevented SDH recurrence (9 versus 24 percent) and reduced 6-month mortality (9 versus 18 percent) without an excess in medical or surgical complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43767/abstract/25\">",
"     25",
"    </a>",
"    ]. A craniotomy with resection of membranes that surround the clot should be performed to prevent reaccumulation of fluid in cases of chronic SDH that rebleed after burr hole drainage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43767/abstract/26-28\">",
"     26-28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Reversing anticoagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coexistent anticoagulation in patients with either traumatic or spontaneous SDH is not uncommon and must be reversed before surgical intervention. Ideally, anticoagulation should also be reversed for those patients who are managed nonoperatively. However the potential benefit of reversing anticoagulation (a reduced risk of hematoma enlargement) must be weighed against the risk related to the underlying need for anticoagulation in this group (eg, atrial fibrillation, mechanical heart valve). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/8/30857?source=see_link\">",
"     \"Correcting excess anticoagulation after warfarin\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Options for reversal of oral anticoagulant therapy include unactivated prothrombin complex concentrate (PCC, also called factor IX complex),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/42/30373?source=see_link\">",
"     recombinant human factor VIIa",
"    </a>",
"    (rFVIIa), and fresh frozen plasma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43767/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. These agents vary in the onset and duration of their effect, as well as potential complications. They have been better studied for the treatment of anticoagulant-associated intracerebral hemorrhage than for subdural hematoma, but have not been compared to each other in clinical trials for either indication.",
"   </p>",
"   <p>",
"    Our approach to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    reversal is similar to that recommended for patients with intracerebral hemorrhage associated with oral anticoagulant therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/3/10298?source=see_link&amp;anchor=H25#H25\">",
"     \"Management of warfarin-associated intracerebral hemorrhage\", section on 'Initial treatment plan'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Immediate cessation of all anticoagulant and antiplatelet therapy.",
"     </li>",
"     <li>",
"      Infusion of prothrombin complex concentrates (PCC),",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/42/30373?source=see_link\">",
"       recombinant human factor VIIa",
"      </a>",
"      , fresh frozen plasma (FFP). In centers in which PCC is available as well as medical staff familiar with its use and complications, we suggest PCC over factor VIIa or FFP because it provides all of the vitamin-K dependent coagulation factors in a smaller infused volume. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/3/10298?source=see_link&amp;anchor=H26#H26\">",
"       \"Management of warfarin-associated intracerebral hemorrhage\", section on 'Choice of agent'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Vitamin K 10 mg by slow intravenous infusion",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The goal of therapy should be an INR in the normal range (ie, &lt;1.2 in most laboratories).",
"   </p>",
"   <p>",
"    Calculation of the dose of PCC (in International Units) or FFP (in mL) can be estimated based upon the patient's initial INR and body weight. This is outlined in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/8/30857?source=see_link&amp;anchor=H15#H15\">",
"     \"Correcting excess anticoagulation after warfarin\", section on 'Significant or life-threatening bleeding'",
"    </a>",
"    .) The dose of PCC is based on the factor IX content of the preparation; after initial infusion of 500 to 1000 international units at a rate of 100 international",
"    <span class=\"nowrap\">",
"     units/min,",
"    </span>",
"    subsequent infusion of PCC should be at a rate of &le;25 international",
"    <span class=\"nowrap\">",
"     units/min.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Other issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with SDH may develop elevated intracranial pressure requiring urgent intervention. Definitive therapy is usually hematoma evacuation; medical resuscitation techniques include head elevation, hyperventilation, and osmotic diuresis with intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/42/3752?source=see_link\">",
"     mannitol",
"    </a>",
"    . The management of elevated intracranial pressure is reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/39/33402?source=see_link\">",
"     \"Evaluation and management of elevated intracranial pressure in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Glucocorticoid therapy is NOT indicated following head injury, and may be associated with increased acute mortality. This issue is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/39/33402?source=see_link&amp;anchor=H33#H33\">",
"     \"Evaluation and management of elevated intracranial pressure in adults\", section on 'Glucocorticoids'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16777999\">",
"    <span class=\"h1\">",
"     RECURRENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrence of an acute SDH appears to be a relatively rare event and is usually associated with an underlying fixed bleeding source such as a dural arteriovenous malformation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43767/abstract/32\">",
"     32",
"    </a>",
"    ], metastases or intracranial hypotension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43767/abstract/33-35\">",
"     33-35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Recurrence of chronic SDH is more frequently described in 5 to 30 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43767/abstract/36-38\">",
"     36-38",
"    </a>",
"    ]. The use of postoperative drainage is associated with a lower risk of secondary recurrence. Older age, thicker hematoma width, and bilateral presentation have been linked to higher rates of recurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43767/abstract/38-43\">",
"     38-43",
"    </a>",
"    ]. Ongoing antiplatelet and anticoagulant therapy also likely increase the risk of recurrent SDH as has been found with SDH risk in general, although this has not been consistently found [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43767/abstract/42,44,45\">",
"     42,44,45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Whether patients can resume antiplatelet and anticoagulant therapy after SDH is a common question. Clinical decision making relies on analysis of risks and benefits in individual patients, and general recommendations cannot be made. Important considerations include the indication for antiplatelet or anticoagulant therapy. The underlying etiology, severity, and acute versus chronic presentation of SDH also likely impact the risk. As an example, the risk benefit analysis might favor resumption of antiplatelet therapy in a patient with active coronary disease after a SDH related to a traumatic injury that was not likely to recur.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/14/24801?source=see_link\">",
"       \"Patient information: Subdural hematoma (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subdural hematoma (SDH) results from bleeding between the dura and the arachnoid membranes.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The estimated overall mortality rate in patients with acute SDH requiring surgery is 40 to 60 percent. Age and neurologic status, as assessed with the Glasgow coma scale (",
"      <a class=\"graphic graphic_table graphicRef81854 \" href=\"mobipreview.htm?28/62/29676\">",
"       table 1",
"      </a>",
"      ), are important prognostic indicators. Head CT findings that correlate with poor outcome after SDH (in some but not all studies) include hematoma thickness and volume, the presence",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      degree of midline brain shift and reduced patency of the basal cisterns. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Urgent surgical hematoma evacuation is necessary for patients with acute or chronic SDH and the potential for recovery who are admitted with signs attributable to brain herniation or elevated intracranial pressure, such as asymmetric or fixed and dilated pupils. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with acute SDH, with or without coma, who have evidence of neurologic deterioration since the time of injury and the potential for recovery, we recommend urgent surgical hematoma evacuation (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). In addition, we suggest urgent surgical hematoma evacuation rather than nonoperative management for patients with clot thickness &ge;10 mm or midline shift &ge;5 mm on initial brain scan (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We suggest nonoperative management for patients not meeting these criteria (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Thus, nonoperative management is suggested for patients with acute SDH, including those with coma at presentation, who are clinically stable or improving, have no signs of brain herniation, and have clot thickness &lt;10 mm and midline shift &lt;5 mm on initial head CT. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Management'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Acute SDH'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with acute SDH and diminished consciousness or coma who are managed nonoperatively should be observed in an intensive care unit with intracranial pressure monitoring and serial head CT scans. We suggest that the first follow-up head CT scan should be obtained within six to eight hours of the initial scan for patients with acute traumatic SDH. If a nonoperatively managed patient develops clinical signs of neurologic deterioration, or if intracranial pressure is persistently &gt;20 mmHg, we recommend urgent surgical evacuation within two to four hours of deterioration (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Management'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Nonoperative management'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Acute SDH'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with chronic SDH and the potential for recovery, we recommend surgical hematoma evacuation if there is evidence of moderate to severe cognitive impairment or progressive neurologic deterioration attributable to the chronic SDH (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). In addition, we suggest surgical hematoma evacuation rather than nonoperative management if there is clot thickness &ge;10 mm or midline shift &ge;5 mm on brain scan (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Management'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Chronic SDH'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43767/abstract/1\">",
"      Haselsberger K, Pucher R, Auer LM. Prognosis after acute subdural or epidural haemorrhage. Acta Neurochir (Wien) 1988; 90:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43767/abstract/2\">",
"      Bullock MR, Chesnut R, Ghajar J, et al. Surgical management of acute subdural hematomas. Neurosurgery 2006; 58:S16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43767/abstract/3\">",
"      Hatashita S, Koga N, Hosaka Y, Takagi S. Acute subdural hematoma: severity of injury, surgical intervention, and mortality. Neurol Med Chir (Tokyo) 1993; 33:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43767/abstract/4\">",
"      Zumkeller M, Behrmann R, Heissler HE, Dietz H. Computed tomographic criteria and survival rate for patients with acute subdural hematoma. Neurosurgery 1996; 39:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43767/abstract/5\">",
"      Ko&ccedil; RK, Akdemir H, Oktem IS, et al. Acute subdural hematoma: outcome and outcome prediction. Neurosurg Rev 1997; 20:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43767/abstract/6\">",
"      Servadei F, Nasi MT, Cremonini AM, et al. Importance of a reliable admission Glasgow Coma Scale score for determining the need for evacuation of posttraumatic subdural hematomas: a prospective study of 65 patients. J Trauma 1998; 44:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43767/abstract/7\">",
"      Gennarelli TA, Spielman GM, Langfitt TW, et al. Influence of the type of intracranial lesion on outcome from severe head injury. J Neurosurg 1982; 56:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43767/abstract/8\">",
"      Kotwica Z, Brzeziski J. Acute subdural haematoma in adults: an analysis of outcome in comatose patients. Acta Neurochir (Wien) 1993; 121:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43767/abstract/9\">",
"      Hlatky R, Valadka AB, Goodman JC, Robertson CS. Evolution of brain tissue injury after evacuation of acute traumatic subdural hematomas. Neurosurgery 2004; 55:1318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43767/abstract/10\">",
"      Servadei F, Nasi MT, Giuliani G, et al. CT prognostic factors in acute subdural haematomas: the value of the 'worst' CT scan. Br J Neurosurg 2000; 14:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43767/abstract/11\">",
"      Howard MA 3rd, Gross AS, Dacey RG Jr, Winn HR. Acute subdural hematomas: an age-dependent clinical entity. J Neurosurg 1989; 71:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43767/abstract/12\">",
"      van den Brink WA, Zwienenberg M, Zandee SM, et al. The prognostic importance of the volume of traumatic epidural and subdural haematomas revisited. Acta Neurochir (Wien) 1999; 141:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43767/abstract/13\">",
"      Seelig JM, Becker DP, Miller JD, et al. Traumatic acute subdural hematoma: major mortality reduction in comatose patients treated within four hours. N Engl J Med 1981; 304:1511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43767/abstract/14\">",
"      Wilberger JE Jr, Harris M, Diamond DL. Acute subdural hematoma: morbidity, mortality, and operative timing. J Neurosurg 1991; 74:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43767/abstract/15\">",
"      Sakas DE, Bullock MR, Teasdale GM. One-year outcome following craniotomy for traumatic hematoma in patients with fixed dilated pupils. J Neurosurg 1995; 82:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43767/abstract/16\">",
"      Massaro F, Lanotte M, Faccani G, Triolo C. One hundred and twenty-seven cases of acute subdural haematoma operated on. Correlation between CT scan findings and outcome. Acta Neurochir (Wien) 1996; 138:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43767/abstract/17\">",
"      Uzan M, Yent&uuml;r E, Hanci M, et al. Is it possible to recover from uncal herniation? Analysis of 71 head injured cases. J Neurosurg Sci 1998; 42:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43767/abstract/18\">",
"      Dent DL, Croce MA, Menke PG, et al. Prognostic factors after acute subdural hematoma. J Trauma 1995; 39:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43767/abstract/19\">",
"      Mathew P, Oluoch-Olunya DL, Condon BR, Bullock R. Acute subdural haematoma in the conscious patient: outcome with initial non-operative management. Acta Neurochir (Wien) 1993; 121:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43767/abstract/20\">",
"      Wong CW. Criteria for conservative treatment of supratentorial acute subdural haematomas. Acta Neurochir (Wien) 1995; 135:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43767/abstract/21\">",
"      Givner A, Gurney J, O'Connor D, et al. Reimaging in pediatric neurotrauma: factors associated with progression of intracranial injury. J Pediatr Surg 2002; 37:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43767/abstract/22\">",
"      Oertel M, Kelly DF, McArthur D, et al. Progressive hemorrhage after head trauma: predictors and consequences of the evolving injury. J Neurosurg 2002; 96:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43767/abstract/23\">",
"      Parlato C, Guarracino A, Moraci A. Spontaneous resolution of chronic subdural hematoma. Surg Neurol 2000; 53:312.",
"     </a>",
"    </li>",
"    <li>",
"     Mayer, S, Rowland, L. Head injury. In: Merritt's Neurology, Rowland, L (Ed), Lippincott Williams &amp; Wilkins, Philadelphia 2000. p.401.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43767/abstract/25\">",
"      Santarius T, Kirkpatrick PJ, Ganesan D, et al. Use of drains versus no drains after burr-hole evacuation of chronic subdural haematoma: a randomised controlled trial. Lancet 2009; 374:1067.",
"     </a>",
"    </li>",
"    <li>",
"     Victor, M, Ropper, A. Craniocerebral trauma. In: Adams and Victor's Principles of Neurology, 7th ed, Victor, M, Ropper, A (Eds), McGraw-Hill, New York 2001 p.925.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43767/abstract/27\">",
"      Lee JY, Ebel H, Ernestus RI, Klug N. Various surgical treatments of chronic subdural hematoma and outcome in 172 patients: is membranectomy necessary? Surg Neurol 2004; 61:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43767/abstract/28\">",
"      Moon HG, Shin HS, Kim TH, et al. Ossified chronic subdural hematoma. Yonsei Med J 2003; 44:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43767/abstract/29\">",
"      Cartmill M, Dolan G, Byrne JL, Byrne PO. Prothrombin complex concentrate for oral anticoagulant reversal in neurosurgical emergencies. Br J Neurosurg 2000; 14:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43767/abstract/30\">",
"      Vigu&eacute; B, Ract C, Tremey B, et al. Ultra-rapid management of oral anticoagulant therapy-related surgical intracranial hemorrhage. Intensive Care Med 2007; 33:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43767/abstract/31\">",
"      Siddiq F, Jalil A, McDaniel C, et al. Effectiveness of Factor IX complex concentrate in reversing warfarin associated coagulopathy for intracerebral hemorrhage. Neurocrit Care 2008; 8:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43767/abstract/32\">",
"      Maiuri F, Iaconetta G, Sardo L, Briganti F. Dural arteriovenous malformation associated with recurrent subdural haematoma and intracranial hypertension. Br J Neurosurg 2001; 15:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43767/abstract/33\">",
"      Mizuno J, Mummaneni PV, Rodts GE, Barrow DL. Recurrent subdural hematoma caused by cerebrospinal fluid leakage. Case report. J Neurosurg Spine 2006; 4:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43767/abstract/34\">",
"      Garc&iacute;a-Morales I, Porta-Etessam J, Gal&aacute;n L, et al. Recurrent subdural haematomas in a patient with spontaneous intracranial hypotension. Cephalalgia 2001; 21:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43767/abstract/35\">",
"      Schievink WI, Maya MM, Pikul BK, Louy C. Spontaneous spinal cerebrospinal fluid leaks as the cause of subdural hematomas in elderly patients on anticoagulation. J Neurosurg 2010; 112:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43767/abstract/36\">",
"      Santarius T, Qureshi HU, Sivakumaran R, et al. The role of external drains and peritoneal conduits in the treatment of recurrent chronic subdural hematoma. World Neurosurg 2010; 73:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43767/abstract/37\">",
"      Carlsen JG, Cortnum S, S&oslash;rensen JC. Recurrence of chronic subdural haematomata with and without post-operative drainage. Br J Neurosurg 2011; 25:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43767/abstract/38\">",
"      Yu GJ, Han CZ, Zhang M, et al. Prolonged drainage reduces the recurrence of chronic subdural hematoma. Br J Neurosurg 2009; 23:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43767/abstract/39\">",
"      Escosa Ba&eacute; M, Wessling H, Salca HC, de Las Heras Echeverr&iacute;a P. Use of twist-drill craniostomy with drain in evacuation of chronic subdural hematomas: independent predictors of recurrence. Acta Neurochir (Wien) 2011; 153:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43767/abstract/40\">",
"      Oh HJ, Lee KS, Shim JJ, et al. Postoperative course and recurrence of chronic subdural hematoma. J Korean Neurosurg Soc 2010; 48:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43767/abstract/41\">",
"      Kung WM, Hung KS, Chiu WT, et al. Quantitative assessment of impaired postevacuation brain re-expansion in bilateral chronic subdural haematoma: possible mechanism of the higher recurrence rate. Injury 2012; 43:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43767/abstract/42\">",
"      Torihashi K, Sadamasa N, Yoshida K, et al. Independent predictors for recurrence of chronic subdural hematoma: a review of 343 consecutive surgical cases. Neurosurgery 2008; 63:1125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43767/abstract/43\">",
"      Yamamoto H, Hirashima Y, Hamada H, et al. Independent predictors of recurrence of chronic subdural hematoma: results of multivariate analysis performed using a logistic regression model. J Neurosurg 2003; 98:1217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43767/abstract/44\">",
"      Forster MT, Math&eacute; AK, Senft C, et al. The influence of preoperative anticoagulation on outcome and quality of life after surgical treatment of chronic subdural hematoma. J Clin Neurosci 2010; 17:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43767/abstract/45\">",
"      Lindvall P, Koskinen LO. Anticoagulants and antiplatelet agents and the risk of development and recurrence of chronic subdural haematomas. J Clin Neurosci 2009; 16:1287.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1110 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-D4C8FA2A70-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_47_43767=[""].join("\n");
var outline_f42_47_43767=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Prognostic indicators",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Timing of surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Nonoperative management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Deciding who needs surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Acute SDH",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Chronic SDH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Reversing anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Other issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16777999\">",
"      RECURRENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/1110\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/1110|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?28/62/29676\" title=\"table 1\">",
"      Glasgow coma scale",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/8/30857?source=related_link\">",
"      Correcting excess anticoagulation after warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/39/33402?source=related_link\">",
"      Evaluation and management of elevated intracranial pressure in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/42/19112?source=related_link\">",
"      Intracranial epidural hematoma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/3/10298?source=related_link\">",
"      Management of warfarin-associated intracerebral hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/14/24801?source=related_link\">",
"      Patient information: Subdural hematoma (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/49/6936?source=related_link\">",
"      Subdural hematoma in adults: Etiology, clinical features, and diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_47_43768="Pretreatment evaluation and prognosis of acute myeloid leukemia in older adults";
var content_f42_47_43768=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pretreatment evaluation and prognosis of acute myeloid leukemia in older adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/47/43768/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/47/43768/contributors\">",
"     Richard A Larson, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/47/43768/contributors\">",
"     Heidi D Klepin, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/47/43768/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/47/43768/contributors\">",
"     Bob Lowenberg, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/47/43768/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/47/43768/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?42/47/43768/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H15842800\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with acute myeloid leukemia (AML), treatment regimens and outcomes may differ among younger and older adults. Although there is no clear dividing line when considering age in AML, in most studies \"older adults\" was defined as over age 60.",
"   </p>",
"   <p>",
"    The management of older patients with AML is a difficult challenge [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43768/abstract/1\">",
"     1",
"    </a>",
"    ]. Older adults are more likely to have impaired functional status and comorbidities that can limit treatment options; the disease also tends to be more aggressive biologically; thus, outcomes are considerably worse than in younger patients.",
"   </p>",
"   <p>",
"    This topic review will discuss the pretreatment evaluation and prognosis of older adults with AML. The following topics are presented separately:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The treatment of older adults with AML (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/29/29146?source=see_link\">",
"       \"Treatment of acute myeloid leukemia in older adults\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      The treatment of adults of any age with acute promyelocytic leukemia (FAB M3 AML) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/11/28858?source=see_link\">",
"       \"Initial treatment of acute promyelocytic leukemia in adults\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      The treatment of adults of any age with therapy-related AML (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/35/39480?source=see_link\">",
"       \"Therapy-related myeloid neoplasms: Acute myeloid leukemia and myelodysplastic syndrome\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      The treatment of younger adults with AML (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/41/30362?source=see_link\">",
"       \"Induction therapy for acute myeloid leukemia in younger adults\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Special considerations for the use of chemotherapy in older patients (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/42/10922?source=see_link\">",
"       \"Systemic chemotherapy for cancer in elderly persons\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6273162\">",
"    <span class=\"h1\">",
"     OUTCOMES IN OLDER COMPARED WITH YOUNGER PATIENTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6273184\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;Overall survival rates for AML decrease as age increases (",
"    <a class=\"graphic graphic_figure graphicRef75742 \" href=\"mobipreview.htm?41/60/42950\">",
"     figure 1",
"    </a>",
"    ). Most series of older patients with newly diagnosed AML have noted complete remission (CR) rates between 40 and 60 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43768/abstract/2-11\">",
"     2-11",
"    </a>",
"    ]. While suitably selected older patients given aggressive induction therapy may achieve CR at a rate approximating that of younger patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43768/abstract/6\">",
"     6",
"    </a>",
"    ], others may spend a significant proportion of their remaining life in a hospital setting receiving treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43768/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Registry data indicate that the median age for patients with AML is approximately 68 years old, more than a decade older than the median age of patients reported on clinical trials. Case series from large referral institutions suggest that 25 to 50 percent of patients with AML who are older than 60 years are not offered intensive remission induction chemotherapy.",
"   </p>",
"   <p>",
"    Older age, defined in most studies as over age 55, 60, or 65, is a poor prognostic factor in AML. Such patients have, in comparison with younger patients, more difficult to treat disease as evidenced by the following characteristics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43768/abstract/2,14\">",
"     2,14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Lower percentage of favorable cytogenetics",
"     </li>",
"     <li>",
"      Higher percentage of unfavorable cytogenetics",
"     </li>",
"     <li>",
"      Higher incidence of multidrug resistance",
"     </li>",
"     <li>",
"      Higher incidence of treatment-resistant disease",
"     </li>",
"     <li>",
"      Lower complete remission rates, shorter remission durations, and shorter median overall survival",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Older adults are also more likely to have comorbidities and a poorer performance status that increase treatment-related morbidity and mortality, and limit intensive treatments such as allogeneic hematopoietic cell transplantation. Although age is one of the most important predictors of treatment-related mortality (TRM, eg, 30-day mortality), it is likely not an independent variable and largely acts as an indirect measure of other prognostic factors. This was best shown in an analysis of 3365 adults with newly diagnosed AML that created a scoring system to estimate TRM based upon age, sex,",
"    <span class=\"nowrap\">",
"     race/ethnicity,",
"    </span>",
"    performance status, laboratory features, and the presence or absence of secondary AML [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43768/abstract/15\">",
"     15",
"    </a>",
"    ]. The ability of the scoring system to predict TRM was similar whether or not age was incorporated. As such, older age by itself is not a contraindication to treatment.",
"   </p>",
"   <p>",
"    An analysis of Medicare claims for 2657 older patients with AML diagnosed between 1991 and 1996 underscored the grim prognosis for AML in the older patient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43768/abstract/16\">",
"     16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Median survival for all patients was two months, with a two-year overall survival of 6 percent. For patients &ge;85 years of age, median survival was only one month.",
"     </li>",
"     <li>",
"      Only 30 percent of patients received chemotherapy; when compared with those not receiving chemotherapy, they tended to be younger (average age 73 versus 78 years) and live longer (median survival seven versus one month).",
"     </li>",
"     <li>",
"      Of those older patients dying from AML during the follow-up period of the study (94 percent of the sample), 31 percent of their remaining days had been spent in an inpatient facility.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The outcomes might be better if more patients were offered induction chemotherapy. A retrospective analysis of 2767 patients with non-APL AML from the Swedish acute leukemia registry reported that early death rates (ie, death within 30 days of diagnosis) were considerably lower in patients receiving intensive induction chemotherapy when compared with those who received palliative therapy, even when stratified for performance status; it remains possible, however, that patients with a better prognosis were more likely to be offered induction chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43768/abstract/3,17\">",
"     3,17",
"    </a>",
"    ]. The difference between 30-day mortality rates for the two groups ranged from 16 to 35 percent. Patients who had de novo AML, were \"fit\" for intensive chemotherapy, had an ECOG performance status of zero to 2, and were age 16 to 55, 56 to 65, 66 to 75, and 76 to 89 had median overall survival times of 7 years, 18 months, 14 months, and 6 months, respectively.",
"   </p>",
"   <p>",
"    In addition, a study of 103 newly diagnosed patients with AML who received intensive chemotherapy suggested that the impact of treatment on quality of life and physical function (both self-reported and objectively measured) was similar between younger (range 21 to 59 years) and older (60 to 80 years) patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43768/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6273191\">",
"    <span class=\"h2\">",
"     Prognostic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of risk factors have been identified that occur more frequently in the older patient and appear to contribute to the worse outcome (",
"    <a class=\"graphic graphic_table graphicRef60295 \" href=\"mobipreview.htm?17/14/17643\">",
"     table 1",
"    </a>",
"    ). The major independent prognostic factors in older adults with AML are [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43768/abstract/4,6,19-23\">",
"     4,6,19-23",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Age",
"     </li>",
"     <li>",
"      Cytogenetic abnormalities and point mutations",
"     </li>",
"     <li>",
"      Poor performance status",
"     </li>",
"     <li>",
"      Secondary leukemia (ie, after an antecedent hematologic disorder)",
"     </li>",
"     <li>",
"      Therapy-related leukemia",
"     </li>",
"     <li>",
"      White blood cell count at diagnosis",
"     </li>",
"     <li>",
"      Multidrug resistance-1 (P-glycoprotein) expression",
"     </li>",
"     <li>",
"      CD34 expression",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The effects of age, performance status, and comorbid conditions are discussed below, while prognostic factors common to all age groups (eg, cytogenetics, secondary leukemia) are presented in more detail separately. (See",
"    <a class=\"local\" href=\"#H15843351\">",
"     'Physical functioning'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H15843372\">",
"     'Comorbid conditions'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/55/36730?source=see_link\">",
"     \"Prognosis of acute myeloid leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The cytogenetic abnormalities most often associated with treatment failure in young patients with AML (eg, abnormalities of chromosomes 5 or 7 or complex karyotypes) are considerably more common in older patients, occurring in 32 to 57 percent of patients in two series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43768/abstract/21,24-27\">",
"     21,24-27",
"    </a>",
"    ]. Conversely, all of the \"favorable\" cytogenetic abnormalities, such as t(8;21), t(15;17), or inv(16), are more common in younger subjects and are responsible in part for their better disease-free survival (",
"    <a class=\"graphic graphic_figure graphicRef65190 \" href=\"mobipreview.htm?16/13/16606\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43768/abstract/26-32\">",
"     26-32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/55/36730?source=see_link&amp;anchor=H649833183#H649833183\">",
"     \"Prognosis of acute myeloid leukemia\", section on 'Older adults'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Preliminary data are available on the impact of recurring gene mutations in younger and older adults with AML. Mutations of",
"    <em>",
"     NPM1",
"    </em>",
"    remain favorable for outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43768/abstract/33\">",
"     33",
"    </a>",
"    ], whereas mutations of",
"    <em>",
"     FLT3",
"    </em>",
"    ,",
"    <em>",
"     ASXL1",
"    </em>",
"    , and",
"    <em>",
"     DNMT3A",
"    </em>",
"    have been associated with poor outcomes over the age of 60 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43768/abstract/34-37\">",
"     34-37",
"    </a>",
"    ]. Expression levels of MN1 and BAALC and mutations in",
"    <em>",
"     WT1",
"    </em>",
"    have also been investigated in older AML patients. This is an emerging area in development with new genomic biomarkers continuing to become available. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/55/36730?source=see_link&amp;anchor=H9#H9\">",
"     \"Prognosis of acute myeloid leukemia\", section on 'Gene mutations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A",
"    <a class=\"external\" href=\"file://www.aml-score.org/\">",
"     web-based application",
"    </a>",
"    has been proposed by the German Acute Myeloid Leukaemia Cooperative Group for predicting the chance of achieving a complete remission and the risk of early death within 60 days after intensive induction therapy in patients 60 years or older with previously untreated AML [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43768/abstract/38\">",
"     38",
"    </a>",
"    ]. This tool was devised using data from 1406 older adults with AML who were otherwise healthy and were treated in the context of a clinical trial with two courses of intensive induction chemotherapy. The application was validated with an independent cohort of 801 older adults with AML treated with two courses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/15/43254?source=see_link\">",
"     daunorubicin",
"    </a>",
"    in another prospective trial. The application uses a complicated formula that incorporates data on body temperature, hemoglobin, platelet count, LDH, age, type of AML (de novo or secondary), fibrinogen level, and molecular and cytogenetic features. Using this score, the predicted likelihood of complete remission ranged from 12 to 91 percent if cytogenetic information were available to be incorporated and from 21 to 80 percent if cytogenetic information were not available.",
"   </p>",
"   <p>",
"    Additional prognostic models for older adults with AML have been proposed that incorporate chronologic age, cytogenetic information, and clinical variables. One study evaluated 446 patients &ge;70 years of age who received intensive induction therapy and identified age &ge;80 years, complex karyotype (&ge;3 abnormalities), poor performance status (ECOG score &gt;1), and elevated creatinine as independent risk factors for early mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43768/abstract/39\">",
"     39",
"    </a>",
"    ]. Estimated eight-week mortality rates were 16, 31, 55, and 71 percent for patients with none, 1, 2 or &ge;3 characteristics, respectively. Data from the prospective AML96 trial, which enrolled 909 older adults (range 61 to 87 years) for intensive therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    -based induction, was used to construct a predictive model for overall survival (OS). In multivariable analyses, karyotype, age (&ge;65 years), NPM1 mutation status, white blood cell count, lactate dehydrogenase level, and CD34 expression were associated with OS. A weighted risk score based on the presence of these characteristics was able to stratify patients with intermediate risk karyotype into a &ldquo;good&rdquo; intermediate risk group versus &ldquo;adverse&rdquo; intermediate risk group with estimated OS at three years of 30 and 11 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43768/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15843336\">",
"    <span class=\"h1\">",
"     PRETREATMENT EVALUATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15843344\">",
"    <span class=\"h2\">",
"     General",
"    </span>",
"    &nbsp;&mdash;&nbsp;The assessment of an older adult with AML includes those studies used for the pretreatment evaluation of younger adults with AML in addition to more specific investigations of physical functioning, and comorbid conditions. Testing specific for older adults is presented in the following sections. The detailed pretreatment evaluation of all patients with AML is presented separately, as is an overview of the comprehensive geriatric assessment of cancer patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/41/30362?source=see_link&amp;anchor=H2#H2\">",
"     \"Induction therapy for acute myeloid leukemia in younger adults\", section on 'Pretreatment evaluation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/56/41864?source=see_link\">",
"     \"Comprehensive geriatric assessment for patients with cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15843351\">",
"    <span class=\"h2\">",
"     Physical functioning",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient's performance status and ability to perform activities of daily living are measures of physical function that can help predict the ability to withstand rigorous chemotherapy regimens.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15843358\">",
"    <span class=\"h3\">",
"     Performance status",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have supported the use of the Eastern Cooperative Oncology Group (ECOG) and Karnofsky performance status as measures of physical functioning and prognosis in patients with AML (",
"    <a class=\"graphic graphic_table graphicRef72901 graphicRef58785 \" href=\"mobipreview.htm?42/57/43932\">",
"     table 2A-B",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/55/36730?source=see_link&amp;anchor=H4#H4\">",
"     \"Prognosis of acute myeloid leukemia\", section on 'Performance status'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A retrospective study of data from five Southwestern Oncology Group (SWOG) trials that included 968 patients with AML found that the mortality rate within 30 days of initiation of induction therapy is dependent upon both the patient's age and ECOG performance status (PS) at diagnosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/47/43768/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Thirty-day mortality rates were 2 to 3 percent for patients under the age of 55 years regardless of the PS.",
"     </li>",
"     <li>",
"      For patients over age 55 years, mortality rates ranged from 5 to 18 percent for patients with a PS of zero or 1. Patients 55 to 65 years old with a PS of 2 had a similar mortality rate (18 percent).",
"     </li>",
"     <li>",
"      Patients over age 55 years with a PS of 3 and those over age 65 with a PS of 2 or 3 had much higher mortality rates that ranged from 29 to 82 percent.",
"     </li>",
"     <li>",
"      The proportion of patients with poorer performance status increased with age. PS of 2 or 3 was observed in 15, 24, 26, and 32 percent in those under age 56, 56 to 65, 66 to 75, and &gt;75 years of age, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A second retrospective analysis of 998 patients age 65 or greater (range 65 to 89; median 71 years) who underwent intensive induction chemotherapy reported eight-week mortality rates of 23, 40, and 72 percent for patients with ECOG PS of zero to 1, 2, and 3 to 4, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/47/43768/abstract/12\">",
"       12",
"      </a>",
"      ]. One-year overall survival rates for the same groups were 35, 25, and 7 percent, respectively.",
"     </li>",
"     <li>",
"      A third retrospective study of 2767 patients with non-APL AML from the Swedish acute leukemia registry also reported that older patients with an ECOG PS of zero to 1 had 30-day death rates after intensive chemotherapy of less than 15 percent, while patients with a PS of 3 or 4 had higher early death rates regardless of patient age ranging from 26 to 36 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/47/43768/abstract/3\">",
"       3",
"      </a>",
"      ]. Seventy percent of patients up to age 80 years had a PS of zero to 2. Of note, there were some long term survivors in all age and PS groups.",
"     </li>",
"     <li>",
"      A prospective trial of induction chemotherapy with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/15/43254?source=see_link\">",
"       daunorubicin",
"      </a>",
"      in 813 older adults (median age 67 years, range 60 to 83 years) with ECOG PS of zero to 2 reported a 30-day mortality rate of 11 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/47/43768/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Together, these studies demonstrate that these measures of performance status provide prognostic information in older adults with AML. However, older adults commonly have impairments that are not adequately reflected in the performance status. This was best demonstrated in a single-institution feasibility study of an inpatient geriatric assessment in 54 patients with newly diagnosed AML &gt;60 years (median age 70.8 years) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43768/abstract/41\">",
"     41",
"    </a>",
"    ]. Among the 38 patients with an ECOG PS &le;1, additional testing revealed the following impairments in a substantial proportion of patients: depression (26 percent), distress (50 percent), impairment in instrumental activities of daily living (24 percent), impairment in activities of daily living (34 percent), objectively measured physical impairment (31 percent), cognitive impairment (24 percent), and comorbidity (40 percent). Studies investigating the prognostic significance of individual geriatric assessment domains are described below. The prognostic value of comprehensive geriatric assessment among older adults with AML is under investigation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15843365\">",
"    <span class=\"h3\">",
"     Activities of daily living",
"    </span>",
"    &nbsp;&mdash;&nbsp;Geriatricians commonly measure functional status by evaluating basic activities of daily living (ADLs) and instrumental activities of daily living (IADLs). ADLs are the skills that are necessary for basic living, and include feeding, grooming, transferring, and toileting. IADLs are required to live independently in the community and include activities such as shopping, managing finances, housekeeping, preparing meals, and taking medications. Assessment of ADLs and IADLs may add to the functional status obtained from the ECOG or Karnofsky performance status [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43768/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A study in general oncology patients found that a significant number of older adults (&ge;65 years) with an ECOG performance status (PS) less than 2 had limitations of ADL and IADL (9 and 38 percent of patients, respectively) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/47/43768/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A prospective trial of 63 adults (age 19 to 85) with newly diagnosed AML measured Karnofsky performance status (KPS) and IADL at diagnosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/47/43768/abstract/43\">",
"       43",
"      </a>",
"      ]. Impaired KPS (&lt;80 percent) and impaired IADLs were noted in 33 and 25 percent of patients, respectively. Impairment in IADLs was associated with decreased rates of overall survival independent of age and KPS. However, fewer patients with IADL limitations received intensive chemotherapy compared with those without IADL limitations (46 versus 93 percent, respectively).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15843372\">",
"    <span class=\"h2\">",
"     Comorbid conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Comorbid conditions are poor prognostic factors in older patients with AML [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43768/abstract/5,19,20\">",
"     5,19,20",
"    </a>",
"    ]. Patients with age-related chronic cardiac, pulmonary, hepatic or renal disorders or diabetes suffer greater acute toxicity from chemotherapy.",
"   </p>",
"   <p>",
"    Older patients may also have decreased bone marrow regenerative capacity, even after successful leukemia cytoreduction. Inability to tolerate long periods of pancytopenia and malnutrition or the nephrotoxicity of drugs, such as aminoglycosides or amphotericin, remains a major barrier to successful treatment.",
"   </p>",
"   <p>",
"    Frequently used measures of comorbidity include a modified Charlson comorbidity index (CCI) and the hematopoietic cell transplantation-specific comorbidity index (HCT-CI), neither of which was originally designed for older adults with AML.",
"   </p>",
"   <p>",
"    Other comorbidity scores have incorporated information on infections prior to treatment and antecedent hematologic disorders. Assessment of other patient-related variables (eg, advanced age, performance status, organ function, karyotype, leukocytosis, CD34 expression) with or without a modified comorbidity index may be helpful for predicting such outcomes as attainment of complete remission, early mortality, and overall survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43768/abstract/3,6,12,15,44\">",
"     3,6,12,15,44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/55/36730?source=see_link\">",
"     \"Prognosis of acute myeloid leukemia\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H6273191\">",
"     'Prognostic factors'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15843379\">",
"    <span class=\"h3\">",
"     Charlson comorbidity index",
"    </span>",
"    &nbsp;&mdash;&nbsp;The original Charlson comorbidity index (CCI) was devised as a measure of comorbidities in older adults. A revised version has been developed for use in older adults with AML with mixed results (",
"    <a class=\"graphic graphic_table graphicRef65323 \" href=\"mobipreview.htm?4/45/4828\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A retrospective study evaluated the use of this modified CCI in 133 patients age 70 or older who received induction chemotherapy for AML [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/47/43768/abstract/44\">",
"       44",
"      </a>",
"      ]. CCI scores of zero, 1, and more than 1 were seen in 68, 13, and 19 percent of patients, respectively. When compared with those with a CCI score of 1 or less, patients with a CCI score greater than 1 had a significantly lower rate of obtaining a complete response (35 versus 63 percent) and had a nonsignificant trend towards higher eight-week mortality rates (30 versus 19 percent) and lower two-year overall survival (24 versus 30 percent).",
"     </li>",
"     <li>",
"      A second retrospective study evaluated the use of the CCI in 92 patients age 80 or above with newly diagnosed AML offered induction chemotherapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/47/43768/abstract/45\">",
"       45",
"      </a>",
"      ]. Intensive therapy was given to 64 percent while the remainder elected supportive care. CCI scores of zero, 1, and greater than 1 were seen in 24, 31, and 45 percent, respectively. Patients with a CCI score greater than one had a similar median survival when compared with those with a CCI score of zero or 1 whether they received supportive care (1.6 versus 1.6 months) or intensive chemotherapy (3.3 versus 4.4 months).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15843386\">",
"    <span class=\"h3\">",
"     HCT comorbidity index",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hematopoietic cell transplantation specific comorbidity index (HCT-CI) was designed to predict outcomes in younger adults undergoing hematopoietic cell transplantation (HCT) (",
"    <a class=\"graphic graphic_table graphicRef59272 \" href=\"mobipreview.htm?7/48/7950\">",
"     table 4",
"    </a>",
"    ). It has had mixed results in predicting outcome in older adults with AML.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A retrospective study of 177 patients over 60 years of age receiving induction chemotherapy for AML reported HCT-CI scores of zero, 1 to 2, and greater than 2 in 22, 30, and 48 percent of patients, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/47/43768/abstract/46\">",
"       46",
"      </a>",
"      ]. Corresponding early death rates were 3, 11, and 29 percent, respectively. The same groups had median overall survival times of 45, 31, and 19 weeks, respectively.",
"     </li>",
"     <li>",
"      A second retrospective study evaluated the use of the HCT-CI in 92 patients age 80 or above with newly diagnosed AML offered induction chemotherapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/47/43768/abstract/45\">",
"       45",
"      </a>",
"      ]. Intensive therapy was given to 64 percent while the remainder elected supportive care. HCT-CI scores of zero to 1, 2 to 3, and 4 or greater were seen in 20, 35, and 45 percent, respectively. Patients with a HCT-CI score greater than 4 had a similar median survival when compared with those with a HCT-CI score of zero or 1 whether they received supportive care (1.9 versus 1.4 months) or intensive chemotherapy (3.5 versus 4.2 months).",
"     </li>",
"     <li>",
"      A third single center study evaluated the prognostic value of HCT-CI among pretreatment risk factors for 145 patients with AML (age 18 to 79) stratified by age [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/47/43768/abstract/47\">",
"       47",
"      </a>",
"      ]. Among patients &ge;55 years of age, higher comorbidity burden (HCT-CI score &ge;3) was the most significant predictor of overall survival and early death. In contrast, karyotype was the best predictor of outcome in the younger group. Treatment administered, however, differed by comorbidity, with more patients with HCT-CI &ge;3 receiving dose attenuated induction therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    More details on the HCT-CI are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/54/34664?source=see_link\">",
"     \"Hematopoietic support after hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5729659\">",
"    <span class=\"h2\">",
"     Cognitive impairment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence and prevalence of cognitive impairment increases with age. Pretreatment cognitive impairment may increase the risk of complications during and after intensive therapy for AML. Cognitive screening may identify patients who are at higher risk for complications, including delirium. Research in this area is still limited.&nbsp;A study of 54 patients with",
"    <span class=\"nowrap\">",
"     AML/myelodysplastic",
"    </span>",
"    syndrome documented impaired performance on a battery of cognitive tests in up to 40 percent of the study population before treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43768/abstract/48\">",
"     48",
"    </a>",
"    ]. Similarly, a second small prospective study detected cognitive impairment in 30.5 percent of patients (mean age 70.8) prior to treatment with intensive induction chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43768/abstract/41\">",
"     41",
"    </a>",
"    ]. Preliminary data suggest that cognitive dysfunction may be associated with survival in this patient population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43768/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15843393\">",
"    <span class=\"h2\">",
"     Family discussions",
"    </span>",
"    &nbsp;&mdash;&nbsp;A discussion with the patient and family members should include a review of the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43768/abstract/50\">",
"     50",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prognostic information allowing them to make informed decisions on the type of treatment to be pursued. Regardless of treatment choice, patients and their family members often report not being offered alternative treatment options and tend to overestimate the chance of cure. Written consent forms required for clinical trials may serve an educational role, even for those who do not desire to enter into a formal study.",
"     </li>",
"     <li>",
"      Implications of the diagnosis and treatment on quality of life, functional independence, and social support.",
"     </li>",
"     <li>",
"      Who has durable power of attorney for health issues if the patient becomes unable to make decisions?",
"     </li>",
"     <li>",
"      Does the patient have an updated will? Do other members of the family know where this information is kept? Will the family have access to adequate funds while the patient is hospitalized?",
"     </li>",
"     <li>",
"      A discussion concerning \"code\" status and the possibility that the patient might need to be transferred to an intensive care unit, with its attendant morbidity and mortality [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/47/43768/abstract/51\">",
"       51",
"      </a>",
"      ]. This should include issues related to \"do not resuscitate\" and \"do not intubate\" orders, such that the patient and family can make properly informed decisions on these matters. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/60/26565?source=see_link\">",
"       \"Ethics in the intensive care unit: Informed consent\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The effect on the patient's employment. Most patients will not be able to return to even part-time work until the completion of induction and consolidation chemotherapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?14/4/14402?source=see_link\">",
"       \"Patient information: Acute myeloid leukemia (AML) (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?37/13/38098?source=see_link\">",
"       \"Patient information: Leukemia in adults (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?33/30/34275?source=see_link\">",
"       \"Patient information: Acute myeloid leukemia (AML) treatment in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15844604\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Older adults with acute myeloid leukemia (AML) have been variably defined in clinical trials to include those patients over age 55, 60, or 65. When compared with younger adults, older adults have more complications with chemotherapy and diminished survival rates. Even so, about half of older adults entered on clinical trials achieve complete remission, and some older adults can attain long term remissions with intensive therapy. (See",
"      <a class=\"local\" href=\"#H6273162\">",
"       'Outcomes in older compared with younger patients'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The pretreatment assessment of an older adult with AML includes those studies used to evaluate younger adults in addition to more specific investigations of physical functioning, and comorbid conditions. (See",
"      <a class=\"local\" href=\"#H15843344\">",
"       'General'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/41/30362?source=see_link&amp;anchor=H2#H2\">",
"       \"Induction therapy for acute myeloid leukemia in younger adults\", section on 'Pretreatment evaluation'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The patient's performance status and ability to perform activities of daily living are measures of physical function that can help predict the ability to withstand rigorous chemotherapy regimens (",
"      <a class=\"graphic graphic_table graphicRef72901 graphicRef58785 \" href=\"mobipreview.htm?42/57/43932\">",
"       table 2A-B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15843351\">",
"       'Physical functioning'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Patients with age-related chronic cardiac, pulmonary, hepatic or renal disorders, or diabetes suffer greater acute toxicity from chemotherapy. Although designed for other populations, a modified Charlson comorbidity index (",
"      <a class=\"graphic graphic_table graphicRef65323 \" href=\"mobipreview.htm?4/45/4828\">",
"       table 3",
"      </a>",
"      ) and the hematopoietic cell transplantation specific comorbidity index (",
"      <a class=\"graphic graphic_table graphicRef59272 \" href=\"mobipreview.htm?7/48/7950\">",
"       table 4",
"      </a>",
"      ) have been studied in older adults with AML and provide an objective measure of disease burden. (See",
"      <a class=\"local\" href=\"#H15843372\">",
"       'Comorbid conditions'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Treatment decisions should be individualized and take into account the age and performance status of the patient and the presence of known adverse risk factors such as cytogenetics. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/29/29146?source=see_link&amp;anchor=H16#H16\">",
"       \"Treatment of acute myeloid leukemia in older adults\", section on 'Selection of therapy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43768/abstract/1\">",
"      Schiffer CA. \"I am older, not elderly,\" said the patient with acute myeloid leukemia. J Clin Oncol 2010; 28:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43768/abstract/2\">",
"      Appelbaum FR, Gundacker H, Head DR, et al. Age and acute myeloid leukemia. Blood 2006; 107:3481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43768/abstract/3\">",
"      Juliusson G, Antunovic P, Derolf A, et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood 2009; 113:4179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43768/abstract/4\">",
"      L&ouml;wenberg B, Ossenkoppele GJ, van Putten W, et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med 2009; 361:1235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43768/abstract/5\">",
"      L&ouml;wenberg B, Suciu S, Archimbaud E, et al. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group. J Clin Oncol 1998; 16:872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43768/abstract/6\">",
"      Estey E. Acute myeloid leukemia and myelodysplastic syndromes in older patients. J Clin Oncol 2007; 25:1908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43768/abstract/7\">",
"      Ferrara F, Annunziata M, Copia C, et al. Therapeutic options and treatment results for patients over 75 years of age with acute myeloid leukemia. Haematologica 1998; 83:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43768/abstract/8\">",
"      Leoni F, Ciolli S, Nozzoli C, et al. Idarubicin in induction treatment of acute myeloid leukemia in the elderly. Haematologica 1997; 82:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43768/abstract/9\">",
"      Juliusson G, H&ouml;glund M, Karlsson K, et al. Increased remissions from one course for intermediate-dose cytosine arabinoside and idarubicin in elderly acute myeloid leukaemia when combined with cladribine. A randomized population-based phase II study. Br J Haematol 2003; 123:810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43768/abstract/10\">",
"      Vey N, Coso D, Bardou VJ, et al. The benefit of induction chemotherapy in patients age &gt; or = 75 years. Cancer 2004; 101:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43768/abstract/11\">",
"      Gardin C, Turlure P, Fagot T, et al. Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial. Blood 2007; 109:5129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43768/abstract/12\">",
"      Kantarjian H, O'brien S, Cortes J, et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer 2006; 106:1090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43768/abstract/13\">",
"      British Committee for Standards in Haematology, Milligan DW, Grimwade D, et al. Guidelines on the management of acute myeloid leukaemia in adults. Br J Haematol 2006; 135:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43768/abstract/14\">",
"      Stone RM. The difficult problem of acute myeloid leukemia in the older adult. CA Cancer J Clin 2002; 52:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43768/abstract/15\">",
"      Walter RB, Othus M, Borthakur G, et al. Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment. J Clin Oncol 2011; 29:4417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43768/abstract/16\">",
"      Menzin J, Lang K, Earle CC, et al. The outcomes and costs of acute myeloid leukemia among the elderly. Arch Intern Med 2002; 162:1597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43768/abstract/17\">",
"      Juliusson G, Lazarevic V, H&ouml;rstedt AS, et al. Acute myeloid leukemia in the real world: why population-based registries are needed. Blood 2012; 119:3890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43768/abstract/18\">",
"      Mohamedali H, Breunis H, Timilshina N, et al. Older age is associated with similar quality of life and physical function compared to younger age during intensive chemotherapy for acute myeloid leukemia. Leuk Res 2012; 36:1241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43768/abstract/19\">",
"      Wahlin A, Markev&auml;rn B, Golovleva I, Nilsson M. Prognostic significance of risk group stratification in elderly patients with acute myeloid leukaemia. Br J Haematol 2001; 115:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43768/abstract/20\">",
"      Wheatley K, Brookes CL, Howman AJ, et al. Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials. Br J Haematol 2009; 145:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43768/abstract/21\">",
"      Leith CP, Kopecky KJ, Godwin J, et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 1997; 89:3323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43768/abstract/22\">",
"      B&uuml;chner T, Berdel WE, Haferlach C, et al. Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group. J Clin Oncol 2009; 27:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43768/abstract/23\">",
"      Valc&aacute;rcel D, Montesinos P, S&aacute;nchez-Ortega I, et al. A scoring system to predict the risk of death during induction with anthracycline plus cytarabine-based chemotherapy in patients with de novo acute myeloid leukemia. Cancer 2012; 118:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43768/abstract/24\">",
"      Bow EJ, Sutherland JA, Kilpatrick MG, et al. Therapy of untreated acute myeloid leukemia in the elderly: remission-induction using a non-cytarabine-containing regimen of mitoxantrone plus etoposide. J Clin Oncol 1996; 14:1345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43768/abstract/25\">",
"      Letendre L, Noel P, Litzow MR, et al. Treatment of acute myelogenous leukemia in the older patient with attenuated high-dose ara-C. Am J Clin Oncol 1998; 21:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43768/abstract/26\">",
"      Schoch C, Kern W, Krawitz P, et al. Dependence of age-specific incidence of acute myeloid leukemia on karyotype. Blood 2001; 98:3500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43768/abstract/27\">",
"      van der Holt B, Breems DA, Berna Beverloo H, et al. Various distinctive cytogenetic abnormalities in patients with acute myeloid leukaemia aged 60 years and older express adverse prognostic value: results from a prospective clinical trial. Br J Haematol 2007; 136:96.",
"     </a>",
"    </li>",
"    <li>",
"     LeBeau MM, Larson RA. Cytogenetics and neoplasia. In: Hematology Basic Principles and Practice, 2nd ed, Hoffman R, Benz EJ Jr, Shattil SJ, et al. (Eds), Churchill Livingstone, New York 1995.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43768/abstract/29\">",
"      Schiffer CA, Lee EJ, Tomiyasu T, et al. Prognostic impact of cytogenetic abnormalities in patients with de novo acute nonlymphocytic leukemia. Blood 1989; 73:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43768/abstract/30\">",
"      Grimwade D, Walker H, Harrison G, et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 2001; 98:1312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43768/abstract/31\">",
"      Moorman AV, Roman E, Cartwright RA, Morgan GJ. Age-specific incidence rates for cytogenetically-defined subtypes of acute myeloid leukaemia. Br J Cancer 2002; 86:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43768/abstract/32\">",
"      Rao AV, Valk PJ, Metzeler KH, et al. Age-specific differences in oncogenic pathway dysregulation and anthracycline sensitivity in patients with acute myeloid leukemia. J Clin Oncol 2009; 27:5580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43768/abstract/33\">",
"      Becker H, Marcucci G, Maharry K, et al. Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study. J Clin Oncol 2010; 28:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43768/abstract/34\">",
"      Marcucci G, Metzeler KH, Schwind S, et al. Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia. J Clin Oncol 2012; 30:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43768/abstract/35\">",
"      Metzeler KH, Becker H, Maharry K, et al. ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category. Blood 2011; 118:6920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43768/abstract/36\">",
"      Whitman SP, Maharry K, Radmacher MD, et al. FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Blood 2010; 116:3622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43768/abstract/37\">",
"      Schwind S, Marcucci G, Kohlschmidt J, et al. Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemia. Blood 2011; 118:4188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43768/abstract/38\">",
"      Krug U, R&ouml;llig C, Koschmieder A, et al. Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes. Lancet 2010; 376:2000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43768/abstract/39\">",
"      Kantarjian H, Ravandi F, O'Brien S, et al. Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. Blood 2010; 116:4422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43768/abstract/40\">",
"      R&ouml;llig C, Thiede C, Gramatzki M, et al. A novel prognostic model in elderly patients with acute myeloid leukemia: results of 909 patients entered into the prospective AML96 trial. Blood 2010; 116:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43768/abstract/41\">",
"      Klepin HD, Geiger AM, Tooze JA, et al. The feasibility of inpatient geriatric assessment for older adults receiving induction chemotherapy for acute myelogenous leukemia. J Am Geriatr Soc 2011; 59:1837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43768/abstract/42\">",
"      Repetto L, Fratino L, Audisio RA, et al. Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology Study. J Clin Oncol 2002; 20:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43768/abstract/43\">",
"      Wedding U, R&ouml;hrig B, Klippstein A, et al. Impairment in functional status and survival in patients with acute myeloid leukaemia. J Cancer Res Clin Oncol 2006; 132:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43768/abstract/44\">",
"      Etienne A, Esterni B, Charbonnier A, et al. Comorbidity is an independent predictor of complete remission in elderly patients receiving induction chemotherapy for acute myeloid leukemia. Cancer 2007; 109:1376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43768/abstract/45\">",
"      Harb AJ, Tan W, Wilding GE, et al. Treating octogenarian and nonagenarian acute myeloid leukemia patients--predictive prognostic models. Cancer 2009; 115:2472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43768/abstract/46\">",
"      Giles FJ, Borthakur G, Ravandi F, et al. The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia. Br J Haematol 2007; 136:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43768/abstract/47\">",
"      Djunic I, Virijevic M, Novkovic A, et al. Pretreatment risk factors and importance of comorbidity for overall survival, complete remission, and early death in patients with acute myeloid leukemia. Hematology 2012; 17:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43768/abstract/48\">",
"      Meyers CA, Albitar M, Estey E. Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome. Cancer 2005; 104:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43768/abstract/49\">",
"      Klepin H, Tooze F, Geiger A, et al. Geriatric assessment predicts overall survival among older adults receiving induction chemotherapy for acute myelogenous leukemia. Blood (ASH Annual Meeting Abstracts) 2010; 116:1535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43768/abstract/50\">",
"      Sekeres MA, Stone RM, Zahrieh D, et al. Decision-making and quality of life in older adults with acute myeloid leukemia or advanced myelodysplastic syndrome. Leukemia 2004; 18:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43768/abstract/51\">",
"      Rabbat A, Chaoui D, Montani D, et al. Prognosis of patients with acute myeloid leukaemia admitted to intensive care. Br J Haematol 2005; 129:350.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 86177 Version 1.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-961E418322-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_47_43768=[""].join("\n");
var outline_f42_47_43768=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15844604\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15842800\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6273162\">",
"      OUTCOMES IN OLDER COMPARED WITH YOUNGER PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6273184\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6273191\">",
"      Prognostic factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15843336\">",
"      PRETREATMENT EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15843344\">",
"      General",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15843351\">",
"      Physical functioning",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15843358\">",
"      - Performance status",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15843365\">",
"      - Activities of daily living",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15843372\">",
"      Comorbid conditions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15843379\">",
"      - Charlson comorbidity index",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15843386\">",
"      - HCT comorbidity index",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5729659\">",
"      Cognitive impairment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15843393\">",
"      Family discussions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15844604\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/86177\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/86177|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?41/60/42950\" title=\"figure 1\">",
"      AML OS by age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?16/13/16606\" title=\"figure 2\">",
"      Survival AML cytogenetic risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/86177|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/14/17643\" title=\"table 1\">",
"      Prognostic factors AML",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/15/9467\" title=\"table 2A\">",
"      ECOG performance scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/11/2236\" title=\"table 2B\">",
"      Karnofsky performance status scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?4/45/4828\" title=\"table 3\">",
"      Modified CCI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/48/7950\" title=\"table 4\">",
"      HCT-CI and CCI",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/56/41864?source=related_link\">",
"      Comprehensive geriatric assessment for patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/60/26565?source=related_link\">",
"      Ethics in the intensive care unit: Informed consent",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/54/34664?source=related_link\">",
"      Hematopoietic support after hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/41/30362?source=related_link\">",
"      Induction therapy for acute myeloid leukemia in younger adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/11/28858?source=related_link\">",
"      Initial treatment of acute promyelocytic leukemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?14/4/14402?source=related_link\">",
"      Patient information: Acute myeloid leukemia (AML) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?33/30/34275?source=related_link\">",
"      Patient information: Acute myeloid leukemia (AML) treatment in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?37/13/38098?source=related_link\">",
"      Patient information: Leukemia in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/55/36730?source=related_link\">",
"      Prognosis of acute myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/42/10922?source=related_link\">",
"      Systemic chemotherapy for cancer in elderly persons",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/35/39480?source=related_link\">",
"      Therapy-related myeloid neoplasms: Acute myeloid leukemia and myelodysplastic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/29/29146?source=related_link\">",
"      Treatment of acute myeloid leukemia in older adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_47_43769="Diffuse panbronchiolitis";
var content_f42_47_43769=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diffuse panbronchiolitis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/47/43769/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/47/43769/contributors\">",
"     Talmadge E King, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/47/43769/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/47/43769/contributors\">",
"     Kevin R Flaherty, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/47/43769/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/47/43769/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?42/47/43769/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diffuse panbronchiolitis (DPB) is a rare clinicopathologic syndrome characterized by bronchiolitis and chronic sinusitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43769/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. In the disease name, &ldquo;diffuse&rdquo; refers to the distribution of the lesions throughout both lungs and &ldquo;pan&rdquo; refers to the pathologic finding that the inflammation involves all layers of the respiratory bronchioles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43769/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The predisposing factors, clinical manifestations, evaluation, diagnosis, and treatment of diffuse panbronchiolitis will be discussed here. The clinical features, diagnosis, and management of other types of bronchiolitis in adults and children are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/43/24247?source=see_link\">",
"     \"Bronchiolitis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/44/16074?source=see_link\">",
"     \"Bronchiolitis in infants and children: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/19/27962?source=see_link\">",
"     \"Bronchiolitis in infants and children: Treatment; outcome; and prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The exact pathogenesis of DPB is not known. A variety of genetic, environmental, and systemic factors appear to contribute.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Genetic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genetic factors are suspected to contribute to the pathogenesis of DPB based on the observation of familial cases and the association of specific human leukocyte antigen (HLA) haplotypes with the disease. In addition to familial cases noted in Japan, it is also common to identify chronic sinusitis without bronchiolitis in first-degree relatives of afflicted individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43769/abstract/3-5\">",
"     3-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Specific HLA haplotypes, such as HLA-B54 in Japan and HLA-A11 in Korea, are associated with the development of DPB [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43769/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. In one report, for example, HLA-B54 was identified in 63 percent of Japanese patients with DPB versus 11 percent of normal Japanese controls (relative risk 13.3) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43769/abstract/5\">",
"     5",
"    </a>",
"    ]. This HLA haplotype has been reported almost exclusively in natives of Japan, China, and Korea, where it is also associated with rheumatoid arthritis and silicosis.",
"   </p>",
"   <p>",
"    The association of particular HLA-A and HLA-B haplotypes with DPB suggests that a disease susceptibility gene might be located between these loci in the MHC class I region on chromosome 6 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43769/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. In a study of this candidate region, affected patients were found to have polymorphisms in two novel mucin-like genes called panbronchiolitis-related mucin-like 1 and 2 (also known as mucin 22 or",
"    <em>",
"     MUC22",
"    </em>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43769/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A separate study similarly suggests a contribution from mucin-related genes. An",
"    <span class=\"nowrap\">",
"     insertion/deletion",
"    </span>",
"    polymorphism of the mucin gene MUC5B on chromosome 11 is associated with DPB [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43769/abstract/9\">",
"     9",
"    </a>",
"    ]. Immunohistochemical staining of lung biopsy samples from patients with DPB demonstrated markedly increased expression of MUC5B-positive secretions in the lower respiratory tract of patients with DPB, compared to normal control samples.",
"   </p>",
"   <p>",
"    Several other candidate genes, including those encoding interleukin (IL)-8 and tumor necrosis factor-alpha have been associated with an increased risk of DPB in small studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43769/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite clinical similarities (eg, sinusitis, bronchiectasis) to the genetic disorder cystic fibrosis (a disease not described in the Japanese population), abnormalities in exocrine function, the cystic fibrosis transmembrane conductance regulator (CFTR) protein, and sweat electrolytes have",
"    <strong>",
"     not",
"    </strong>",
"    been identified in patients with DPB [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43769/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Other factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nongenetic factors have also been considered in the etiology and pathogenesis of DPB.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Environmental cofactors appear to play a role, since DPB is rarely seen in people of Asian ancestry living abroad.",
"     </li>",
"     <li>",
"      The possibility of an underlying systemic disease is suggested by a case report in which DPB recurred in the lung allograft 10 weeks after bilateral lung transplantation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/47/43769/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A potential role for lymphocytes in the pathogenesis of DPB is suggested by the prominence of lymphocytes in and around the bronchioles on histopathology and in the bronchoalveolar lavage fluid (BALF). Macrolide antibiotics, used to treat DPB, significantly reduce the number of lymphocytes and activated CD8+ cells in BALF of patients with DPB, and also increase the",
"      <span class=\"nowrap\">",
"       CD4/CD8",
"      </span>",
"      ratio [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/47/43769/abstract/14\">",
"       14",
"      </a>",
"      ]. These findings suggest activation of CD8+ cells in the airway lumen of DPB patients, further supporting the hypothesis that lymphocytes are important contributors to the bronchial inflammation.",
"     </li>",
"     <li>",
"      BALF also usually shows an increase in the number of neutrophils, although the role of neutrophils in DPB is unclear [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/47/43769/abstract/14-17\">",
"       14-17",
"      </a>",
"      ]. On histopathology, they are not significant components of tissue-based inflammation. It is possible that the presence of neutrophils in the lumen is a response to airway bacterial colonization. Neutrophils may contribute to development of bronchiectasis proximal to the affected bronchioles.",
"     </li>",
"     <li>",
"      Abnormal regulation and expression of human beta-defensins (antimicrobial peptides involved in innate host defense) may play a role in the pathogenesis of DPB. This theory is supported by the finding that patients with DPB have elevated levels of human beta-defensin-1 and -2 in BALF, and increased serum levels of human beta-defensin-2, compared to control subjects [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/47/43769/abstract/17\">",
"       17",
"      </a>",
"      ]. Serum levels of human beta-defensin-2 appear to correlate with disease activity, and therapy with macrolide antibiotics reduced serum human beta-defensin-2 in one small study [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/47/43769/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;DPB occurs mainly among the Japanese and has rarely been reported outside East Asia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43769/abstract/18-21\">",
"     18-21",
"    </a>",
"    ]. However, cases of DPB have been recognized in the United States, Canada, Latin America, and Europe, raising concerns that it might be under-diagnosed in these populations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43769/abstract/22-29\">",
"     22-29",
"    </a>",
"    ]. As clinicians, radiologists, and pathologists become familiar with this entity, the number of cases identified worldwide may substantially increase. The disorder is slightly more prevalent in men (approximately 1.4 to 2:1, male to female ratio) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43769/abstract/2,30\">",
"     2,30",
"    </a>",
"    ]. The majority of patients are nonsmokers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms of DPB typically develop in the second to fifth decade (mean age at presentation 40 years) and are slowly progressive over months to years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43769/abstract/2,20,30\">",
"     2,20,30",
"    </a>",
"    ]. Often patients have failed prior short-term treatment courses with nonmacrolide antibiotics. In case series, the time from onset of symptoms to diagnosis was in the range of one to four years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43769/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Common symptoms and signs at presentation include the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43769/abstract/2,18,30,31\">",
"     2,18,30,31",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Chronic sinusitis, found in at least 75 percent of Japanese patients with DPB, often preceding chest symptoms by years or even decades",
"     </li>",
"     <li>",
"      Cough, usually productive of copious amounts of purulent sputum, exceeding 50",
"      <span class=\"nowrap\">",
"       mL/day",
"      </span>",
"      in half of untreated patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/47/43769/abstract/2\">",
"       2",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Breathlessness with exertion, which usually develops several months after the onset of cough",
"     </li>",
"     <li>",
"      History of wheezing",
"     </li>",
"     <li>",
"      Weight loss, especially when pulmonary symptoms become progressive and severe",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Chest examination may reveal decreased breath sounds, coarse crackles, or wheezes. Clubbing is uncommon.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11948957\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation for possible DPB is typically initiated in adults with a chronic cough, particularly when the cough is productive and the patient is at risk for DPB due to genetic, clinical,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    geographic factors (eg, Asian descent, sinusitis, residence in Asia).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Laboratory testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;No specific laboratory abnormalities are diagnostic for DPB. However, when evaluating patients with chronic sinusitis and lower respiratory tract symptoms, laboratory testing can help identify processes in the differential diagnosis. (See",
"    <a class=\"local\" href=\"#H18301849\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Laboratory testing typically includes the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complete blood and differential cell counts (looking for eosinophilia or abnormal leukocytes that would suggest an alternate diagnosis).",
"     </li>",
"     <li>",
"      Cold agglutinins, which are usually obtained when suspicion for DPB is high due to the clinical setting or radiographic findings, are frequently positive in DPB. However, we do not obtain serologic testing for M pneumoniae, which is typically negative.",
"     </li>",
"     <li>",
"      Serum immunoglobulin levels (to exclude common variable immunodeficiency).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other laboratory testing that may occasionally be appropriate includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Antineutrophil cytoplasmic antibody test (for possible granulomatosis with polyangiitis [Wegener&rsquo;s] or Churg-Strauss syndrome). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/14/21738?source=see_link\">",
"       \"Respiratory tract involvement in granulomatosis with polyangiitis (Wegener's)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/34/27177?source=see_link\">",
"       \"Clinical features and diagnosis of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Genetic testing for mutations in the CFTR gene. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/34/35370?source=see_link&amp;anchor=H29#H29\">",
"       \"Clinical manifestations, pathophysiology, and diagnosis of chronic rhinosinusitis\", section on 'Evaluation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In areas endemic for human T-cell lymphotropic virus type 1 (HTLV-1), a screening enzyme-linked immunosorbent assay (ELISA) is usually obtained due to similar clinical presentations of DPB and HTLV-1-associated bronchiolitis. (See",
"      <a class=\"local\" href=\"#H18301849\">",
"       'Differential diagnosis'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/54/40808?source=see_link&amp;anchor=H22#H22\">",
"       \"Human T-lymphotropic virus type I: Disease associations, diagnosis, and treatment\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In the absence of clinical findings to suggest underlying systemic lupus erythematosus, we do not routinely obtain serology for antinuclear antibodies, although these may be positive at a low level. Similarly, rheumatoid factor may be obtained, as bronchiolitis obliterans associated with rheumatoid arthritis can have a similar radiographic appearance and can rarely precede the onset of frank arthritis. However, rheumatoid factor can be present at a low level in DPB.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Among patients with DPB, the following nonspecific findings may be seen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43769/abstract/2,18,32\">",
"     2,18,32",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Mild peripheral blood neutrophilia",
"     </li>",
"     <li>",
"      Increased serum IgA",
"     </li>",
"     <li>",
"      Positive C-reactive protein",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15291324\">",
"    <span class=\"h2\">",
"     Sputum stain and culture",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with a chronic productive cough, sputum samples are usually obtained for gram stain, acid fast stain, and cultures (including mycobacterial). Sputum cultures have grown",
"    <em>",
"     Haemophilus influenzae",
"    </em>",
"    in 44 percent and",
"    <em>",
"     Pseudomonas aeruginosa",
"    </em>",
"    in 22 percent of patients with DPB [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43769/abstract/2,18\">",
"     2,18",
"    </a>",
"    ]. The frequency of",
"    <em>",
"     P aeruginosa",
"    </em>",
"    can increase to 60 percent after four years of treatment. In early disease,",
"    <em>",
"     Streptococcus pneumoniae",
"    </em>",
"    and",
"    <em>",
"     Moraxella catarrhalis",
"    </em>",
"    may be seen, but less commonly than the above organisms. Mycobacterial cultures are obtained as infection with these organisms is in the differential diagnosis. (See",
"    <a class=\"local\" href=\"#H18301849\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Pulmonary function tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary function tests are obtained in most patients to evaluate whether a patient with a chronic cough or dyspnea has a pattern consistent with asthma or COPD, whether there is a concomitant gas transfer defect, and also to assess the severity of the respiratory impairment.",
"   </p>",
"   <p>",
"    In DPB, an obstructive defect is common [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43769/abstract/25\">",
"     25",
"    </a>",
"    ], although a mixed obstructive-restrictive pattern may also be seen. Patients with DPB exhibit less airway hyperresponsiveness than those with chronic obstructive pulmonary disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43769/abstract/33\">",
"     33",
"    </a>",
"    ]. The diffusing capacity (DLCO) is variably reduced. Hypoxemia is common, while hypercapnia occurs in the terminal stages of the disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;A conventional chest radiograph is typically obtained to evaluate adults with dyspnea and a persistent productive cough. In DPB, the chest radiograph can reveal several different abnormalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43769/abstract/25,34-36\">",
"     25,34-36",
"    </a>",
"    ]. These include normal or hyperinflated lung volumes, diffuse ill-defined nodules up to 3 mm in diameter,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    an increase in bronchovascular markings (reticular \"airway\" pattern). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/62/5096?source=see_link&amp;anchor=H5#H5\">",
"     \"Evaluation of diffuse lung disease by conventional chest radiography\", section on 'Basic patterns'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    High resolution CT (HRCT) scanning is usually obtained to evaluate abnormalities seen on chest radiograph or abnormal gas exchange on pulmonary function testing. In DPB, the HRCT scan may show centrilobular nodular opacities, nodular and linear (tree-in-bud) opacities corresponding to bronchioles with intraluminal mucous plugs (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef63211 \" href=\"mobipreview.htm?4/37/4690\">",
"     image 1",
"    </a>",
"    ), thickened and dilated bronchiolar walls (bronchiolectasis), and, as a late finding, large cystic opacities accompanied by dilated proximal bronchi [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43769/abstract/34-37\">",
"     34-37",
"    </a>",
"    ]. A diffuse pattern, uniformly identifiable throughout the lungs is suggestive of panbronchiolitis, while a focal pattern is more commonly seen with allergic bronchopulmonary aspergillosis, cystic fibrosis, or mycobacterial infection. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/29/16858?source=see_link&amp;anchor=H9#H9\">",
"     \"High resolution computed tomography of the lungs\", section on 'Centrilobular nodules'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/10/12458?source=see_link\">",
"     \"Clinical manifestations and diagnosis of bronchiectasis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Inhomogeneity in lung density, as a result of peripheral air trapping, may also be seen, although this is less common. Expiratory images may enhance the airway trapping due to the obstructed airways. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/29/16858?source=see_link&amp;anchor=H15#H15\">",
"     \"High resolution computed tomography of the lungs\", section on 'Mosaic attenuation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11949590\">",
"    <span class=\"h2\">",
"     Bronchoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bronchoscopy with bronchoalveolar lavage is often performed in patients with centrilobular nodular and tree-in-bud opacities on chest imaging to exclude infection (eg, mycobacterial, nocardial), particularly when the patient is not raising sufficient quantities of sputum for culture. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/41/25239?source=see_link\">",
"     \"Basic principles and technique of bronchoalveolar lavage\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/11/24759?source=see_link\">",
"     \"Overview of nontuberculous mycobacterial infections in HIV-negative patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In DPB, bronchoalveolar lavage findings are nonspecific, as are transbronchial biopsies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43769/abstract/31\">",
"     31",
"    </a>",
"    ]. Cellular analysis of bronchoalveolar lavage fluid (BALF) usually shows increased numbers of lymphocytes and neutrophils, although the presence of neutrophils may be a response to local bacterial superinfection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43769/abstract/15,16,38\">",
"     15,16,38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Transbronchial biopsy is more helpful to identify other processes (eg, hypersensitivity pneumonitis, sarcoidosis), than to secure a diagnosis of DPB. The low sensitivity of transbronchial biopsy for DPB was illustrated in a study of eight patients who underwent transbronchial biopsy prior to a surgical lung biopsy that showed DPB; all eight transbronchial biopsies showed nonspecific inflammation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43769/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H18301849\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Lung biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lung biopsy is often NOT necessary in patients with typical clinical, physiologic, and radiographic features who live in countries where the prevalence of DPB is high. However, for patients living in countries with a low prevalence of DPB and those with atypical features, lung biopsy is typically obtained by video-assisted thoracoscopic surgery or thoracotomy in order to confirm the diagnosis because no other findings are specific for the diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Pathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The histologic lesion of DPB is centered around the respiratory bronchiole and consists of a transmural infiltrate composed of lymphocytes, plasma cells, and distinctive lipid-laden \"foamy\" macrophages, also known as foam cells (",
"    <a class=\"graphic graphic_picture graphicRef77745 \" href=\"mobipreview.htm?40/8/41090\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef57780 \" href=\"mobipreview.htm?31/33/32273\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43769/abstract/23,30,39-41\">",
"     23,30,39-41",
"    </a>",
"    ]. Mucus and acute inflammatory cells fill the lumen of affected airways and alveoli, although the alveolar walls are spared.",
"   </p>",
"   <p>",
"    Narrowing of the lumen of these small airways occurs as the disease progresses. However, obliterative bronchiolitis with submucosal fibrosis is not a prominent feature. Persistent inflammation and superinfection combine to produce secondary ectasia of more proximal bronchioles in advanced disease. Hyperplasia of bronchus-associated lymphoid tissue is also common [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43769/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The panbronchiolitis (PB) lesion (chronic inflammation of membranous and respiratory bronchioles and prominent interstitial foam cells) is a",
"    <strong>",
"     not",
"    </strong>",
"    a specific histologic finding. A PB-like lesion has been reported in pathologic specimens of at least 11 other diseases (eg, constrictive bronchiolitis, follicular bronchiolitis, cystic fibrosis, bronchiectasis, aspiration pneumonia, hypersensitivity pneumonia, bronchocentric granulomatosis) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43769/abstract/41\">",
"     41",
"    </a>",
"    ]. However, when a PB-like lesion is found in these other diseases, the airways with the most marked changes are the proximal membranous bronchioles rather than the respiratory bronchioles. Alternatively, the PB-lesion is a minor finding and other histologic lesions (eg, poorly formed granulomas, lymphoma, vasculitis) lead to the specific diagnosis. Thus, the diagnosis of DPB can be made only in the appropriate clinical setting, with careful histopathologic analysis, and when other conditions have been carefully ruled out [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43769/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11949013\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In countries where DPB is prevalent, a lung biopsy is often not needed to make the diagnosis, and clinical criteria for DPB are used instead [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43769/abstract/32\">",
"     32",
"    </a>",
"    ]. Definite cases should fulfill the first three criteria and at least two of the remaining (",
"    <a class=\"graphic graphic_table graphicRef86536 \" href=\"mobipreview.htm?33/34/34347\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Persistent cough, sputum, and exertional dyspnea",
"     </li>",
"     <li>",
"      History or current symptoms of chronic sinusitis",
"     </li>",
"     <li>",
"      Bilateral, diffuse, small nodular shadows on a plain chest radiograph or centrilobular micronodules on chest CT images",
"     </li>",
"     <li>",
"      Coarse crackles",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       FEV",
"       <sub>",
"        1",
"       </sub>",
"       /FVC",
"      </span>",
"      less than 70 percent and PaO",
"      <sub>",
"       2",
"      </sub>",
"      less than 80 mmHg (10.64 kPa)",
"     </li>",
"     <li>",
"      Titer of cold agglutinins of 64 or greater",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients who reside in an area where DPB is not prevalent, the diagnosis is based on the clinical criteria described above and histopathologic examination of a lung biopsy. The characteristic histopathologic features of DPB are centered on the respiratory bronchiole and consist of a transmural infiltrate composed of lymphocytes, plasma cells, and distinctive lipid-laden \"foamy\" macrophages, also known as foam cells (",
"    <a class=\"graphic graphic_picture graphicRef77745 \" href=\"mobipreview.htm?40/8/41090\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef57780 \" href=\"mobipreview.htm?31/33/32273\">",
"     picture 2",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Pathology'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18301849\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of DPB includes a variety of sinopulmonary processes as well as infectious and inflammatory causes of bronchiolitis, which are more common than DPB outside East Asia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/43/24247?source=see_link\">",
"     \"Bronchiolitis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Granulomatosis with polyangiitis (Wegener&rsquo;s)",
"      </strong>",
"      &ndash; Patients with granulomatosis with polyangiitis (GPA) often have chronic sinusitis and occasionally have bronchiectasis, although the pattern of diffuse centrilobular nodules seen in DPB would be atypical for GPA. In addition, the non-sinopulmonary manifestations of GPA (eg, renal, neurologic, cutaneous) would not be expected in DPB. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/14/21738?source=see_link\">",
"       \"Respiratory tract involvement in granulomatosis with polyangiitis (Wegener's)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Churg-Strauss syndrome",
"      </strong>",
"      &ndash; Patients with the Churg-Strauss syndrome (CSS) typically have a combination of chronic rhinosinusitis and asthma. Migratory pulmonary opacities reflecting acute eosinophilic pneumonia may be seen. Radiographic findings suggestive of bronchiectasis would be unlikely in CSS, although centrilobular nodules have been reported [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/47/43769/abstract/42\">",
"       42",
"      </a>",
"      ]. Peripheral eosinophilia would be a clue to the diagnosis of CSS. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/34/27177?source=see_link&amp;anchor=H14#H14\">",
"       \"Clinical features and diagnosis of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)\", section on 'Evaluation and diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       Aspirin",
"      </a>",
"      <strong>",
"       -exacerbated respiratory disease",
"      </strong>",
"      &ndash; Aspirin-exacerbated respiratory disease (AERD) refers to the combination of asthma, chronic rhinosinusitis with nasal polyposis, and reactions to aspirin ingestion that include bronchospasm and nasal congestion. Chronic sinusitis and obstructive airways disease are common in both AERD and DPB, but other clinical manifestations, such as crackles on physical examination and centrilobular nodules on chest imaging, are atypical in AERD (but characteristic of DPB). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/0/39944?source=see_link&amp;anchor=H14#H14\">",
"       \"Aspirin exacerbated respiratory disease\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Immunodeficiency syndromes",
"      </strong>",
"      &minus; Selective antibody deficiency (polysaccharide non-response) and the various forms of hypogammaglobulinemia typically present with chronic rhinosinusitis and bronchiectasis. Deficiency of immunoglobulins (eg, IgG, IgA, IgM, or IgG subclasses) or lack of specific antibody responses to pneumococcal vaccine will identify the responsible immunodeficiency. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/28/17866?source=see_link\">",
"       \"Clinical manifestations, epidemiology, and diagnosis of common variable immunodeficiency in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Primary ciliary dysplasia",
"      </strong>",
"      &ndash; Primary ciliary dysplasia (PCD) is associated with chronic sinusitis and bronchiectasis like DPB, although the clinical presentation is usually in childhood in PCD. The diagnosis of PCD is made by examination of ciliated epithelium under high speed microscopy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/37/9817?source=see_link\">",
"       \"Primary ciliary dyskinesia (immotile-cilia syndrome)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Cystic fibrosis",
"      </strong>",
"      &ndash; The sinopulmonary manifestations of cystic fibrosis (CF) include chronic sinusitis, chronic productive cough, and as the disease progresses, radiographic findings of peribronchial cuffing, mucous plugging with subsegmental atelectasis, and saccular bronchiectasis. Unlike DPB, patients with CF often have extrapulmonary manifestations: in childhood, failure to thrive, steatorrhea, and meconium ileus are common, while in adulthood, pancreatitis, nonspecific gastrointestinal symptoms, diabetes mellitus, and infertility are common. The diagnosis of CF is made based on sweat chloride results and analysis for mutations in the CF transmembrane regulator (CFTR) gene. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/49/28442?source=see_link\">",
"       \"Cystic fibrosis: Clinical manifestations and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Allergic bronchopulmonary aspergillosis",
"      </strong>",
"      &ndash; Allergic bronchopulmonary aspergillosis (ABPA) typically occurs in patients with asthma or cystic fibrosis. The presentation is usually recurrent episodes of bronchial obstruction, fever, malaise, and expectoration of brownish mucus plugs. The affected airways are typically more central in ABPA (manifest on HRCT), than in DPB. Some patients with ABPA also have allergic fungal rhinosinusitis and nasal polyposis. Peripheral blood eosinophilia and elevation of the total IgE are the typical findings of ABPA that help to differentiate it from DPB. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/48/33545?source=see_link\">",
"       \"Allergic bronchopulmonary aspergillosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/34/35370?source=see_link&amp;anchor=H6#H6\">",
"       \"Clinical manifestations, pathophysiology, and diagnosis of chronic rhinosinusitis\", section on 'Allergic fungal rhinosinusitis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Mycobacterium avium complex",
"      </strong>",
"      &ndash; In non-HIV infected individuals, Mycobacterium avium complex (MAC) lung infection can cause chronic cough, sputum production, and HRCT findings of tree-in-bud opacities and bronchiectasis. Chronic sinusitis is typically absent. The diagnosis of MAC is typically made by sputum acid fast stains and mycobacterial culture. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/11/24759?source=see_link\">",
"       \"Overview of nontuberculous mycobacterial infections in HIV-negative patients\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Sarcoidosis",
"      </strong>",
"      &ndash; Sarcoidosis can present with chronic sinusitis, chronic cough, and radiographic findings of scarring and traction bronchiectasis. A tree-in-bud pattern can be seen on HRCT, but would typically be associated with beading of the interlobular septae. The diagnosis of sarcoidosis is typically made on the basis of granulomas on biopsy specimens from the lung or mediastinal lymph nodes. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/25/21914?source=see_link&amp;anchor=H37#H37\">",
"       \"Clinical manifestations and diagnosis of sarcoidosis\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Inflammatory bowel disease-associated bronchiolitis",
"      </strong>",
"      &ndash; The pathologic finding of panbronchiolitis can also be seen in bronchiolitis associated with inflammatory bowel disease. &nbsp;Panbronchiolitis may precede bowel manifestations in patients with ulcerative colitis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/47/43769/abstract/43\">",
"       43",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Pathology'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/22/29034?source=see_link\">",
"       \"Pulmonary complications of inflammatory bowel disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Obliterative bronchiolitis in rheumatoid arthritis",
"      </strong>",
"      &minus; Considerable overlap exists in the clinical features of DPB and obliterative bronchiolitis associated with rheumatoid arthritis (RA). Both groups of patients typically manifest productive cough, exertional dyspnea, wheezing",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      coarse crackles, but chronic sinusitis is absent in RA [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/47/43769/abstract/44\">",
"       44",
"      </a>",
"      ]. A similar high resolution CT appearance to DPB has been reported in RA [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/47/43769/abstract/45\">",
"       45",
"      </a>",
"      ]. However, the histopathology is different: the primary obstructive lesion is in the respiratory bronchioli in DPB and in the membranous bronchioli and the proximal small bronchi in RA. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/21/26969?source=see_link&amp;anchor=H14#H14\">",
"       \"Overview of lung disease associated with rheumatoid arthritis\", section on 'Obliterative bronchiolitis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Human T-cell lymphotropic virus type 1 associated bronchiolitis",
"      </strong>",
"      &minus; Human T-cell lymphotropic virus type 1 (HTLV-1) infection is endemic in certain parts of Japan and occurs sporadically elsewhere. It has several features in common with DPB, such as radiographic findings (eg, centrilobular nodules, thickening of the bronchovascular bundle, bronchiectasis), bronchoalveolar lavage fluid lymphocytosis, and lymphocytic bronchiolitis on histopathology [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/47/43769/abstract/2,46-50\">",
"       2,46-50",
"      </a>",
"      ]. Identification of HTLV-1-associated bronchiolitis is based on a positive screening enzyme-linked immunosorbent assay (ELISA) with a confirmatory Western blot or polymerase chain reaction (PCR)-based testing to detect proviral DNA in peripheral blood mononuclear cells. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/54/40808?source=see_link&amp;anchor=H22#H22\">",
"       \"Human T-lymphotropic virus type I: Disease associations, diagnosis, and treatment\", section on 'Diagnosis'",
"      </a>",
"      .) &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     TREATMENT AND PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natural history of untreated DPB is characterized by the development of diffuse bronchiectasis, progressive respiratory failure leading to cor pulmonale, and ultimately death over the course of a few years. However, long-term treatment with macrolide antibiotics has markedly improved outcomes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Macrolide antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend using a macrolide antibiotic in all patients diagnosed with DPB, based on the dramatic improvement in prognosis associated with the use of macrolide antibiotics. Nearly 50 percent of untreated patients die within five years of diagnosis and 75 percent after ten years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43769/abstract/32,51,52\">",
"     32,51,52",
"    </a>",
"    ]. In contrast, the use of long-term treatment with macrolide antibiotics has resulted in a greater than 90 percent 10-year survival rate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9578552\">",
"    <span class=\"h3\">",
"     Mechanism of action of macrolides",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanisms by which macrolide antibiotics exert their beneficial effect in DPB may include both antimicrobial and anti-inflammatory effects. In the treatment of DPB, the serum and sputum",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    levels are below the minimum inhibitory concentrations of the common superinfecting organisms, suggesting that antimicrobial effects may be less important than anti-inflammatory effects. In addition, other antibiotics with greater activity against the specific organisms in the sputum (eg, quinolones) had less effect on the overall disease control [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43769/abstract/38\">",
"     38",
"    </a>",
"    ]. On the other hand, novel antimicrobial effects of macrolides, such as impairment of biofilm formation and inhibition of flagellar function of",
"    <em>",
"     P aeruginosa",
"    </em>",
"    , may contribute to the overall efficacy of these agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43769/abstract/53,54\">",
"     53,54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of anti-inflammatory effects are attributed to macrolides. Impairment of neutrophil chemotaxis is a potential antiinflammatory mechanism, based on in vitro, animal, and human studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43769/abstract/15,55\">",
"     15,55",
"    </a>",
"    ]. In addition, macrolides have been shown to [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43769/abstract/16,54,56-61\">",
"     16,54,56-61",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Reduce the level of neutrophil superoxide production, at least partially through augmentation of superoxide dismutase activity",
"     </li>",
"     <li>",
"      Reduce BALF neutrophil-derived elastolytic activity",
"     </li>",
"     <li>",
"      Reduce mucus production by decreasing glycoconjugate secretion",
"     </li>",
"     <li>",
"      Stimulate phagocytosis by alveolar macrophages",
"     </li>",
"     <li>",
"      Enhance lymphocyte apoptosis",
"     </li>",
"     <li>",
"      Reduce the circulating pool of T lymphocytes bearing HLA-DR, a marker of cellular activation",
"     </li>",
"     <li>",
"      Reduced expression of matrix metalloproteinase (MMP)-2 and MMP-9",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Macrolides in general and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    in particular are concentrated intracellularly in alveolar macrophages to levels approximately 400 to 800 fold above serum concentrations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43769/abstract/53\">",
"     53",
"    </a>",
"    ]. Intracellular concentration may enhance both antimicrobial and anti-inflammatory effects and explain why relatively low doses are effective.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18301557\">",
"    <span class=\"h3\">",
"     Erythromycin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/29/36304?source=see_link\">",
"     Erythromycin",
"    </a>",
"    is the drug of first choice in the treatment of DPB, due to the greater clinical experience with it and lower cost. Most patients respond to erythromycin 400 to 600 mg per day [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43769/abstract/2,38,62-65\">",
"     2,38,62-65",
"    </a>",
"    ]. The following studies provide support for the use of erythromycin in the treatment of DPB:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study reported that the long-term administration (average 19.8 months) of oral low-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/29/36304?source=see_link\">",
"       erythromycin",
"      </a>",
"      (600",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      resulted in improvements in dyspnea, body weight, chest radiographic findings, pulmonary function, and arterial oxygen (PaO",
"      <sub>",
"       2",
"      </sub>",
"      ) level [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/47/43769/abstract/62\">",
"       62",
"      </a>",
"      ]. The same group of investigators retrospectively found a significant survival advantage among 63 patients who received erythromycin compared with 24 patients who did not [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/47/43769/abstract/64\">",
"       64",
"      </a>",
"      ]. However, these results do not definitively demonstrate an effect of erythromycin because the study was nonrandomized and most deaths were due to causes other than DPB.",
"     </li>",
"     <li>",
"      Another study showed that an",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/29/36304?source=see_link\">",
"       erythromycin",
"      </a>",
"      dose of 400 to 600 mg daily for more than two months relieved the productive cough and dyspnea, and improved the pulmonary radiographic manifestations in 16 of 19 patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/47/43769/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a case series of patients who had high resolution computed tomography (HRCT) before initiation of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/29/36304?source=see_link\">",
"       erythromycin",
"      </a>",
"      and after three months of therapy found a significant reduction in the extent of small nodular opacities, the severity of peri-airway thickening, and the amount of mucous plugging [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/47/43769/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18301408\">",
"    <span class=\"h3\">",
"     Other macrolides",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients who are unable to tolerate",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    due to an adverse effect and those who are unimproved after several weeks of therapy, an alternate macrolide may be substituted, although data regarding dose and efficacy are limited.",
"   </p>",
"   <p>",
"    In case series, the 14-member ringed",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    (200 to 400 mg orally once per day) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43769/abstract/66-68\">",
"     66-68",
"    </a>",
"    ] and roxithromycin (150 to 300 mg orally once per day) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43769/abstract/69,70\">",
"     69,70",
"    </a>",
"    ] show beneficial effects against DPB [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43769/abstract/32\">",
"     32",
"    </a>",
"    ]. One group treated 10 patients with DPB with clarithromycin 200 mg per day for four years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43769/abstract/67\">",
"     67",
"    </a>",
"    ]. Treatment was associated with clinical improvement that peaked at 6 months in most patients and a significant increase in FEV",
"    <sub>",
"     1",
"    </sub>",
"    at six months. In this study, long-term clarithromycin was not associated with clinically significant side effects.",
"   </p>",
"   <p>",
"    The 15-membered ring macrolide",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    has also been assessed in patients with DPB [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43769/abstract/71-73\">",
"     71-73",
"    </a>",
"    ]. In a case series, azithromycin was administered to 51 patients with DPB, initially at a dose of 500 mg intravenously for one to two weeks, then orally for three months, and then three times a week orally for 6 to 12 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43769/abstract/71\">",
"     71",
"    </a>",
"    ]. Clinical cure was achieved in 27 percent and improvement in 71 percent. The five year survival was 94 percent. In a separate series, azithromycin was administered to 60 patients at a dose of 250 mg twice a week for three months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43769/abstract/72\">",
"     72",
"    </a>",
"    ]. Sputum volume and dyspnea decreased, but details about pulmonary function and radiographic improvements were limited [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43769/abstract/32,72\">",
"     32,72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based on case reports, macrolides with a 16-member ring (eg, josamycin) are ineffective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43769/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18301376\">",
"    <span class=\"h3\">",
"     Duration of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal duration of therapy is unknown, but most patients are treated for a minimum of six months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43769/abstract/2\">",
"     2",
"    </a>",
"    ]. Macrolide therapy is continued until clinical manifestations, radiographic findings, and pulmonary function measurements are improved or stable. In the majority of patients, therapy is stopped after two years. However, in patients with advanced bronchiectasis, therapy is continued indefinitely.",
"   </p>",
"   <p>",
"    After discontinuation of macrolide therapy, patients are monitored clinically for any increase in dyspnea, cough, or sputum production. If symptoms reappear, the patient is evaluated for recurrent DPB or evidence of an intercurrent illness, such as a flare of bronchiectasis or sinusitis. A sputum culture and a chest radiograph are usually obtained. Macrolide therapy is resumed if recurrent DPB is diagnosed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9578907\">",
"    <span class=\"h2\">",
"     Other therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other therapies, such as bronchodilator medications, and bronchial hygiene, may be useful in selected patients. We recommend not using systemic glucocorticoids, due to their adverse effects and lack of evidence of benefit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43769/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Inhaled short-acting beta agonists and anticholinergic agents are sometimes used to promote bronchodilation and reduce bronchorrhea, particularly in patients who do not respond promptly to macrolide therapy and those with bronchiectasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/47/43769/abstract/74\">",
"     74",
"    </a>",
"    ]. Their use is generally empiric and symptom based. Bronchial hygiene measures may be beneficial in patients who have radiographic evidence of bronchiectasis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/11/38073?source=see_link&amp;anchor=H9#H9\">",
"     \"Treatment of bronchiectasis in adults\", section on 'Bronchial hygiene'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5806730\">",
"    <span class=\"h2\">",
"     Exacerbations of bronchiectasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients whose DPB is advanced enough that airway scarring has led to bronchiectasis may periodically develop an exacerbation that is due to bacterial overgrowth rather than recurrent or worsening DPB. These exacerbations may occur during ongoing macrolide therapy or after discontinuation. Exacerbations are usually manifest by an increase in sputum production, more purulent appearing sputum, and dyspnea. Depending on the severity of symptoms and degree of concern for recurrent DPB, a chest radiograph may be needed to exclude recurrent DPB or intercurrent pneumonia.",
"   </p>",
"   <p>",
"    Prompt treatment of exacerbations of bronchiectasis is important to prevent further scarring. The choice of antibiotics should be guided by sputum gram stain and culture results, although it is often difficult to distinguish colonization from infection. Treatment of exacerbations is similar to that for other causes of bronchiectasis and is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/11/38073?source=see_link&amp;anchor=H3#H3\">",
"     \"Treatment of bronchiectasis in adults\", section on 'Acute exacerbation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17733117\">",
"    <span class=\"h2\">",
"     Chronic sinusitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal treatment of chronic rhinosinusitis (CRS) in patients with DPB is not known. Treatment of CRS may help alleviate symptoms such as cough and sputum production. We typically follow the treatment outlined for CRS without nasal polyposis, which includes oral antibiotics (sometimes prolonged macrolide therapy), intranasal glucocorticoids, and sometimes a course of oral glucocorticoids. The management of CRS is described in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/4/30794?source=see_link&amp;anchor=H14#H14\">",
"     \"Management of chronic rhinosinusitis\", section on 'CRS without nasal polyposis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23638431\">",
"    <span class=\"h2\">",
"     Evaluation and diagnosis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Diffuse panbronchiolitis (DPB) is a distinct clinical and pathologic syndrome that involves the upper and lower respiratory tracts. It occurs mainly in Asians (in particular among the Japanese) and has rarely been reported outside East Asia. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The etiology of DPB is unknown; genetic, environmental, and immunologic factors appear to play a role. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      DPB is slightly more prevalent in men; peak incidence is in the second and fifth decades of life (mean age at presentation is 40 years); the majority of patients are nonsmokers. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Common symptoms and signs include chronic sinusitis, cough, wheeze, dyspnea, and weight loss. Chest examination may reveal decreased breath sounds, coarse crackles, or wheezes. Clubbing is uncommon. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      No specific laboratory abnormalities are diagnostic of DPB. In patients with a suggestive clinical picture, we typically obtain a complete cell count and differential, serum cold agglutinins, serum immunoglobulin levels with IgG subclasses, and sputum cultures for respiratory tract organisms. In selected patients, testing for cystic fibrosis and human T-cell lymphotropic virus type 1 (HTLV-1) infection, a rheumatoid factor, and an antineutrophil cytoplasmic antibody may be appropriate. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Laboratory testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pulmonary function tests typically show an obstructive defect, although a mixed obstructive-restrictive pattern may also be seen. Diffusing capacity (DLCO) is variably reduced. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Pulmonary function tests'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The chest radiograph findings in DPB include normal or hyperinflated lung volumes, diffuse ill-defined nodules up to 3 mm in diameter,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      an increase in bronchovascular markings. High resolution computed tomography (HRCT) scanning typically shows centrilobular nodular and linear opacities corresponding to thickened and dilated bronchiolar walls with intraluminal mucous plugs (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef63211 \" href=\"mobipreview.htm?4/37/4690\">",
"       image 1",
"      </a>",
"      ). Inhomogeneity in lung density, due to peripheral air trapping, may also be seen. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Imaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In countries where the prevalence of DPB is high, a lung biopsy is not usually needed, and the diagnosis is based on the presence of specific clinical criteria described above (",
"      <a class=\"graphic graphic_table graphicRef86536 \" href=\"mobipreview.htm?33/34/34347\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Lung biopsy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11949013\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In countries where DPB is infrequent, lung biopsy is generally needed to confirm the clinical suspicion and exclude alternative causes because no noninvasive clinical or radiological findings are sufficiently specific. The characteristic histopathologic features of DPB are centered on the respiratory bronchiole and consist of a transmural infiltrate composed of lymphocytes, plasma cells, and distinctive lipid-laden \"foamy\" macrophages, also known as foam cells (",
"      <a class=\"graphic graphic_picture graphicRef77745 \" href=\"mobipreview.htm?40/8/41090\">",
"       picture 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef57780 \" href=\"mobipreview.htm?31/33/32273\">",
"       picture 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Lung biopsy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Pathology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11949013\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis of DPB includes a variety of sinopulmonary processes as well as infectious and inflammatory causes of bronchiolitis obliterans. These can typically be excluded on the basis of clinical features and routine evaluation. (See",
"      <a class=\"local\" href=\"#H18301849\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21489965\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend using a macrolide antibiotic in all patients diagnosed with DPB (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). The agent of first choice is",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/29/36304?source=see_link\">",
"       erythromycin",
"      </a>",
"      400 to 600",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      due to the greater clinical experience with it. For patients who are unable to tolerate erythromycin or do not improve, alternative macrolides include",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/57/10138?source=see_link\">",
"       clarithromycin",
"      </a>",
"      , roxithromycin, and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Macrolide antibiotics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The optimal duration of therapy is unknown, but most patients are treated for 6 to 24 months. The longer duration of therapy is used in patients with extensive bronchiectasis or a recurrence of disease after cessation of therapy. Occasional patients with recurrent disease need indefinite therapy. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Macrolide antibiotics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Inhaled beta 2 agonists",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      anticholinergic agents may be helpful adjunctive therapy for symptomatic control of cough and sputum production. Systemic glucocorticoids are not beneficial in DPB. (See",
"      <a class=\"local\" href=\"#H9578907\">",
"       'Other therapies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with advanced airway scarring and bronchiectasis due to DPB may experience exacerbations due to bacterial superinfection (without evidence of recurrent DPB) that require treatment with broad-spectrum, as determined by sputum gram stain and culture. (See",
"      <a class=\"local\" href=\"#H5806730\">",
"       'Exacerbations of bronchiectasis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/11/38073?source=see_link&amp;anchor=H3#H3\">",
"       \"Treatment of bronchiectasis in adults\", section on 'Acute exacerbation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The optimal treatment of chronic rhinosinusitis (CRS) in patients with DPB is not known. Treatment of CRS may help alleviate symptoms such as cough and sputum production. We typically follow the treatment outlined for CRS without nasal polyposis which is described separately. (See",
"      <a class=\"local\" href=\"#H17733117\">",
"       'Chronic sinusitis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/4/30794?source=see_link&amp;anchor=H14#H14\">",
"       \"Management of chronic rhinosinusitis\", section on 'CRS without nasal polyposis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43769/abstract/1\">",
"      Poletti V, Chilosi M, Casoni G, Colby TV. Diffuse panbronchiolitis. Sarcoidosis Vasc Diffuse Lung Dis 2004; 21:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43769/abstract/2\">",
"      Poletti V, Casoni G, Chilosi M, Zompatori M. Diffuse panbronchiolitis. Eur Respir J 2006; 28:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43769/abstract/3\">",
"      Suzuki M, Usui K, Tamura N, et al. [Familial cases of diffuse panbronchiolitis (author's transl)]. Nihon Kyobu Shikkan Gakkai Zasshi 1981; 19:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43769/abstract/4\">",
"      Danbara, T, Matsuoki, R, Nukiwa, T, et al. Familial occurrence of diffuse panbronchiolitis accompanied by elevation of cold agglutinin titer in a father and his two daughters. Jpn J Thorac Dis 1982; 20:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43769/abstract/5\">",
"      Sugiyama Y, Kudoh S, Maeda H, et al. Analysis of HLA antigens in patients with diffuse panbronchiolitis. Am Rev Respir Dis 1990; 141:1459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43769/abstract/6\">",
"      Park MH, Kim YW, Yoon HI, et al. Association of HLA class I antigens with diffuse panbronchiolitis in Korean patients. Am J Respir Crit Care Med 1999; 159:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43769/abstract/7\">",
"      Hijikata M, Matsushita I, Tanaka G, et al. Molecular cloning of two novel mucin-like genes in the disease-susceptibility locus for diffuse panbronchiolitis. Hum Genet 2011; 129:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43769/abstract/8\">",
"      Keicho N, Ohashi J, Tamiya G, et al. Fine localization of a major disease-susceptibility locus for diffuse panbronchiolitis. Am J Hum Genet 2000; 66:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43769/abstract/9\">",
"      Kamio K, Matsushita I, Hijikata M, et al. Promoter analysis and aberrant expression of the MUC5B gene in diffuse panbronchiolitis. Am J Respir Crit Care Med 2005; 171:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43769/abstract/10\">",
"      Emi M, Keicho N, Tokunaga K, et al. Association of diffuse panbronchiolitis with microsatellite polymorphism of the human interleukin 8 (IL-8) gene. J Hum Genet 1999; 44:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43769/abstract/11\">",
"      Keicho N, Emi M, Nakata K, et al. Promoter variation of tumour necrosis factor-alpha gene: possible high risk for chronic bronchitis but not diffuse panbronchiolitis. Respir Med 1999; 93:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43769/abstract/12\">",
"      Akai S, Okayama H, Shimura S, et al. Delta F508 mutation of cystic fibrosis gene is not found in chronic bronchitis with severe obstruction in Japan. Am Rev Respir Dis 1992; 146:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43769/abstract/13\">",
"      Baz MA, Kussin PS, Van Trigt P, et al. Recurrence of diffuse panbronchiolitis after lung transplantation. Am J Respir Crit Care Med 1995; 151:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43769/abstract/14\">",
"      Mukae H, Kadota J, Kohno S, et al. Increase in activated CD8+ cells in bronchoalveolar lavage fluid in patients with diffuse panbronchiolitis. Am J Respir Crit Care Med 1995; 152:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43769/abstract/15\">",
"      Ichikawa Y, Ninomiya H, Koga H, et al. Erythromycin reduces neutrophils and neutrophil-derived elastolytic-like activity in the lower respiratory tract of bronchiolitis patients. Am Rev Respir Dis 1992; 146:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43769/abstract/16\">",
"      Oda H, Kadota J, Kohno S, Hara K. Erythromycin inhibits neutrophil chemotaxis in bronchoalveoli of diffuse panbronchiolitis. Chest 1994; 106:1116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43769/abstract/17\">",
"      Hiratsuka T, Mukae H, Iiboshi H, et al. Increased concentrations of human beta-defensins in plasma and bronchoalveolar lavage fluid of patients with diffuse panbronchiolitis. Thorax 2003; 58:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43769/abstract/18\">",
"      Sugiyama Y. Diffuse panbronchiolitis. Clin Chest Med 1993; 14:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43769/abstract/19\">",
"      Kim YW, Han SK, Shim YS, et al. The first report of diffuse panbronchiolitis in Korea: five case reports. Intern Med 1992; 31:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43769/abstract/20\">",
"      Tsang KW, Ooi CG, Ip MS, et al. Clinical profiles of Chinese patients with diffuse panbronchiolitis. Thorax 1998; 53:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43769/abstract/21\">",
"      Chen Y, Kang J, Li S. Diffuse panbronchiolitis in China. Respirology 2005; 10:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43769/abstract/22\">",
"      Poletti V, Patelli M, Poletti G, et al. Diffuse panbronchiolitis observed in an Italian. Chest 1990; 98:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43769/abstract/23\">",
"      Randhawa P, Hoagland MH, Yousem SA. Diffuse panbronchiolitis in North America. Report of three cases and review of the literature. Am J Surg Pathol 1991; 15:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43769/abstract/24\">",
"      Homer RJ, Khoo L, Smith GJ. Diffuse panbronchiolitis in a Hispanic man with travel history to Japan. Chest 1995; 107:1176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43769/abstract/25\">",
"      Fitzgerald JE, King TE Jr, Lynch DA, et al. Diffuse panbronchiolitis in the United States. Am J Respir Crit Care Med 1996; 154:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43769/abstract/26\">",
"      Martinez JA, Guimar&atilde;es SM, Ferreira RG, Pereira CA. Diffuse panbronchiolitis in Latin America. Am J Med Sci 2000; 319:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43769/abstract/27\">",
"      Sandrini A, Balter MS, Chapman KR. Diffuse panbronchiolitis in a Caucasian man in Canada. Can Respir J 2003; 10:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43769/abstract/28\">",
"      Adams NP, Congelton J. Diffuse panbronchiolitis. Eur Respir J 2008; 32:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43769/abstract/29\">",
"      McGrath EE, McLaughlin AM, Fitzgerald MX. Diffuse panbronchiolitis: East meets West. Eur Respir J 2007; 29:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43769/abstract/30\">",
"      Homma H, Yamanaka A, Tanimoto S, et al. Diffuse panbronchiolitis. A disease of the transitional zone of the lung. Chest 1983; 83:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43769/abstract/31\">",
"      Xie GS, Li LY, Liu HR, et al. Diffuse panbronchiolitis with histopathological confirmation among Chinese. Chin Med J (Engl) 2004; 117:1299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43769/abstract/32\">",
"      Kudoh S, Keicho N. Diffuse panbronchiolitis. Clin Chest Med 2012; 33:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43769/abstract/33\">",
"      Koyama H, Nishimura K, Mio T, et al. Bronchial responsiveness and acute bronchodilator response in chronic obstructive pulmonary disease and diffuse panbronchiolitis. Thorax 1994; 49:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43769/abstract/34\">",
"      Akira M, Kitatani F, Lee YS, et al. Diffuse panbronchiolitis: evaluation with high-resolution CT. Radiology 1988; 168:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43769/abstract/35\">",
"      Nishimura K, Kitaichi M, Izumi T, Itoh H. Diffuse panbronchiolitis: correlation of high-resolution CT and pathologic findings. Radiology 1992; 184:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43769/abstract/36\">",
"      Akira M, Higashihara T, Sakatani M, Hara H. Diffuse panbronchiolitis: follow-up CT examination. Radiology 1993; 189:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43769/abstract/37\">",
"      Ichikawa Y, Hotta M, Sumita S, et al. Reversible airway lesions in diffuse panbronchiolitis. Detection by high-resolution computed tomography. Chest 1995; 107:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43769/abstract/38\">",
"      Nagai H, Shishido H, Yoneda R, et al. Long-term low-dose administration of erythromycin to patients with diffuse panbronchiolitis. Respiration 1991; 58:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43769/abstract/39\">",
"      Yamanaka A, Saiki S, Okamoto K. [Characteristics of the small airway area and etiology of airway diseases]. Nihon Rinsho 1978; 36:2427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43769/abstract/40\">",
"      Sato A, Chida K, Iwata M, Hayakawa H. Study of bronchus-associated lymphoid tissue in patients with diffuse panbronchiolitis. Am Rev Respir Dis 1992; 146:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43769/abstract/41\">",
"      Iwata M, Colby TV, Kitaichi M. Diffuse panbronchiolitis: diagnosis and distinction from various pulmonary diseases with centrilobular interstitial foam cell accumulations. Hum Pathol 1994; 25:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43769/abstract/42\">",
"      Feng RE, Xu WB, Shi JH, et al. Pathological and high resolution CT findings in Churg-Strauss syndrome. Chin Med Sci J 2011; 26:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43769/abstract/43\">",
"      Desai SJ, Gephardt GN, Stoller JK. Diffuse panbronchiolitis preceding ulcerative colitis. Chest 1989; 95:1342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43769/abstract/44\">",
"      Homma S, Kawabata M, Kishi K, et al. Diffuse panbronchiolitis in rheumatoid arthritis. Eur Respir J 1998; 12:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43769/abstract/45\">",
"      Sugiyama Y, Ohno S, Kano S, et al. Diffuse panbronchiolitis and rheumatoid arthritis: a possible correlation with HLA-B54. Intern Med 1994; 33:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43769/abstract/46\">",
"      Ono K, Shimamoto Y, Matsuzaki M, et al. Diffuse panbronchiolitis as a pulmonary complication in patients with adult T-cell leukemia. Am J Hematol 1989; 30:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43769/abstract/47\">",
"      Kadota J, Mukae H, Fujii T, et al. Clinical similarities and differences between human T-cell lymphotropic virus type 1-associated bronchiolitis and diffuse panbronchiolitis. Chest 2004; 125:1239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43769/abstract/48\">",
"      Fujii M, Sumi Y, Atarashi K, et al. Muscle weakness in extremities and diffuse centrilobular nodules in lungs. HTLV-1-associated bronchiolo-alveolar disorder. Thorax 2011; 66:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43769/abstract/49\">",
"      Okada F, Ando Y, Yoshitake S, et al. Pulmonary CT findings in 320 carriers of human T-lymphotropic virus type 1. Radiology 2006; 240:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43769/abstract/50\">",
"      Yamashiro T, Kamiya H, Miyara T, et al. CT scans of the chest in carriers of human T-cell lymphotropic virus type 1: presence of interstitial pneumonia. Acad Radiol 2012; 19:952.",
"     </a>",
"    </li>",
"    <li>",
"     Izumi T. A nation-wide survey of diffuse panbronchiolitis and the high incidence of diffuse panbronchiolitis seen in Japanese respiratory clinics. In: Sarcoidosis and Other Granulomatous disorders, Grassi C, Rizzato G, Pozzi E (Eds), Elsevier Science Publishers, New York 1988. p.753.",
"    </li>",
"    <li>",
"     Nakada K, Inatomi K. Annual report on the study of diffuse interstitial lung disease. Grant-in-Aid from the Ministry of Health and Welfare, 1981.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43769/abstract/53\">",
"      Steel HC, Theron AJ, Cockeran R, et al. Pathogen- and host-directed anti-inflammatory activities of macrolide antibiotics. Mediators Inflamm 2012; 2012:584262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43769/abstract/54\">",
"      Altenburg J, de Graaff CS, van der Werf TS, Boersma WG. Immunomodulatory effects of macrolide antibiotics - part 1: biological mechanisms. Respiration 2011; 81:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43769/abstract/55\">",
"      Nelson S, Summer WR, Terry PB, et al. Erythromycin-induced suppression of pulmonary antibacterial defenses. A potential mechanism of superinfection in the lung. Am Rev Respir Dis 1987; 136:1207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43769/abstract/56\">",
"      Goswami SK, Kivity S, Marom Z. Erythromycin inhibits respiratory glycoconjugate secretion from human airways in vitro. Am Rev Respir Dis 1990; 141:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43769/abstract/57\">",
"      Kadota J, Sakito O, Kohno S, et al. A mechanism of erythromycin treatment in patients with diffuse panbronchiolitis. Am Rev Respir Dis 1993; 147:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43769/abstract/58\">",
"      Sugiyama Y, Sugama Y, Takeuchi K, et al. [Analysis of peripheral lymphocyte subsets and changes due to erythromycin therapy in patients with diffuse panbronchiolitis]. Nihon Kyobu Shikkan Gakkai Zasshi 1990; 28:1574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43769/abstract/59\">",
"      Morikawa T, Kadota JI, Kohno S, Kondo T. Superoxide dismutase in alveolar macrophages from patients with diffuse panbronchiolitis. Respiration 2000; 67:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43769/abstract/60\">",
"      Hashimoto N, Kawabe T, Hara T, et al. Effect of erythromycin on matrix metalloproteinase-9 and cell migration. J Lab Clin Med 2001; 137:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43769/abstract/61\">",
"      Kanai K, Asano K, Hisamitsu T, Suzaki H. Suppression of matrix metalloproteinase production from nasal fibroblasts by macrolide antibiotics in vitro. Eur Respir J 2004; 23:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43769/abstract/62\">",
"      Kudoh S, Uetake T, Hagiwara K, et al. [Clinical effects of low-dose long-term erythromycin chemotherapy on diffuse panbronchiolitis]. Nihon Kyobu Shikkan Gakkai Zasshi 1987; 25:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43769/abstract/63\">",
"      Tredaniel J, Zalcman G, Gerber F, et al. Diffuse panbronchiolitis: efficacy of low-dose erythromycin. Respir Med 1993; 87:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43769/abstract/64\">",
"      Kudoh S, Azuma A, Yamamoto M, et al. Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin. Am J Respir Crit Care Med 1998; 157:1829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43769/abstract/65\">",
"      Friedlander AL, Albert RK. Chronic macrolide therapy in inflammatory airways diseases. Chest 2010; 138:1202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43769/abstract/66\">",
"      Mikasa K, Sawaki M, Kita E, et al. [Long-term chemotherapy using erythromycin (EM) for chronic lower airway infection: effectiveness of clarithromycin in EM ineffective cases--the fourth report]. Kansenshogaku Zasshi 1992; 66:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43769/abstract/67\">",
"      Kadota J, Mukae H, Ishii H, et al. Long-term efficacy and safety of clarithromycin treatment in patients with diffuse panbronchiolitis. Respir Med 2003; 97:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43769/abstract/68\">",
"      Tamaoki J, Takeyama K, Tagaya E, Konno K. Effect of clarithromycin on sputum production and its rheological properties in chronic respiratory tract infections. Antimicrob Agents Chemother 1995; 39:1688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43769/abstract/69\">",
"      Kadota J, Sakito O, Kohno S, et al. [Roxithromycin treatment in patients with chronic lower respiratory tract disease--its clinical efficacy and effect on cytokine]. Kansenshogaku Zasshi 1994; 68:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43769/abstract/70\">",
"      Nakamura H, Fujishima S, Inoue T, et al. Clinical and immunoregulatory effects of roxithromycin therapy for chronic respiratory tract infection. Eur Respir J 1999; 13:1371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43769/abstract/71\">",
"      Li H, Zhou Y, Fan F, et al. Effect of azithromycin on patients with diffuse panbronchiolitis: retrospective study of 51 cases. Intern Med 2011; 50:1663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43769/abstract/72\">",
"      Kobayashi H, Takeda H, Sakayori S, et al. [Study on azithromycin in treatment of diffuse panbronchiolitis]. Kansenshogaku Zasshi 1995; 69:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43769/abstract/73\">",
"      Hanon S, Verbanck S, Schuermans D, et al. Evidence of improved small airways function after azithromycin treatment in diffuse panbronchiolitis. Respiration 2012; 84:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/47/43769/abstract/74\">",
"      Tamaoki J, Chiyotani A, Tagaya E, et al. Effect of long term treatment with oxitropium bromide on airway secretion in chronic bronchitis and diffuse panbronchiolitis. Thorax 1994; 49:545.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4366 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-8C269A7C77-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_47_43769=[""].join("\n");
var outline_f42_47_43769=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Genetic factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Other factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11948957\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Laboratory testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15291324\">",
"      Sputum stain and culture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Pulmonary function tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11949590\">",
"      Bronchoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Lung biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Pathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11949013\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18301849\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      TREATMENT AND PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Macrolide antibiotics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9578552\">",
"      - Mechanism of action of macrolides",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18301557\">",
"      - Erythromycin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18301408\">",
"      - Other macrolides",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18301376\">",
"      - Duration of therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9578907\">",
"      Other therapies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5806730\">",
"      Exacerbations of bronchiectasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17733117\">",
"      Chronic sinusitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23638431\">",
"      Evaluation and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21489965\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/4366\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4366|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?4/37/4690\" title=\"diagnostic image 1\">",
"      Diffuse panbronchiolitis CT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4366|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?40/8/41090\" title=\"picture 1\">",
"      Diffuse panbronchiolitis Light",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?31/33/32273\" title=\"picture 2\">",
"      Diffuse panbronchiolitis Lung",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4366|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?33/34/34347\" title=\"table 1\">",
"      Diagnostic criteria for diffuse panbronchiolitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/48/33545?source=related_link\">",
"      Allergic bronchopulmonary aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/0/39944?source=related_link\">",
"      Aspirin exacerbated respiratory disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/41/25239?source=related_link\">",
"      Basic principles and technique of bronchoalveolar lavage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/43/24247?source=related_link\">",
"      Bronchiolitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/44/16074?source=related_link\">",
"      Bronchiolitis in infants and children: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/19/27962?source=related_link\">",
"      Bronchiolitis in infants and children: Treatment; outcome; and prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/34/27177?source=related_link\">",
"      Clinical features and diagnosis of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/10/12458?source=related_link\">",
"      Clinical manifestations and diagnosis of bronchiectasis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/25/21914?source=related_link\">",
"      Clinical manifestations and diagnosis of sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/28/17866?source=related_link\">",
"      Clinical manifestations, epidemiology, and diagnosis of common variable immunodeficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/34/35370?source=related_link\">",
"      Clinical manifestations, pathophysiology, and diagnosis of chronic rhinosinusitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/49/28442?source=related_link\">",
"      Cystic fibrosis: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/62/5096?source=related_link\">",
"      Evaluation of diffuse lung disease by conventional chest radiography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/29/16858?source=related_link\">",
"      High resolution computed tomography of the lungs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/54/40808?source=related_link\">",
"      Human T-lymphotropic virus type I: Disease associations, diagnosis, and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/4/30794?source=related_link\">",
"      Management of chronic rhinosinusitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/21/26969?source=related_link\">",
"      Overview of lung disease associated with rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/11/24759?source=related_link\">",
"      Overview of nontuberculous mycobacterial infections in HIV-negative patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/37/9817?source=related_link\">",
"      Primary ciliary dyskinesia (immotile-cilia syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/22/29034?source=related_link\">",
"      Pulmonary complications of inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/14/21738?source=related_link\">",
"      Respiratory tract involvement in granulomatosis with polyangiitis (Wegener's)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/11/38073?source=related_link\">",
"      Treatment of bronchiectasis in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_47_43770="Jones metroplasty AB";
var content_f42_47_43770=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F71446%7EOBGYN%2F50489%7EOBGYN%2F66362&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F71446%7EOBGYN%2F50489%7EOBGYN%2F66362&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 472px\">",
"   <div class=\"ttl\">",
"    Jones metroplasty AB",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 452px; height: 628px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) In the Jones procedure, the common cavity is initially reached through a wedge resection of the septum. (B) The septum is totally removed as the two cavities are unroofed.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 512px\">",
"   <div class=\"ttl\">",
"    Jones metroplasty CD",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 492px; height: 638px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (C) Uterine closure is begun in the lower portion of the cavity. The anterior and then the posterior walls are closed, including the endometrium and a small portion of the myometrium. The suture may be continuous or interrupted. (D) Beginning inferiorly, a row of interrupted sutures is then placed in the remaining thickness of the uterine wall.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 523px\">",
"   <div class=\"ttl\">",
"    Jones metroplasty E",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 503px; height: 339px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFTAfcDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAgW7tmumtluITcqMtEHG8D1I61PXmlnbXdjroj0W0a8zd3Ux/tDSXie1d1kYut0QFcFmCYG5ir/AHsA1S04+JX0gr9u1hbyaSwS4Q2cweFjdRid1eQFMbC+QmYwFzgDqAesUV546axa689vHNrMlzFeRJbuyu9u9l5SeYzNjyy+7zOvz7gMfLjOXY3Otx6TNa3EGs3KtPAkmpEXqk5SQvJ5GFlX5lQFIzs/eLggK1AHq9R288NzEJbaWOWIkgPGwYHBweR7giuP02XWX+Ft21wbv+2EtLtI2aJo5iVMgiO1stkgIRnJPqetVNfXWEk02Dwa5XS7mwBgeJcxQeT88YzjAEoZU/3QfSgDvty7tuRuxnGecU1Jo3lkjSRGkjxvUMCVz0yO2a8o1y01vVtEElxbaizXWmz3TKISssW67ilSHgZDLH8uzqdp4JrQlsr+PWL3UtM/tj/j70pIt4lXzYWkRJi6EAtiNnzuHy4zxjNAHpVFcR8RZNTguLGbTRqFwI0kP2K1WdPOfK7T50QIUjBAWT5Duycbc1nzy68L+4MP9rf2gLi+E6mOQ232UJL9n8rjYXz9n+78xJfOccAHo9FeYS2mvQRXUkU+uPJDYafdwhnkYNdPLIJxj+IbUTMf3V3Z2jINXvDTa63i121S5vIz9ouVkgNrOYXhy3k7ZP8AUrhQhBXDHJDc5wAeg0VwesPq8fjgC1/tC6hl2oiIJoYrYeU2W3YMMgLYzuIcHgdADiXWu60NBaaZtXtfJ07TY5pJLWSNvtDXAWfaGX5m2kD5Qc5GM0Aer0jsqIzuwVFGSxOABXld6+vllWB9Xj8PG6uPKkeK6e5C+XD5e8J+/wBvmG5xnsEzxil1rTdd1Xw74hS9u9WuWXS4EhijhMKXMjQ/vCI9u7JbqueOmOtAHptleW19brPY3ENzA33ZIXDqfoRxUwZSSAQSOoz0rzi7g1Cy1u7gkXVxoZvkE01qkjTOgtF2ndGPMZfM4LLyCACcZqG/fUlnu4o7fVlsri7g23nk3HmKgs05dYdsjktkHkAMMEjGKAPSxNE07wrIhmRVdoww3KpJAJHoSrYPsfSn1wvw9TVZNSa81qG5W5l0LTY5ZZoTHvlWS7Lg5H3huUkdtw9RVeGy1e61a2a6uNZSG41O9gnCSSRqtsvmNFjGNgyqYcYJzjODigD0KivMbC78S7/DmnXE12JtXtIXnkk+WS0MDAzsQRkeYrIvThjnvUM0/iRdH1Z7T+2Tqq6RfNdK8UhQXgA8j7PkYP8AHgR5BGN3zYoA9Uorz29stXs9TvWtLjWZY7fUNO+zhpJHVo5JY1uSf7yhCxOchOSNtc61r4j1Hw5qUOqS6m969nvu7RbW4AM6zRsTFI3yYAEgCxfeBBxkUAexsyopZiFUckk4Apa821m21W6svEstpNrMtvDYxrYW0sTYlZozuJVk3M2ccHoe2asrqGt/2rFZGPU96ahfNK/2Z/K8gxytBiTbtIyUxgnng80AegVHBPDOHMEscgRzG2xg21h1U46EeleXG18Qx6PLOs+uvdpotteqpeQ5vsvvXb3OAoMX3f8AZzzXbaUFHjDXhb/6kw2plC/d+0Yk3Z/2vLEGfbbQBv0UUUAFFcH4i+JFlbX0ukeFbK48UeIE+VrPTyDHA3P+vnPyRDgjk59q7HSXvZNMtX1WGGC/aNTPFA5dEfHIViASM98UAW6KKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAyZ9ciTWf7Nhtbu5mQRmd4UBS3DkhS5JB5wThQSBycDFc94V8X2DeH9Fc2Jt1ntrSS4NpCFtrWW5VWVDznlnHQHG4FiM5roJdDU62+p219eWskojFxFCUMc4jJK7gykjgkEqVJHXoKyrHwLp1lb2VtBd3ws7eO1SS3LRlLk24URNJ8mcjYmdpUHaARjigBw8c6WbK5vDHci0il8iOUhAJpN5TavzZU7h/Ht456ZNVNR8f2Y0G6u9Jt57y8itriYwKEPk+VwxkO7bt3EfdJyOVzU1x4B025vbi8urq8lvJduyfEKtEVfepG2MbyCAP3m/jI6E5lvfBdvd27xyapqKyS28tpNNGIFaWGTGUIEe0YxwVUHrzyaANifVoLSysLi9JRbp44gQPlV3HGfQE8Z9SKx08b6Zd2cM+nO0oke1GXRlCrNdfZxnjIO5XwP9nnA5rV1vQrTWdAfSLtpRbMEG6NgHBRlZSDjggqD0qifB+meZfOhnj+13dreMqMoVGt5FkRVGOFLqSR6u2CM8AGVb+OLi5j0mWHRboC7vbi0MI2s7eUJcFCWA6x87sAcjnrW7ceIbb/hFE121O61kijlTzAV4cgDIAJB5qKw8K2tlcWkiXV46Wl1NdwROU2xtKH3LwoJX94xGST05xxUg8NWY8KxeH/MuPsccaRB9y+ZhSCOcYzx6UAVG8ZWn237NBYajO7Ty2sRjjXbLNETvRSWHICscnC4B5zxWbL4zsbu6kFzYvc6H9gstR8/yg3kiWWYbpVY8BTEh4BIOT0GRu23hmzt7q1nSS4L297cXygsuC8wcMDx90eYcd+nJrMj8A2EaJEl/qItfscFjNb7oilxFC8jKHOzdyZWB2lcjigCy3i+0e58qCK4CpffYZJpomSPeGKsFbGGIK/T3pyeLbeTSW1NNPvxYlVkhmkEUazRt0dS7gKO/wA+04I4qc+F7E26wM87RrqD6lgleZGdmKnj7uWPHXHeqQ8FwixsbUatqnlafIkljuMLfZtisgAzGdw2uR8+49CDkZoAgtfH2n3NzE0UEx0xtPfUHvsgpCqOyuGA9Nh5BPtnrUtn470y8bybaG6lvy6JHZp5bSSb1dlIIfYBtikPzMCNpBAOAVh8DadHAsLXN7LC1vcWtwkjIRcxTOzur/LxyzYK7Tz3p8fg+NBA39r6k1xbyLLbz7YA8RCOhHEQDAq7A7wx6HgjNAD9L8URt4IXxFqqeRGsbyyoiklQGIxjPXgd6nh8T2bCMXEFzbSvbXF2I5Arfu4TGHO5GZT/AK1MYJzz6VYsdCisfDq6Ra3V0kaqyrOShkGSSTyu09e649qxE+H+nw24jtb6/tpCLhZJYRCpkSfZ5i7fL2KD5SfdVTlc5yTkAX/hLtPGuXLS6bMscNtasl+EUkrcPhUPcDcF9e/THOhf+LNPs2KGO7ml+3HT1iggMjtMITNgAdtgPPQd8Dmq914Msp1kVby+hSS1gtnWNo+fIYtFJyhw6k54+U9wamsvClrbXEFw95e3NxFqDal5kpTLytbtAQQqgbdrE4AHOO3FAFKX4h6DDNdLNLKkdus7GXCkOYQTKoUEsCu1uqgHacE10OjaiNUshcrbT24LEBJihJ9wUZlI9wTWTbeEoLSa5ax1C+toZnlkEMYhKxvISWZWaMt95iQCxXnGMYFXfDPh+18PWtzDZvI/2mc3MrOqLlyqrkKiqq8KOgGTknJJJANeiiigAqK3toLbzfs0EUPmuZX8tAu9z1Y46k+tS1zPjjxbD4at7eC3t31HXr9jDp2mQn95cyep/uRr1eQ8KPfAIBd8V+JtJ8KaX9v1y7W3gLiKNcFpJpD0SNBy7H0A/QVyDab4m8fqra21z4Z8LyDP9mQvtv7tc9J5FOIlIxmNDuwSCw6DS8L+CGh1SLxF4uu11rxSFISYri3sQ3WO2j/gHbecu3c84rtqAM7QdE0zw9pkWnaHY29hZRfdhgQKue5PqT3J5PetGiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiisXV/FOiaQzpf6lAk6Y3QRkyS89P3a5b9KANqiuH/4WA06sdO8LeIbsA9RFFGCPXDSBh9CM1lRfFSeXVprCDwT4kvGhIWSWy8iaONj/AAM/mBVccZQnIyMigD02iuJ034m+HryaSGZ7qzlj/wBZ50O9I/8AekjLxr9SwrqRqunHSzqYv7Q6aEMhuxMvlbR1bfnGPfNAF2iuIu/HvnRSSeHdEvtTtk/5fpWW0tG9kkk+aTPYojA+tcpqXxS8S6ffaUl34WsbfT9RZxFfi9mmjTapY7lWAMOATwDgKxOADQB7FRXFt4q8QWmXvvCNxPAMZk027WbPuFlWIkU61+I+hsQuox6ppMv8S6hp8sSr9ZApjH/fVAHZUVn6XrWlasWGl6lZXpUZYW86yED3wTiuc8SeNPJ1V/D/AIVtV1nxNgF4VfbBYg9HuZBnYMchRl27DnNAGl428WWHhHSkur1Zbi5ncQ2dlbrvnu5T0jjXuf0FZHgDwzfQ6je+KvFscB8VakgiKROXSxtgcpbIx64PzMRwzE9QAaueGvBcGnan/bes3Uus+JWQodQuBtESnqkEWSsSew+Y5+Zmrd1vWNN0LT3v9av7Wws04aa5lEag9hk9z2HU0AX6K4BvGeueIAY/A3hyZ4T01XWw9na9MgpGR50n/fKj/apsXw/1HVH87xl4v1rUmbO6z0+U6daAH+HbERIwHTLOc0AdfrGvaPoke/WdVsNPT+9d3KRD82IrkLj4ueF3meDQ21LxFcJwY9FsJbof99gbP/Hq0NG+GPgnR5fNsfDOmefu3edPCJ5M+u+Tc2fxrsFUKoVQAoGABwAKAOO8P+KfEGsanbo/gjUtM0uTO+7v7qBHQYOP3KszEk4Hbr7V2VFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFU9W1Oy0exkvNTuY7a2Tq7nqT0UDqWJ4AGSTwATQBcrjNW+IWmway+jaHBca7q8ePPhsQGjtckjM0v3U6H5eW4+7WUuo614qLz3DyaNoTfLDZgMl3cKc/NMw+aIEchFGRn5nHKjZ0bQ7XSbKG10+0htLSL7kEaBY0687c4z77s+xoAx2t9e19ZH8Q6hFbWm47LDTZHjjZeeJJuGf6DaD3U10Ol+HtPsYIbaGC2t4T8wgt41jGfXaB9fm6+/WpjPb27OfNiWVlwByzsPrxgfXNRR3E8qfKsgAPKwMsefxBwR096AIfHl1Bo3he9kSVIZ5FWCGRzvMRdgm8Kc527t2O+K4Hw1piT36g3EdpbxrEsMtvA7eTGc+XHHI5AUjaCflJ8wtuAzXX+O7AS+A739yqL5sMjqrZIUSrvZm9hubtjFcvoOrWty9pbbmuXu4S63OnGREZ1OJg6rmITLnJBGWKkEcg0Acr4u8KQaDcTR2GoMzXJ3Rk/6PMqgks29ABlflPAG5TzkdPJ9IudbvfiZpGmxwNPpJ1G3eSylINu0pZVZpI2yDJg7SzKWGc8nDV7jr9xq0cMEPiWzs5tOuCds6p5y2kpJXa6N/Cc5DckbyBjIB5L4ey6dD8X7S0uNUigZLSe1t47iNXkjuCYPLRCwJbAO5W6YX0oA+hby0nMKahdy2cV7bxt+8kDPBAvJLhSRzjALEjgHoOKram1rrnh6+XULe5gjt085LiaEx4ZV3CVBncMYzg4PYjmr8wsFs5rJ3e8e1Ane384yTEqd4yM5OSBgHjoOnFYeuaxa+HPCtzfTxXqPJDLLFBdzs7EsplYPkkLtywxzgLheMCgDH8GwTp4Zt408ny7d5bdJRFKyyIkrIp+Xp8qjpXQR20oQBLdBIwwz7Jdp+u4Yx9a5L4Z29zb+C9Gtm0qQOsAaXzoMHexLMS24dz3P5Vm3bTfEq9uLXR4zF4HgZoLq9tEZG1pwcPDG4IItwQVZ1b58EA4yaAM6/mHjTU8+DLeCC2tpdl14rW2ReASrx2Llfnc/MplJwuCVycGul8O+H77wVbPF4OvDNYb/Ol07UlVw7ty8huU+ZXPcvvHsB00NQvdJ8LaTFLeoNKtbcLBAi23lDPQRRKFYuxA4VeuK5mDRdV+IqG48TS3ul+HWP7nQfNCXU65PzXp3KRkYIiU46biSOQDYh+Jl34quE0zwDZ2kl8wPmahqEwFlGy/fWIod1yy99nycg7+a3fDvgC0tNQi1jxLdyeI/EaHK394gCwdOLeHlIRwPu/MTnLGmzeF7TUdMg02OCAadbkNapCvlC3KnhomjP7thzjawPXjrUj65ZeBLSZPGXi2ye3+/aG72x3RTnKkA5mI4wVXPrk80AdnRXmlp8T7rxHC0ngLwlq+tQ7tq310VsLRhkglXk+dsEcgIaW6g+IU9tJc674p8N+FrRef9CtDcMq/7Us7KoP/AADH1oA9KorwvVL/AMHefDHq3xi12+mckeTp2pRAMfTbaxhh9M1VNh8Jnfz00DxNr8zDDPJZandbvr5g2n8KAPX9Y8Z+GNFJXVvEOkWbj+Ce8jRvwUnJrR0XVbPW9Mh1DTJjNZzZ8uQoybsEgnDAHGQee9eU+HdR020mDeCfg5qdrdp8ouLrT7fTOPeRzvI/A/nXremSXc2n28mo28dreOgaWGKXzVjb+6HwN2PXAoAs0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFZviDWbXQtMe9vTIyghI4Yl3yzyH7sca/xMew/PABNAEfibXbbw/p4uLlXlllcRW9vGR5k8h6KuSB0BJJIAAJJABrjLfTtR1rWY9V17b9qgLG2t4XJjs1Ix8uQAXIOTK2PRQBnK2Wl3V3qsmt+JmWTU2OLa3HKWMZxiJBkbm4BaQlQx6blCgdQkJkaMMADGOFbORnvsAH6Kv1NADIbJ3dNjBUxu+Vc8nsCeB9UBHNXJIVtihkw7O+07pQCTj1PJP0x0q3CHJKsQGb7xwCemO3A9sk1Uu40NwxkeQJkKBISsY+gyoJ685agAR8Rv57QoVYgmNXGR0Gc9frzTIdpUtBc7164PJ/MrTktAw83Cl1JAZcA4/DdmlkMdtbvPK7QxLyzvK6hQOpJK8D3NAC2UC3lrqFpd248iUmNvmVhIrLggkd+v5ivHtBurjwV4tvNFv5CLN5WlaBIwPtSlfmKEfxlmSTaSGyzhSduK7yDx34LivVZ/FmiKy5yG1VDyeOQSP/AK1Yfj6y0bx/pkuqeFdRstR1DSSAz2E8dyHQqTtKq2GIyxCt1+YDG7IAM3WJLey8LI2jTQ32g+YXnVzlo1LrzuyflBAyR91iGxivLfCOm6rd/GK31e31htKVCbXzrqCPcLUCNdq7hjzGMm0MgxnHYkVpXXxAGkXGn2t29wY7uKZXggtSxDrgsFQAho2DscHkZ7hsmh4e8dRWfxB0jWU0PWNSsLQXMgms9LcOsTxuNiqcDg7STnaPmOBmgD6PsLqDSb+WySXT7Gytw0kkB3SzsuM+bI+75dxIPzBi3rk4HG+OUudfm8MeFxPcyrezGV5J0CSvFHzJM6gAKMHaowMlug4rC0z4i6urW8ek+EvE2nafdy4F3qFrEm4Eq8tzKSckhBJwOOByeALgt7628L+MPF/h+wj/ALW1GZrPTo5/uJFJOFeQnJzlnZz2+QY4xQBrfFzWzql/H4J0u68qe6h8/Vplfabax3AMgbnEkvCAYJC7mx0puteINI8HadY6bBp0017cRiHStJsIUaWcgcbBjiNRyztgAep4rntVuNZ+HOkwabpFq+qeKNe3Xeo63qCskSyZABcICzH+FYlOFGOvOdTSrLS/A9lNr/ivVmn1m+VUl1S9hV57tzj91BGPmC+kaAjgE560Aavhjwjqk+rx+JvGcLT60iMlnZ2pT7LpcbdViDcmU4+aXgnoMAc6+v8AxG0TRtQbSklvNW17lhpOlRC6uVHGd4UbY8ZB+cjjmuetrPxJ4yZZNQ87wr4eb7tnbyIupXak5xPICPJUjHyJ83UFhUVxq/h3wTt8M+B9Ai1PWyCPsFgFzGeu+6nZ28se8mSfQ0Aad5J4z8Qllur+08HaVtLOtqRc3mMHO+UqYovXgMRj71cf4f1HwvZa1dD4feHLzxd4gCnztaS4zHu4z5l7OxDMeD8gIx0HGK2rf4eX3iFDcfEXURqEbOJE0yyc21hCeDhiq5mIP8TnByRivQrHSbTT7OKCyhtbS2iXEcNr5caqPRcIMUAeY6xpXxAvUDah4htdNtjI8sul+GYTDJMvUn7XIvyyEnuFVjnJXII6Xwp8N/h/e2kWrw6NHq004+e41gvdzFhwwcTFtrAggjAwc8V20GISJFmlEQPzLI6kEHvwD/MdK5qaG40zUn1rw5FJPBO+b2wQY83C84XosygAqeA6/K3/ACzYAHYWVla2EAhsbaC2hHSOGMIo/AVYqnpOp2er2S3enTrPAxIyAQVYdVZTyrDupAI7irlABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUVxuu+JL2/nOl+DhFNcs4in1JxvgtMnBIA/1rj+6PlU/eI6EA0vFXimy8PrHE/wDpGoTDMNojYZhnG5j/AAoD1Y/QAsQp5bR1Ooa3ca5rFxNdXECvbwRsnlQ2rHqYweU44LOd7EfdXAURx6V/Y1xqFt9uW51e72tcXBYmcx52+ZLJkevyxqURR7V02m2qWUFuieXBFGuyMuQmeOccA+/yqufU9aAHWto8Ugknch26Egpk9wv8Z/AKT3LVpwxLyACAOdm3aOe+wcn/AIFUNsieYQiPul6tITEWx3x98/8AAqtoCpZMfL0xGNoz7Acj8TQBIpjXaZS+/wDhU9fwUf8A66ivpbdWQPPHHMcAKXCM2e2cZ/KrUa5TDIVHoTz+OKp3loPM3RLGA5+fdtGep5JUk/SgCv8AarN24lV8NjY6SSkH1APT8q8e+NEmmjxT4cfxXbXh8Cor3E7QW48k3gdRGLgqpIjwWwD1PXIzj2V2dox/rIuo2qkz/qNv8qa9ojoPOi81MHLeUoz7HzCTQB4pqPif4XCyII8GxRcGOO2gFy+QflCxIvXpx0rvvg62m32nXuq6b4aHh2WVxbXEB09bRp2jyRLtGDtO84DcjB+p17zSdOsp0u4rKK2mfP70LHEw47Mik+vQd+TU+garYWGmSxX13bWi28rf66VU+Undu5OQDk9cdOg6UAeM/GPw+/hbxHFqNjAJdN1EMixghTbTYYh4yTjeu4lRxkErwFFc38ONQ8UDxS9jBJY+HoEgkni1TXLeUTMG2ruETzKmXwGxt4x+J938Rwad8RvB2safY3NpdPDIVilt5kkVZkwyHIJ254znsfoa+SvC9pDp/jRtPj8MaHJqYhmdY9ccG1RmAABQoSzcKFBbGXxgdQAe82UlrqGm6d4N0LUbee7ubryb2axZGghjiQSTSq3VpGZ1yxyS5I+6K9jA0u0sUsC1rHa24SBYGYYQKAVTB9tuB9K8Q8JwR+EPA+s+JdD0UiSF49I09LS3DSyKJVjknAOAzM7M3PGVI6VR15/Emj2tndeJNVh8C6LqN0Y7hYZxPqc6bWd2e4CkK5CjaIlLZYD6AHqPir4g29nqieH9CtF1bxVIwAsRKFS2UjmW4kGRGoH8PLtkALzXJtDpvg7UINd+IGrw6r40vS32aOG3klkRegt7KAcqvOM4yxJLHk4zvC8l61h/Z/gy0tfA/hiRvMa/uJIZtTvWOMsUkbEZIzkylmxjAHbvfDHg/RNFd7zTrd5tRmX9/qM0iXF1cZA5eV3YkHHQYHoKAMNrXxf4ztQkqSeCNGf762yFtUuE7ZdRsgB+UkLuYYxkV1Phjw1o3hXTltNJsrKxtFOHk8t45ZX/ALzyt8zE/wB4k+n02DFDuZUkeVx1WNYSR+GKZB5wXy9t2hYkhniP/sjADp7UASsyF0cS2QjRQiv5x349C3erELRSHcXY4OQyz/Kf/HqZHMyxoJzIsjHGPKf+jH+dTb5JG3JIVTnoRwfxXigCnePK8RyLiBcHOGz9DnoPrvH9K5vV7u40KGPVLFfPgif/AImShCmbYD5nBUEb487uvIyPTHURBpW86IM43YL/AC5YfVG6fgTUF9Zi7t5mngMgKfc+XP0y6Dj3JoAwJbGewvLfVtCvLeaS6Vf30j/udQjwNiSuuQJMYCTYOR8pDcZ6PQNct9YSeNUe2v7Vgl3ZTYEtuxGQGAJBB6hhlWHIJrz34X3C6FqGueC52M1nZ3KyWMVxIHMdpNgpHnc2VU71H+7XaahoMWptBeWVw1reQx7ba7UfvbfODtP99DgZRuO+QcYAOkorm9J8RSpdrpniWCPTtUJ2xOHzb3nbMLHue8Z+Yf7Qwx6SgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoqnq2pWmk2TXV/MIoVIUcFmdjwFVRksxPAUAk9q5yKXxH4iCvDKvh7TieNqpcXjj3zuii+hEh+h4oA6+iuXbwitwf9N1bWJAOBsv5oy3u21gufooqxbeEtPt41UXOsMR/EdVuRn6gOB+lAHQVi614n0rSLhba5uDJfsNyWdsjTTsMdRGgJA/2jgDuRUU3hLS54zHO+qSxnqkmq3TKfqDJg06107QPCtrL9jtbWwilGWjiXHmkf7P8AEeetAGTd2Ou+Kv3OpxnR9EcHzLRZQ1xcKf4ZXU4RcdUQnPQsRlS3xLr2meCdHkhskhjkjiPJwkcICnBY8AAf3RjA9OKwPE/xE826k0vRUmu9RlOyCysTuuX6He3/ADxX/aYgAd/Tg/Gnhm9bTbu58cX0Nz5EJvrvTraQra2kabnSNiMNNI5XJJwuFYhc7TQB2nwwuW1bS5vE0jRvPqMpkF0752QKSsfDfKhOCQMM2GAIFd3FC43N5kodgQCyssjj/wBGNj6oOmBXPeCbVdH8GaDaSGVJbWxgj3SKvmr8gztQ4WIdRubB9ecGuiW4YyBUDDd/Cjkb/rK3zNjJ+4DjpQBZhjjhwtx8sr8+XnLP6naM5+rFquGYxxDfttgThQ5BJ9gAcflmqFs53OEIjXdlhGDvPrnq7Hr2U1oxWycsysrngnPzH8c5/WgBGuliJUrMzEblJQnP5DI/KonkumB/dnyzxwgU/XJcH9BVi6ieYKqOEGfmOWB/Qis5zDbzjz2QOD1lMaKfXrlv5mgB6COQ/N9maQDrsUsPfJY0CEKwAt4snqwi4P5J/WnLdwSuu27thg87bkt+mRTDImWby4Jhy29YlwR9S/J96AOe+JGma5qXgjV4fDssVpq625FnJGWQoc5bB42kqCAR0JFeBLZ6JovhpdRm+FGqXGq2GyS+udYaN47phjzQXkdt27OQVTg44xkV9LXflmaOSa1vZVCfLENvkA47qCfXvnrXK/ES5a68IahJMjyWqGHfbIpZDH5qblZQvzDaTzkCgDe8OeH9I8ONPqWjafZaTZXkEbz21rbiMbgDhsIMZwcdPWvCvi3Zt4W+MkOrxuDY6nZzyQBiWUTNBKrFT6gsH/LHbHver6/4bKRjUdasrNjkIZrhYTz/ALxHpx615N4p06z8R6Vo4lubaWDR/GVvb2jxXKy+daTSRgoShOAfMIx6IOg4AB6h4d0a1HhCw8PCPEenpbJcBwDudQkhB5+8WwTn1z6U/wAZ6FpGp2uj2eoQQ+Xb38dzAGZVCMmScZP90sMDt7DFcfdePdR0nxHrGi6L4fv9du47p5JVs4DiAMFK+ZIzBOecDIOAOO54X4g/E3UW1TRYPEui3OgW8d5HcYv4GRXSIrK+1gWSQ5RVCgnJccDqAD3maHT7C2+wWsapGBlrdUBVs92JU+gqJroQ2yFY4xg9IoSAB9cj8+KSwluLmwt52urkiaNWZVKuRkZwdqMB/wB9H6mrLWwdeZLkgjo0eQfqClADok863EiJM8oYrlZGHH4uM/nUqrMG+dJgv97JPH0Dk/pUclvHHH5YXIfDlR5e72+VgBinIqqhWOMKTxmRYyMfRSKAJYSVbanm/wC8xkOf++gfX1qF932k/armHAOIkExRgSOQSMZ+mKfuYKJJoB5Skk7YN5P0CsT+lVmluZAxSNZbdycJLujcD3Dj+hoAtTQN5hkaJ5HxnO2MgH68N0pjvHEXMs7orA5MhdFx9WyM/TBqrDOoP7u0lQjBJhCsMZ4B2EfXnPerbTlmGJZYyck5jZAB77lI/lQB458Ybe+0m+8PeLNFu0keO6WwuXa4aUS28zAoGULlQsgXBBJBfv0rrvDHjKLUbma1nT7HrtsDLPYNjzlDAgso6SxkhWDpkcHO08Uz4vwvdfDnxYnmee0Nm9zGWMi7HhXzVIAG1juQEdB61ipY2niPT9O123t472cFbqARkqzxMwYIj5DI3KlWBBVu+CwIB6heR2GsWU1hqtvb3NtNlWilUPG65Ur1/wB5Px+lZNrpGu6ETHo1/FqOmj/V2eps/mRD+6twNzFf99WP+1WRb2ms2dhHJpDnX9KmGY3LrDeQg5yDu2xy4yR83lsvQlj0mt/G1pbSFdUWbSnUkul7E0AOWB4LkKx+/wDcLD5lwTQBojxPqluuNT8JaxG4JG60eC5jP0w4f80FSp4nu5SBbeFfEEgIzllt4gPr5kqmrlrrqT2yTpBLNG+NslupkR+D90jj7wwPXIPriUa9YeYEeSSNznAkidTx9RweDweaAM3+3tb8wD/hENR8vPJ+12ucfTzP606XxZDZ7m1jStX0yJes01uJYwPVmhZwo92wK0rrXNNtFVrm7SKNm2CVwQmfdsYH509/smqxqI5ndVw6TQOyjkHBDrweD0yfcUAWrW4gu7eO4tZo54JFDJJGwZXB6EEcEVLXIWtu3hvW7MBohbalK0NysY2J55BaOYL0UuEZWA6sVPrnr6ACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAOMtbNfEviG6v7xw1taO9vZxqfuKC0csgOeHdldMjkImBgu1dRe39jpkIa8uYLaNRxvYLx04H6Vg/DCFY/AmiSK5d5rOGSTPUOUXeP++txPuTXI/EYWlnLfzPFqF/NGhC2ygtJcylSY4Ygq7jyw5GSAWJ6cgF7XPijY6ZfJapHdTCZittLHb+f55HXZGjCRsHP3UPAzmlg8d63eKWsfDt+3PCS6fdQkjHXMiKOv8vxrT+FGjaTZ+ENJ1LT2W9vL6zikuNTly89yxUFi7tlvvZ+TOF6YGK7WgDzqx1Lx9eTSL/wj6WyZ+SW9v4olbHQlY1kYD26k9TjiqSfDjW9YuWl8UeJmhtnHz2ejRmEue5adyznOewXtzXqVUdY1SDSrYST75JHOyGCIbpJn7Ig7n9AOSQATQBhW+naT4J0yLT/AAvpdtFeXb7IYATuncdXlkOWYKOWZiTjjkkA+Y/GyaHRvDEOmm7aa+v72K3ubsKN00s7gSHbz92NCAv8I2gdK9E1NjoWj3etau4/ti6QK5TMggTPEEQAyRkgcDLsQfQDz7xt4CfxD4d1jxT4ojmjGm2E13pWl79pilVN5mmxw0hKjCcqozncScAHpUELAbywSPfuLlwEB/vb2yC3H3gHOe69K0IoEYgvvZH4LZMSN7Fid7nH1B9qht3yY7hyiZHyO7gkjHQOevHOIwB6GrKTGJgyIiyOCBJc/u92PQHLn6HFAGnbBY4wihEXoiKm3A9MU1o5ZM7/AJRn5SJD+oGP51DaNK5DM80g908tPyPzfzqxK4MJET5YjAK8n09D/KgDFv8ATfPZ1v528hzt8suIkkHozZZ29cZA9qiisdLtPKNnb2cTDCqEjaXdg8fNkenetS5tXYKGQzjnAJzg+p3HH/jpp8VvcKpUGKIZJ4y306BR/OgCGK5dpMvPsXG3YPLUA+vJJq8oSeNXDEg85jkOPwIqJrfamXllz/sgsPybdVZ7G3ZJNsTSbxyjQhc/+g/qaAJ5gqRsZkhBII+bMpIz6Yyfp715/wDEXw5aeIfD8kClLKe7lit4p4YAroXkVd2dvBAJOcnpXSyaDGsRH2eRkHIj4wv/AJEHT61y3j+/fRPC0tzbWsjvDPa3UIhjDmRo7iN/KGzPLgFRz1PWgDZ0j4TeBdMhKJ4Z027kZi8k9/CLuWRicli8u45J5rE1zwta6NLbQWOn2tjpkviWwu4IrSMRqpCoD8q8D51PYdab/wAJT8RtR3yaf4Bkgs5ATGb/AFWG2lwemUUOVPTqc9fbEWj3Wpf2Nev4i09tMu7bXbFngluxdbS8kILhgcBW35AAGOe+aAPS9JtxC166yLIk1y0ilWyBwAR7cg8eufWuf+Ii6Vc2tpY69Y2moWM7Nut54hIdwHysoyOc8cf3q5ufwh4l1/X9QB8UahovhuGVhb21nt8+STIyWZwwVBtBUAc7icjjOF4s8EeLNAtDJ4b8ZWtzdzSIkP8AblugaLBySsqYUcD+KM+gIzyAeqaVollHoVtZmyhWCKIQxQlWCxxjhVUMSVwAOKqoLCxjNvBI/lLnJhuwoz3zgjms3wlPd33hKwgRL0S7Ajre3hnkRlPzb5hGQ54POeeOnbehsDFEqTK3mjjCElSPqE/SgCoggeMpFdX0ZOMYvHkP/s2O9WXS8DqYtUlUA/MtxGmOBnCnYuePenyQKyENAG9FMRI/H93SWtnhiUQRSEDKorKAPQcJQA8Jc3G5nLSAgbSgUBfUZVwf1q3Erpk7nJ6fxcfnuB/CoZEljjLjDSYAIBJI65zwxP6/hTEAcAzQKx5wcpkfgVFAE8wMiKJFL5BO11Ug/gcHj+lQJNbL96dVbbyqs8Sr6nGcCgtsk3AGMdGdmUA+nRxz+FWhiZflUPgjG58j68E+9AHI+P5kk8IeIWCWdxI1hOu9Y1Y/6tgMnJP5rj6VwOg2eu/CrQbPSfExW+0eKSOK31i0BCQJuyFuFP3ACcBuVxjJB4PefEgbvBmrwSdZYxDGqqF5dggOCSQMt2A/rXb3MEN1by29zFHNBKhjkjkUMrqRgqQeCCOMUAcraahDpksmoodukXc226X+G0n6GT2Rzjd6E7j1cjrJI0ljZJUV0YYZWGQR7ivKrKzufAHi220maRrnwdq0hjtXnzIbNvLctbOTncrYXYTzgFTkgE9ramXw7dRWUuX0SQiO2mJJNq3QROT/AAHordiQp/hJAI7nwF4UnkMn9gafDKeTLbQiBz/wJMH9afH4N0qNVWKbWY0XoqazeKo/AS4ro6KAPGviJ8M4NKs7rxX4XlmfWNNhe5MGqTyXsdwqfOQplZmjk+X5WU47EEHI2PhrqfiTVdHtdagTR7jT76NJWgjupQ0fXOwMpAz1wSOnbPG58Sbgz6emhrNLbpqEUr3U0ZwyWsYXzQp7M5dIweo8wkcgVU8BeDYvDtrFd6bLPaxSRAjTY3DW6AksQgJ4yNuCTwQT/E1AGl42uJEgsjyqfabRtrdmN5AByO+GI611VcprUltrWr6HaWdwtxBJP9smMUgK7LZiR07iZouP9k+hrq6ACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAOQ8Fz29rrGtaBCNkumylzGc48mZmliZc/wAPzyJ9YvpUvjLTv3LanEu64t0Y784fHVQPQZ79enpXO/ESG4g+Jnga60e6js9VulvbLc65S4jWHzhHIOpTdH25BbI9D2ktw19pVzbX1o8FybdvOhOWj6chZMBWHPt7gcigDm/ANy1n4g1TSlwNPu4U1eyQLjymditzH6f61fM+sx9K7yvPPAa/bPEK3cbl4raxliYk/wAUly3A9sQZ/wCBZ710WqXd/qd1c6doU62/2Yf6TdlQdrkZWJCQRuxgsSDtBHBJ+UAn17xJp+kXlnp8k8Umr3zFLOxDgSzkAknHUIACS2MAD1wDDFF/Z0zX2qSpd6vMNiKgwsSEj5IxyQuQMseWOM9FUZ1r4A8PXlrDc634f02XWXVZJ7tk8ycSgdROf3mR2IbjHHQVzvi/wvdaKJdQh1m5fQ2KR3SXrtLLZRtIA8kcxJbYFZiQ+dv3g2BigDovDtg+u6p/wkGpMZYInI06A/dXA2mfGcbm5C+i89WOOm1iyXUtJvbGQ7UuoHgY+gZSP61Yghjt4I4YEWOKNQiIowFUDAAp9AHn3gO6a48K6Lcz7kuZLSOK4YkiRpFULIm85dvmU8IMA966OMrCWzKtsZBwzYjZh7l9zk57kCuJsrttE8S+I9FmB8w3Rvbd9uDJbz5fr3Ak85cYfoOOcV0ltcgoEjmeNGByIQkBz/wIoc++ygDajMSv5pRiRjmVXbA6cO5AGfb9aupdxOrHcPl/hVtzfkua56xurKCVI0e0852zvaZnf36KMn8fxrUhmVi6mYTL97iJuPoXYjNAGiJ1bdtSUkdjGRn8wBTkdm6xsn1x/Q1TiuFSQgrdttQZJh6+g4GfX2p7XUgYiWERxddxZv1wMD86AGXLThMmXyxnHUEH8TtP5GqS3YhR5DfRKm3JLzgkH6ZYVZWe3ScmJE3P1dEZ2J+oH9ainlkLGYRb2VclmVV2Adw27gfnQAsmoWUtuzW1xBNIMEGU5HYZ/wD1Yrn/ABTdgSaTIQFR71JGligxvEatLt3ZzyE49cY5ziuijuHuUBt5A6t0eMOwYezEgfjk5rgvijo91eafbW665/ZeoXF3DHayxQuzh2cDIfPynG4k88Z7UAekC+ia2Eybmyu4Lj5vpj8D+Veb+LTBPZ6/cKksTXaWM0iK2csk6qjbCQVY4AyBghQc8DM9r8EfBMaIbyz1HULhRg3F3qdyzv05OHC54HQDoK5nxXpel+DIL/SNFl8sSS6a0UE8kkpiSS9jXYGcklTscgA/Lz0yMgHoWo/EHwrpL3f9oarZWksc7QMksqo7uoXPUjpkDn0rnfGPiSx1DR7zVkuLddMs4CYbyKdZA0jgKgyhPzFyvyg5x9a3tD8H+GLnVdV1x9Fs7jU7y7kEt1cxLK52NsG0tnauFHTGcZNcz8RvA3hCbU9PmuNC0tJFkjkLRRGFifNVRuKYBGHf73dRjPIoA9C0acQ+H7Sef9yZkEoS4Uwspf5trAjIbnkHJznNNmkj1B1ICnaDjCbs/wDfUZ9O1Zfh/T0S3gtbeEtbxRhFeVRIoA6ZJ2tn8/etm509FCSBWZhgFYo48fX58kfnQBB5aq7K5XbjgyIoJ/AooP51LChK7re3g/3o4k5+hD8UJCi5MU1wvP8AyzeJQc98Dj8etSSyusR+aWQ+jiNgefQEUASk8qzQyGVVIUEEkHGOvIB981BbTozqkpfzADnbLn6/KHJPep5rgtFGBKI3Yjkpuz7YByPzpIrZUXy5HLhck7y+CfqWPv60AIjSlmAebbnglTx+aU87ZMtNEjAZ5cDO3vnIGP1pjQgqf3cERP8AEjjJ9Bkr0prolrE0geVT3Kbec9ySAO/egDlPFSw3KaFpkQV1vNVt9q5UgCFvtDZVBt+7D3JNd5XIZTUfH+nwvEXbTLOS7MuSwR5T5cfOAoJUT8L6V19AFDX9ItNe0e60zUYzJa3CbWAOCDnIZT2YEAg9iAa4vQ/F1k1jrWgeJGa61XSp/wCz54HVWkv/ADEDRlEHXzEbofRsnAJr0OvNJPCGm6t8UtZ192jgv7dLOyikK5PmKrSuQDwWKPFg8kbO4yKANPSdT8T6dDJHdeGry506Jv3LtewveeX6Om7axXpnzMkY4JyT1Gi6xZazbNNYyMTG2yWKRDHLC/8AddGAZT0OCOhB6EVoVxHjiO0/tPT7iw1Z9L1cXMVvcT2vltIYDk7JQ4ZQvO4Fhx2I3HIA34gTLDq1irK7vc6bfwwgdDIoilA+pETflXWTvMmmLLpiQzMqBo4x8qyjHCqei57HoK82+KWpXui+HPtPiCe3E2lzpqNjfRBoo7kxZ823dcna8kRlQc4bccYxiut+HniSz8R6DHNZSq6p9w4ALx5+R8DoCB+lAGb4MFjP468RX9pFc2s01rbCeyuMK1vMHm3nYCQC48slhkNgMCc5ru65HXrKPSvGmneKAmIXtm0y/cHARGdXilb/AGUcMpPYTEngHHXUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVBfXdvYWk11ezRwW0Kl5JZGCqijqSTT7qeK1tpbi5kWKCJS7uxwFUDJJrjrSyufF+oJqGrRzW2j20yvZWT/K0jKciWUeuein7uOzZwAVpNEbxNqcXiu8t50m08g6NbldsixBg0jlWxteYLt5wVTb0JYV0fi6/Wz8OXErMI2lURoHUk7m4AAHVvQetbdeSw3cnxI+JGo2SS58I6DGIpwi4+2XUgPyb8fdVeTtIPzKDwSKADwzfreWUOn2F2LOzuJvK82LeftDgBdonGFVF27Plbe7D5SoOT1vhnw4mj6Rb2+g6m+y2LoA8EflOxbdISFVSSWySQ3XPXpXTPZ2z2Js2gj+yGPyvKC4UJjGAB0GKjsiLexto2d5AMRh/LIJ7AkdunXp9KAK1sbzUYVkmM2nAEqYU2MxIOCSxBG3jjABxyeuBPdQoulTQ3Ya9hKFZVlCkuh+8CAADxnjHNW40WNdqDAyT+JOTVS1nll1C9TcrW8ewIwHR8Hcvvj5T+JFAGP4ElMOnXOjSuzy6NN9iDOwZnhCq8LE9yY2QE92DV0tcf4MJfxBrbEqxSCyidl+6ZBEScfgyn6EV2FAHn3xO01YNT0TxGke8W8osLxdobfBMyhTg9Ssojx7M1aFtLaBeIjCwbaRIQhB9wZFxXRa/pVrrui32l6gm+1vIWhkA6gEYyD2I6g9iAa43wVrUz2TWGtXUUesabJ9jvY8PEHdQMSKA5wHUq4+UcP9aAOijukCHMsQQ9SJFAx9fN/zzVmO6jdHyy7PR5FYfj+8NMTUEm+6u7jPyTSfT+6KsLNlgVhuAcfxmUf0oAclxhRKkCs7nG5VPI9cqG/nUV9OsUyytKtuCuN7skY/EspbPpxipJbmQALJEFyOGEpGPz2k/wCelRW8Tz2xeeTzXTJXy+Afp8zn9fwoAb9pW4t0lhmmkQ5UOsUjbvcbdox79/WmrdyQEMYpXCnYWYBeOv8AHJn8aQTpbny7hYmYjLbnY/yQZ6UW195hMcYcsvZEJAH4PQBHc6jfyjdbwLDGAdwco7N9CJABj3BrifH1vN/YV9dakLwWtts1DztplVPKdXJ4yRgBiOcYFegCa9YPst2UkYG/nn/vquW+Ld6q+BLi381FS/CQSBiGJjeRFcA5x91iO9AGCnxT1rVImm8O+AvE15a8bJ5bdLdJVOPmQyNkj0O3vyOKyn1288Sy3w17TNQ0q5S80WEWV2qqcHUFbeACRgjo2c8MO3Pt0ZDRoVJKkAgnuK8m+I13DN4htLizdpE+16OsrjIVANSC5zjkhsgg88jHegBNL1/xXYa1rGgeHPCsmpCG7lmfU72Y2lqN5yFViGLsD1C9K5/4iXPj6ERTXXhCC6mnuIUBsNQE6Z3fKSjKjcNsB/hIOCVODXt+nXdpcPcC2uA8gk/exF8tE2BlSP4fXHuTWN4q1KFVtI4vKmEu85Chx8qFlGcjbkqDkZOQOOcgAb4Nu74eHbFbvTb63uFiAlW9ZVk3DjcQpZBuIzhW4B6Vr/bZ5TtgjjVj0DOrE/gGrC0uygvbmITAlF+dQJAMdD937wH4/jXUxRx20KpGGCDgDljyfzoAhje8CnfHCxB65KcY/wCBZ/SiK4eRMvEV+m/+qioZfMmd8I6Nns0mCPYfKB+dRLDKQGEO4HvIvmY/OQ/pQBb3IzkMsowPR2H5EYqK4bFy6yIpBxtP2Rn492BP9KRziTyQm0bchltWx+YNJ9nCgqks6DsI1cf1x/KgCWGNQA0cQHb5IjHj04JFV5H8l/LwqTHnMaqGxn0+Ynp6UnkBCqTtcuCMfvmiYfrXO+Mr6fTtJktrcsl7euLGzxn5p3+VTzgEKPmOFIAUkkdaALHw723/APbWvAlk1G8aOAly37iD90vJ9WWRv+B12FU9G0630jSbPTrNSttawrDGDycKMDJ7n1NXKACuB0rVY4fHeqjUkjgsp7iVrC6kbaskkcEKTKc9GHluR6qHI6Gu+rzTVby21bw5qXh9rKz1HUJbm9QxSgPHbs08ojZwQTuIIIUDOMngc0AdSL6+v4LK7hm+ywXbAW0abSXBBYNIzA4BVfuqM89fRui2mq29vPZXCWmVYvJM6s4u95JJ6jaeqkHOMDHGBWto10t7psLmJoZFULLC67WicAZUj29uCMEEgg1beVFSRtwIjBLY5IoAxLbTI3jjtmiEVmJDKLV13Km3Ksi+iEkEexIwAcDybT/s3w4+IEEGlRyQeHtVMs0cEsDxvbuMF4EVgAUIy646bCvpn1zTdMhvYIr/AFaCK5vJ0D4lQMIQ3OxAegHQnqcZPtT8YeErTW/Cl/pdvGkUzJ5tk/a2uUyYpUH8JVsHjryD1NAHQssF7Zsrqk9tOhVlYZV1I5BHcEVg6JcS6Lfw+H78loWU/wBm3JJPmxrz5LE/8tEX1+8o3dQ2Oa+DHie+16zu4tQgeMLFb3UJYHpKmXTP+zIrrXda5pker6dJayO8L5DxTx/fhkU5V19wefQ9DkEigC/RWN4Y1Sa/tpbbUkSLV7JvKu40ztJ/hkTP8Dj5h6cg8qa2aACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDmtaVtZ1+DS1INpZBLu6GeHcsfKQ/Ta0hHqsfYmujjRY0VEGFUYA9BXPeCntdR0+XWrcsw1C4lnVyeGXIjQ4/65xp+Z9TXR0AZXid5F0S5EBZXddu5eqjufyzXn/watJdI8F6Vd2lr5kmvK13LyBsldncO/qPLKrkf3FHcY77xOjPprKkYkLfLjnJz249RkfXHrWF8KpIJvCdlbwSxs+jtPpEqqOUaGTZj2+VFOPRgaAOiFnqAy/9qMZM52GBPL+mPvY/4Fn3pssP9qNNFNLdWzW7lCIJim7IBD5HPfp065zWpTVRVZmCgM3U+tAGJC2pWd4mmyXC3KyozwXcqgOgUgFWAwHb5gQRjIBz0y08miI8JQXt8j4wHSXaB/wADZ3/ALtaMkKyTxSNnMWSo9yMZ/LI/GpScDJ6UAc74GtjBpV1JPKs17PfXD3MqjAeRZDGMDJwAsaKBnooroqwvBQR9BS7iDCO+mmvV3dSssjOp/75YVu0AFcF48EnhzWLfxVbnZYOqWWr4Yrsi3/urg4IyI2Zg2f4JGP8Fd7UV5bQXtpPa3cSTW06NFLG4yrqwwVI7gg4oAw4pJXASSLODnLThvx/1lSwi2b5Ws8jJJUN+ZIzya4nwkJNI1m78LXqzJc2JMlg5yxurLOI5NwVyWTPltnHRWP3xXYw/aApIiu1wxACYBx68xigC+glGFtrWOFRgqWXAPv8pP61YuInmgImjgypyN2XX3JHHvUUT3G0HbIwx0lbBz/wFalk8+WMFPkkHVQ2AfxK5/L1oApBvIXid4Y2OAEhSEbvYPyaRLeSWZtwvCp7faXUY/IfoatSW7HEsmyRgMABTnB7fM2PzqszRwzIrKYWIACyGFRj8MntjigCte2dhLEITE1xEckNLfEgkdOSxJrm/GPg/wDtHRNSe3kFjM9tIHuZB5xUYJ3LtwcjAI9x0rtle42sGXzGB4JdhkfUIB/Oue8b6zbWvh+9tY5i8kkLxyeVLlkBGG+bOQQCTwM8dutAHI+HNK+JdxpkEsWoeGtLtZkWQQtHNes+V6ltyABuuADjjmsrVrTX9Livl8UzWN1cRT6Oyz2UbxRyxJfo2WViRv3NJkgnO4d69U0PV4V0qNbvbDJAPLZVU4wvG4D04/zkVxvxGvLTUdRaxikEq7tME+HGMNqMYQpjnIKtu/4D70AZ03h/xZrvirXZtDv9G0fTlvGjaaS2kuJ5JAqgsE3Iq/KF7nJz0qj4l8P/ABN06OOPTNS8N6jcXh8jzPsMkD5K/NIQHZfu7sngfieevi8eaXoOs6zYeIbq2sYorz9zPJKEVw4zg7j1zuHHXB79cvx7410K706O5sNc017a3+dp0uVKqSdo5B4PQjPr36UAdH4Xa8TQbOLVpbhtRjUi4EqxowbcflCRPsAHQYzkDnJzWmxiZstZXBYnhorRAP8Ax7NPsdesta0O31LSpy9tcDfEzqY2ZM43bXKkA9RnqMHBzTo5A+/zjIVPH+sQqfqC7D9BQAwSJGGbydQXb1H2ZOfyWoV0tXVZbVri3GCQEjWMtn+8NhB/EVZiMSIywSJG7Lj5pI1b8NoNVdjJtW6topLiQ5PlWUrjHqXJAz9aALUcF4CMrIF/2Vj/APiasbJnXY9vJtIwcmMj+VUZ1ghYAeUpB43QhMc+jMCRTri1E7KFtS2ecuqoFAPUkL/UmgBsgC7rZEAJzuDTYxxyCkeM8eorE0BJPEfjObV5V/4l2kGS1tjs2ie6I2ySjqSEXMQJJyWk6Yqr4lv7wQWei6E0b6tqLmGGVCWW3jxl7khhtwgxgAHLFFyM12+i6Zb6PpVtp9kGEECbVLnczHqWY92JySe5JNAF2iiigArkfDmm2R1/xDNAjRXLXm+7YcF32KEweqjywucdc/n11ctqM0GheKBeXkwtrHUgkZuGbai3CkKqOTx+8UgAnoY8dWGQDVjj+1atdblAtoUEDoRnzmIDHd6gKwA/3m9qkGj2MWxrS3jtJE+69uojI9jjgj2PFLYSbb++hdgWdxNGcfeQqq/jgqQfw9RTrnVLK11GzsLi5jju7vcIIieX2gscfgCfwPpQAaSJmtvOuJCxmYyKmABGh+6owOwxnrzntgVdrK0bUoJt1oN0ckTvFGJBjzVQ43L6gdD7g07xNrVp4e0G91XUJFjgtYjIdzAbjjhR6sTgAdyQKAOI+E00MbeKri4e3hi/tW6FuuQNtulxKqtn0LeZj2I9a7rT9Vt9QvL23tRI4tH8qSbbiMyd0B7le+OBnGc5A8v8EaBftodsviB10u0lZGkCfLNeSFc7U/iRQzP23MSxAUHJ9Y0+CG2soIraHyIVQbY8YK+x9/WgDC8T79K1Kw1+IkQxEWl8vZoHYAP9Y3IbPZWk9a6Wq+oWkOoWFzZ3Slre4iaGRQcZVgQRn6GqXhWe4uPDmnvesWvFhEc7HqZF+Vz/AN9A0AatFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAc54kt1vtd0SznluUt5PPdlguJISzKoxkowJxk8dKm/wCEV0zGN2p4xj/kJ3PT/v5S6qmfFWgt2Vbj/wBBWtygDnYfBmjQRRxQpfxxRrsRE1K5CqPQASYAp/8AwiWlf9RH/wAGdz/8crfqrqeo2Wl2jXWpXUFpbL1kmkCL9Mnv7UAZEng3R5VCyJfuoIbDajcnkcg/6yoLLwH4esXuHsrS4t2uZDNMYr2dTLIerth+W4HJ5qvceLLy9QNoGmsbZvu3+oH7PCfdFbDOOv8Ad9iarw3Wt3kjqNZXeDyLKzaSPt8u4rgH/gdAGyfCWkEEFLwg9Qb+4/8Ai6UeEtIAx5d3+N9P/wDF1yfguw1Wx0V4JvFU0twl7cri4KB+ZX2p82/GB0AJ46eldAlz4mt2C+TbXoT74JAb67gV/wDRf0zQBbHhDRwQRFd5AwP9On6f991G3grQmGGtrhh6G9nIP/j9LB4pijuEttVtJ7GcruztLx4+oG4d/vKvSt63niuYEmtpY5oXGVkjYMrD1BHWgDnf+EG8PhQos5goG0KLybAHoBvqjc+G9L0bXvDtzptvNHM980bH7TKwKm2mJyCxB5AP4V2lYniEgap4bznnUGHH/XrPQBt0UUUAcv4+8Oya3p0FzpyQjXNNk+02EkpIUtjDxMRyEkXKH0yDjKisrwvrtvrukQ3VpaNDI2UmtAIy8EinbJG6hCwZWBB4/Hpnva868U2beHfE66lEVj0TWZEhvQY96294cLFMQcgLIMRsdv3hGe7GgDrYTAsiArbREjJXywjfqwI/KtGNZlZQWXyxkcqc/nurJg+1Qny90DnH+r3Op9emT+WwD2xTkSWLDyWtsq4xuaQJjPGM+WP50AWGkuI5Sha7bnIIVDx+C1XublzIABsJ+8jTkN+W5cVaguYo3j8zdGWH8c4Yf+hHP5UXm2ZjJDdFQF/5ZzgdOvGD60AVZ286Fo57hViOMgFf5s5rK1Gy00WL+Ulu9xIywpPcKkixs3ALKhGQPqOvWtSG6cKoW4fgAHzlyfrncM/gKxfFRu72wkgjurdAMOpMUhYuOQBhmHsc+tAGS3wR8F3USDWbfVNXmQbRNe6rcswXGMDEgAAAA4HauX13wtpnhDVLjT9KaeOwnl0WSOKW5kmMRGpRggFyTtOBgZwCGPeuis/ixHd6eLrTNE1vWopBmJ9O02Z0PtvICcdOD/Kue1zX28T6290dO1bSYY73Q7VrbUrYQzFv7Q3hgmTx0AbJHDehoA9FtfAGgtrWp6tq+l2Gp6jeT7xPdW6ytFGB8sa7s7QOemM55rC+Jnw98E3+jx3GqeHrQCG4idmsreOOaRQwJTcNpKkZBAIOOR6HNj1vxxZ+LNeGieGrvWNLkm3LLNcwwJFJsAKrvIZlGAMgflWZ418eeIrTSJTr/g3XbFwEUpBCl3A25woPmRswVgT0OM9OvUA7rwrpqWemPaaemsC2iZnSXWZ5GZQeiKxbdsUcDPYdTWpFLC7yKsF1JgkK8PmOmf8Ae3YP6VW0PxONV0SzunNpM8qq0j2c7GHJ67HKjcAeM8dOg6Vr25a7Xc0w2Z5Efzfnyw9OCKAKqSIJlR0u7cHkK0j5f2AGf0J/lTp9OSZnkWNbcMoV2OSCAc5IY49eSpNT3AhPkiFGlcHdgNIgHuQi4zwOopyp84bY7zDoyQkMB/vSf40AVktYUYmF2dV5CxrlM9/u7VB+v1pNR1G2sbGa4vLoQxxRvL50n7zaFBJIA+XIHPGfei7vLcgmUwHHRGYzt/3znC9OuawVNx4v19LSTeugaW4e7DkH7XdAho4jtGCiDazY4LFRzhsgFvwHp1/NJceI9e85NR1BFWC1lwDZW/URkDjzGPzOR32rzsBPYUUUAFFc745u7620u0TS7v7Hc3V9b232jyhIY1eQAkK3BOOOfWo49E8Qrjf4smbH/ThCM/pQB01ZHi7TP7Z8M6np4jSVp4GVY5Puu2MgH0BIHPaqbaPr5Hy+J5AfexiNINH1/v4of/wAioAq+HNI8P3Wi28miM0BVS6Sxy4mt2PDDHIU5GGUjGVwRxXnvirUNSTVLecziXUB4jttOt5JSEEavaTCMnaB/HOenWuum+Hl82rz6jB4ourWacHzkgtIVjkY/wAZUg/N0yRjPfNJD8OrpJZpH8RyymSWCfEllCQksL7o3XjgjofUD65AONbWF1Twoftt2t1p+hW93NdXKHyPtRjmdIlGCSnmFBuOexHfIyYLPV/GfirQfIezGh2dtixlvr3Y93Mq7PtMMYBd1CqxUnaCTuBIANdjbfBpbTQtb0i18RXK2WrTCaZHtIn2YkMm1cjG3cW4OfvGt8+BtROqWV9/wksoe2ne42Czj2yuyFAX9dikhR0FAGz4d8Mxac1vdX8iXmpQx+UkwQokS9NsaEnb8uBnJJA684roq5xtK8REjb4kjHXrp6H/ANmqJtI8UEfL4phB9f7MT/4ugDqKwvB9wZ7C9UjBh1G7i/ATuR+hFVTpPijPHie2A99LX/45VTSvDfiPTIZo7fxNbOJriW5YyaWCd0jlyOJBwCcD2A+tAHZUVza6d4pHXxDprfXSm/8Aj1P+weKOf+J9pn/gqb/4/QB0NFYP2PxJuz/bOl49P7Mf/wCP0mi3GqDxDqVhql1a3KRWtvPE0FsYcF3mVgcu2f8AVr+tAG/RRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBg6sceK9AHHK3Pb/ZWt6sPVDjxToQJ6pccevyrU/iPXLXQrDz7ndJLI3l29vHzJPJjIRR68degAJOADQBH4l16LRLeECM3N/dP5VraIQHmfv9FHUnt9SAcC20bz7wap4kmTUL+JjtDYW1sj/djU5y/bdgn3HFLpGm3C+ZrmvywR6jLGXnkZjiCEc+VF6IoPJGCxJ6ZycLUviXo1sGTSIZNQMKHMqALHAmDznKqi4B53A+vagDtGETu5lQTSdQkmUGPcHMjfiMegFZmi+I5Nbu5Taxyy6bDwL6COTyZpAcFIgAC6jBy5O3PAB5xwFxqPi7xlb2yR2CadoM55ildg96pDN91AhEeBnbkFgOuCQetgsNdeQRNc2a28TkeUlmQuFOAFjZ2AAG3JAwPTtQBe8CWhs9Gv5r+9vNUF9ql1cfv4N7Q4kKGPC5AA2dBjGTW3LJDbqixwugY4ADywLn0AxjPsK848HeGtS8P2T6da3Nrd2iSTXfnS6cigF5C+xdrLtXnOcnG4fw9NKLWtbtLqWC+stPmtEX99unmhA+9gjczqQcKOg78YFAHbzElCtwtyLc87bmISoR9V+YeuW6Vz8ljcaTe/bNBk8pZm3tAcPDdA+jAZLY6E4b03Abaz7Pxa9oywXNlqVu2SpDjegx1ZHQYIGT96MDg5IxWpZa5p1/YzS21zHJATmUBBkc/wAaA7T2yVKnPSgDofD2uW+tWztEDFcwtsuLdvvRN/UHBwe/sQQIPEf/ACEvDf8A2ET/AOk09cfrstympW2p6Ggk1iFf3bBysV5FjLQyuemQMK7dG256bqmtPHWj+Jtd0Cwt/tVjrEF9vn0y/hMFzEDbTnO08MP9pSR70AejUUUUAFUta0y01rSLzTNRiE1ndxNBMh7qwwf/ANdXaKAPP/BOqSNbS6VrO4X+kymxumb5RMwAKS8EDEiMj9D1I6jjr4QgXejsFPzEk7Af/HRn6VyXjxB4d12x8XQuYrZgmnarjO0ws37qVsMv+rkbBP8Adkb0FdPZSJOWaMKJR1QD5l5xz8oP6/nQBaUkkgPiQ9AWznHoN9TruVWy6gLySynH6moIiXYxhsr/AL2fr/FmpMKsoTyRjscE/wBMfrQAx5HuIwY1cp1DIw5PrkOOPaqeoLMtuXdQQqMQGj3kEKT93zPm6dKfeGN7gC1eFZyMMSM5HYcA/wBD0qg81xEVXNsshO4Ebhz07UAbmmvBJp1q9kEFq0SNEEXaoQgbcDsMYrg/GIgm8VpB5UZkaXSZzIW/u3jkde/ykDHXJ6Y55vwv4e8e6rpMsNv4m07QLGGeRbdbeyN1MUydpZmZUGVK8BTxjoemHqGl674S8W6Qdb1pvEMn9t6UiTtarbbY5jdRYKoSDtyW98jpigD2Xw9c2cOq61pcKrBNBdB/LLkl1eJG3jPbJYYHA20zxNqq2z20UbB2LqzKkpQnLBQMjpy2eeuOoOK8+0vwTN4p8ReIdQu/EGuWaW+rywRLZzRxZQIhyWMbMTkhcAgAL65rlvH/AIF1I6rYeHdF8bX6200sfmi/t4ZtjbgAu9ArEHPKMCDxk4Y0Ae6Xdrp9pZKLZTaxu7SKLORYdzMSzN1CnJJJJ7nNUIbWXynkuLwm2Uby0srErz03DIx7ZP4Vm6St1ZaNbQ6rqE0s9tEsMv2a2kt4eAB8qgrt+meOlTwRQyXkOIyszkHzZpGVxgccsz+w/rQBpM8u7FhKtvYtyp8s/Oc8nccDnjvnj3poSFE33lyskhUjli2M8Y2gk/hu5qOCO3thIFiCysC5Lqd4z2AwmPwqZ7nyGDxQuX2EkIoyfyDN9eaAOa8WX00LWGlaNYNJq+qMY7Z5FCJCuP3kzcEkKDnruY4XcNwNdp4d0i30HRbTTbQu8cCYMkhy8rE5Z2PdmYlifUmuT+Gol1y71DxZd7ytyzWmnhmz/o6OcyADp5jD3+WOPnk13tABRRRQBzPjsZt9F6/8he06f9dBXTVzfjcZt9H9tVtf/RgrpKACiiigAoorndd8VW+nzmy0+3m1TVN2z7Lbc7DjP7x+icEHB5wcgGgDoqztR1zStMkWPUdSs7WRhlUmmVGP0BOTXLour6kr3Gu6utjbheLTTyRj/ef75OD1yB7VU1G00LRLaC9/td9BtoreZwkTRJLdnKnecqd5XoBzkvz7gG/B458NXBkFrq0NwYnMcggVpDGw6q+0HafY4Naena9pOpS+VYalaTzYyYklBcD3Xr+leZ6FpOmS6jcxa7q0qxNdO8iCZrX7fLJBZssz+WVyR8wwe79K2NGsNN/sOOzvoG12yklklgkvpVeSBSx2xLuUFdvQYPykEZ6UAejUVwf2DW7FDN4bv7iERja2m6wWuU74/eBi6+xDEY/hatTSvFqPcx2PiCxm0bUXcRIJTvt53PQRTAbWJ7K21/8AZoA6iiiigArDs/8AkeNW/wCwdZf+jbqtysS0/wCR11Xp/wAg+z/9GXNAG3RRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBwPxT1C/0uXRbvSpbWC4DyxtNcRGVUV1C5CgjJ3FO/TPWvGdQ+ONloniHVbWDw/rWq+IrSSW2kvLwqX2rwdiAEQoSBlVXpgnJr2v4jeHYPFGp+HtPuby7tIvMnkL2jqshxH0yQRjJB6dhVK4v7zwW1rp2sXNzrQuU8rTnhAS7nlX/lmwXCnqDuOFAyTtA5APJbDx7beJEkm8SXAuYFdJUtYpTJArbuBs4MjZ4O7ceMBRkiu/8ACnh+bxTdrea4Ps1gjlrSwIXeXDb/ADZuzkZB2qCo3g/eBxU1H4cXN8l1rd0tvD4jmO+KKBUjgVsEGFztGZWBH749TgY2/K3R/D3Wk1Bbu2jAjnDsrRzYZ1O9s7h/DJlsMuDjAzxzQB29vBCEAIVEbrjbkFv4STznDHHsT7VP1jDnLknClcnac4Hc4PzEEj36VDFMwZUJfDAgFNoAPsD6cL1xk4I6mrbcurc4J+83G0cfKOh5OPX+VAETB9km3duO5lzGSilTgfLnPp0ODjIxVG6sYXuC89sJRlEDOeQDhRg4Bz87+p68jIrQJaQECNlcqSoYcKeDyeRnJ7Z6Gq146K0kn90lVY4JLY5C59doXAx39jQByutxiGxkugkRg2/vEkQNvc5HJz79M9DjjFeR65F9le2uLGSVo0nIxAgidHkypw55UqNz8nAJ6HA2+seJ7R3hj+13MaCLDzzMWUnJPKYPy8tnqeMZHpyOj6ANQN1farvn0i3k/wBGjyX+0so2hzktvGRtQHgnexBAGQDz7Q/C3xG8Z6Tez3XjF9G0kn78mHnlU4KcoocjoBlyxyPlAIz13w0u7K+1/wAHwHVo9cu9IL2sOpu4WW5BhuGc7cklAGVVJyTtLcZ576/sXuE07SJyQ11IsNwsTHDD5nkXcSTtwJB65GerA10euwxQXvheOCFUjjvyqKigKg+zTjAHYdqAOgooooAKKKKAK+o2Ntqen3NjfwrPaXMTQzRP0dGGGU/UE1574DurnSHufDOrzNJeaQywpLKw3XVsR+6nAPHIG1sZO+N69KrgviZp72c9j4rs4ZJX04GHUIY13NPZN9/5f4mjbEgHoHA5agDqlkDNGG+RsZG4YA6c9Vz26CrcSqG8tBIEAxzu7+5H9a57SpoLmGCTTblZI5FEivBIQHUjrjBDducD61et5JWyYmR+epjwB/wKPI7nvQBaaZ4ZjC7FgeI0V13Eeh3HJqQvI8ThVYALj768ce3+IquLoT4Z4S5UZ3QzbsH6Kcim3LzxuCWYo33cwbse3LA5/CgB/h+VZLdyZGeY7TIXxkkAITxx1jb8q5T4heF9Q1S/0u703Enl6xpl1KuQCkcErFznuMMOP96t6KZrW7KSNJF524wSMFCgt8xDDJbgjOf9s+mRdXUI7izRp5JLOViRhfm5B5wcEMPw/KgCv4bjMN9rsW0AfbjJ8owMtGjf1BPua5HxdIX8baXHAy+bHcxu5Mwy0a/vGBznaAQMAAA55JPFdadUtrfT7x7Is7RKztLKuzc5HHUDJJ4GBjsK5Hw9pMgY6lfboLq6I3CKTaCxA3EHORnpgsOhPVjQB0moWSXsgv8AzponGI5Y4Y8uD3GWBwpGOCoPI6ZxTbdbSHdC1u0gPI3PtOSemNq8Z/zzUttBDFazsPmKuvyptI9vvjHUnnH51JHIzwMqhoo1+95eFA79QxGf+A8+lAEMFtHBEQLRYsHADKcc5/56HH5c1y3jm7aDTzZRv9ov75lsbaOIgBZZDsViSNxUZ3HbwArHI4z1e9GtmeKMEDOZFUkknngKBnqONv51z+gW0/iDx0NQn3f2doysI4yBtN24K7hgAApEWBHrN7cAHd6XYwaZptpYWabLa1iWGJeuFUAAfkKs0UUAFFFFAHO+Nhm20jk8araf+jBXRVzvjUZh0fgn/ia2p47fPXRUAFFFYXiHWJoI5rPRVin1XA5kP7q1Df8ALSY5GABkhc7mxgdyADM8V63dzXraJoLFbsbftM4z+6BwdinaR5hU56HaMHByKp6TpUFjbrbFmZslhEjM2SeSScksSe5LHuabpGmxwvJDuknZydyklRI5+YtIRgyOTkn7qjPAOAa6G0TMMkOxFRW5ZPuqeucYwen8QH1NADbCOOW4WOGBUjjYc4GTjrk4PPXrtPP5ZXizTfCcazX/AImhstSurK2kkjXUisu1W+9sVvlXcUx8o7Yrd1f+zJ7WOPUhBKi/MizA7Ccdx0I56V534tsfhhapO/iK08NzaoYljjSZIlchiwRUGBzknJAyO/agDWXwv4c8SatPbavpltfW8LGS1SYkmEG3tVO0564A568dai8P6fpGjWosPDht49PimlCRwsxYfvGydzZyck85yapW/hzQde8SXg8RBHkimuY7VftTwyeUggjJBRl4/dc/StTwF/ZUPgzSLXRrlJNJhiCQiKSGRcA4J+Ysx5yfXmgDpJ57yKSKK7kjSVuImwuZPVSuRlh/sMD7EVJe29nqdnc2l/awT2sqeXLFMoZSp5wc8jn1A9ueakiaS7hkhleOdD1LAcfmoH6HrVdrO8Gx4pY3hBIAkABVT6MMgjnpx05z0oAwLHWLjwlqtrpOryXN1ot1KILO+m+d7WRiAkMz9WVidqSHnPysSSGbvq4HxRYtc2lxZ6naieK4gZVUqWWQ4PyHA+XI78cjjBxVj4beIpry1fRNblP9t2AA3SH5ruD+CYHoxwQr46OD0DLkA7asS0b/AIrbVF/6h9oen/TS5rbrBtCf+E61QY4Om2nP/bW5oA3qKKKACiiigAooooAKKKKACiiigAooooAKKK5fW9eurjUZNE8LrFNqiAfabmQboLAEZBfB+ZyPuxjk9TgckAoeNdaey8VaBZaXAt9rMiztHaB9oVSoAkkb+GMc5OCTggAniluPBsr6Xe3k919t8UyqsiXrDaI2Rg6xRD/lnHkY9TkliTT7PQbXQvEOirC8s93cNcSXN3OQ01y+wfM5x26ADAA4AArs6AOc0rUI9U0e31GNTJHPbqJwWC7sjqQPusvU8Dhu+BXC+JoB4e1waxHEXsb6VFvAwI2TBSqSHB48zaI2OOGXtuyOruN/h/WZYvJjOnXjGSAleFkJ3SRnsM/MQeOGbsgzZu7NL+3kgeNbqF1KPazgFbqE4DIwP/LRQOCeuBzySABul6na3k5WM+chO5t2CWJ+Yjb7NgAAAggk5ya31n2KN7xKgbaGAIUDIwOuOnfP4dq8fura+8B3sMlsnneHZ5Nq6i6M8tmmCBHIMbsg/KD74PzD5vRrHUre7ceQSMIo2LMy4GcD5V7AkrkDjHc4FAG8CNv7slm2FRmQnPOPf8+tZutSzLuEUmx1jco/ltnOCuMjr8xU44+6PwZFdNhjKRNaxwqSX6u2QeA3sOpHJPUYNcr4u1iSzMsGn2/2jV5YjDbbI9pdlAI3MRgIPvNnAUMDznIAOW1i5l8S/EKbQrLzvsVsiTX84iMYWEFhsQ9fMLYVSOu5iMgc+lS26Rx2kaRJFJEQQoG1YsEqihf7q7ScgYwjH+I1keCNDi0KykM7xXF/IRcXDr1uZz90kn7qLkhFPQZbGekurXU8/wDoWnCOXUb3cE3ZIAON8rDtGAQB324HVxkAv+HLb7Rrl5e5JgtAbSAk53sdpkbPQ4CRJn+8j+tXPEjEan4aA6HUSD/4DT1qabZpp9jDaxMzLGuN7nLOepY+5OSfc1k+JyBqXhnJx/xMj/6TT0Ab9FFFABRRRQAUUUUAeNw3Y8I+OrjwtexytpU+270q4Vc+QkhfNsWH3drI5QHI2cDlRnv42m2AxzrdFeQzht20843p8w/EAVxfxgjgXX7VLuIS21/pc0bjO0hobi3dSpHO4eY5GORjIrP8J+IG065ttK1udmklbFlfqny3H+ycfdlGOQAc9QByAAen/aHlTa9uzoVO1srMqk+p4/nmpI2SWJYd8G0jBUWzBff+LA+uarWrNNsmG2U4Pzj5vyYZP5sv0qby0uCWIZjjGVIkyPxDAfTNAD5beG2gUZgELZOFOwnjqMtg9e/GKymtLiSZmsNR+yAgqNhVuexxvIJ78g/zzr2dw3nSIH3oAf3YCKy4xycN0x7CoTfQbCr3eBychZDxn1Df1oAz7TS59jHUL++v5Qcl3LIv/AUVNv4jJ96vmyRG8xYMheryDOfwLKBj0xikM4jlUJMzF14G9iefYyf0qO7dFuE3589sbQQTJ9MAA/8Aj3+FAFiNysRZP3qKG+YEeWmfQ/ICOo4yfcd66pE218xSsoJzFmUA+5xkfiwx60kpmhkkMexrtsb98mXC9QMKQV5+vHc1k6xq8dqsUt7OrTyMyQwQqDNMR2jDHOBnljwOp9KAI/HGuxaD4Wu9QaWSSYgQ20EY3NcTsdscSYByzMQACzADkjAON7wPoknh/wAL2NhdSrPfKm+7mHSSZuXYe2cgDsAB2ry3xjbXl5eeFr7WGV7658SacLS2HKWyIxkcrkZLFUILtywXgKvFe30AFFFFABRRRQBgeMCPK0jIB/4mdvjJx/FWrqN/b6dAJbl8bm2Iijc8jdlVRyx9hWP41dY7fSpZCFjj1GB3Y9FUEkk1hazqN08dn9hhz4g1nKW25gWsoTySRjKAKAWI6txnIUUAXNe1+5jtj9snXRY/vOiFJroJ6n/lnET6kv7c9OY0vxPb61ry6N4XUJp9rbG5u3MomdpJWATzMMSzECQ4LZOQSQBml1Cx8O6bp8l4y2WtXShpLjUtSzJbIw6hI/usxOQqLzwdzZ5PPfD3RNQ0rxN4kv8AVbaWKXWVtbpYCpDrEnnKDKgAVCcZCgjaMDrkUAerWMEcdqgVt5bq2BhhjoMcH0wN9bFvBGpDPucgDbvHI+g7dOwHSsO2a9n8ySF4o1PPEnmcY/2Rj/voH9cVq2zNAFEsksjAdo/LX6c4H5c0AQard+RNKLOGzkusAMXLFhxxuCIxxg8ZxXm/inxZ4asZby08YaQNQ1sbYWki055CEK7lIkMfygbjgnGDk+59PubyeRStrFIhxksydPofun8zXC6z8QTp66jp8VlqNzqQAkWe3s5ZIUQqPmkdEwhBDDucAHpQAl7/AMIpYrct4v0tb0SXd3NG8mmPeog89gfuRtsP3euM8elTeCbjSpdB0eXSbCW00VbYJb2bWyxTYyfmZO2T82RgnOcmtu116HSLi6tbm1v5IzcTyebbWslwEPmEkNsUleGBGff0rF8EajY+INNt9VtLDUYbFh+5tGUsQnQEhgOCMEYPTFAHYW9xaLDjbJasRgeaSCwx0DE/pkdKltmjJSRh8zAklDuzn6En8qVBGkSCGGO1V+WV28tsdj8p/nSyK/lBYnSUEAY3liR36k5/KgAuFnW4iaKUkZ+YOgbHbjoa8q8ReP8AwXqGpXljqd5aWt/p88waa2naK6t2Rym4Nt2qfUl8c88HFenYlYAC3X5mC7eNo9+gzxXjXhnT73w3qUGvAQ3X9taleX1m8a+WweWQl7R2HDB0QMjMfvLjjC5APSNG16ePSl1G3v08RaIfmNzDsNxEgyCxEfyTAEc7NpAzgMeK09OliuPGd9PBIskUml2bo6nKspkuCCD3yK5C5itbXxr4a1vwo9tY6fqU00GqKEASWQgbN8fGyTKuu8YO4qrbsgVr+Cllh8aeJ7ae0mtlhjh+z78bXiaa5YFcHpktxxjjtigDuaKKKACiiigAooooAKKKKACiiigAopk0scELzTyJHEilnd2AVQOpJPQVxhku/HWVgaay8KH70oyk+pD0XvHCe5+846YHLAE15qt74muptN8MzNb2ETGO81hQDgg4aK3zwz9QXwVX3bgdFomk2WiadHY6bAIbdMnGclmPJZieWYnkseSetWbS2gs7WK2tIY4LeJQkcUahVRR0AA4AqWgDD1Un/hKtCGeNlwcf8BWtysTVBnxVoftHcn9ErboAralZQajZSWt0paN+4OCpByGB7EEAg9iK5DUBPokQt9SeRrEENDexKFEb543D7qE5xg4Ru2wnae4pHVXRkdQyMMEEZBFAHLWMebTyJWiuzcREPAyYhu1xg7QxO1scFT2GDwAw858VzXXgK+07UNNiN54cubkQsrsUls5OCsUjHJK5X5SejbQT0Nd9d2x8O3scSOy6LdMFjx/y6SAcBfQcEjtxtPVQI9c0seItM1LStQEXl30TW8+31IADqPVGMbqSfuvjqtAHETeP31VbG08OWUz6jcFYEUqVjQYG7LYIAXLMecgKSAQDns/CHhU2Ky3t1Kl7qt2A8tzKhUSc5HyjogJJCk5Y8scgbfLP2bLb7fpN/qt5GPtMU50yMSqAA4A80jAHDFogfQFgOpr2XXNSlNrHY2YM95cymGFWbAcDId5MdEB3HA/u987aAItV1iJrl4ooVuribMcEKYO5iME9CCcYBY/KoznjOdXw9pDacks93Is2oXBzK652qMkhFzzgZPJ5Ykk9cB2g6JBpMW4kT3zria6ZcM564A/hXPRRwPc8nWoAKxPEQB1Lw5ntqB/9J5626xPEX/IS8Ocn/kIn/wBJp6ANuiiigAooooAKKKKAOH+KNvHs0G+chfJvjbliBjE8TxBTnsXaMGucWwstQspI9RgWaxlCiRXXOz03j1HZuD05r0Lxlog8R+F9S0kyeVJcwkQzf88ZR80cg91cKw9xXFeGb+TVdOt7ueH7NczqfNRV2tBMvyTQkf7Dh1+gB74IBY0yLUtEVvs051axxhBNLsmX/ZMo+9/wIBv7zGt+HWbR40kvzLZsTtBvoA0QHtKuU5/3zSW1hslVkkWIsMEZDROP6H6flVrUNPgtoxPG7W0xblkfZkn1IA3D2PHTpQBbjZVtHeA/aCwUlopmYdMgjkkDBB49aRbp2VdxuAG4IO2M/QblX9KqwWv23iVbObAyDLEJSp/76BHb8qqajpM8cGJXM0IOFVZpFwMcDBk4/P0oA0vM2sA4Pygbw0zNx9AW/XFVLvVYbeNjEIpIyPlQDy9zDplvTr/D271lQaUskkSmzCRA5DBYyQfXczN79u9XLfTk+2OViidigx+8U8A8cIFI+ooAyrmS/wBSkhiW9a2iZfmhtv8ASGZgeSJHzgdOgUjnNTR2KafN5mBJcSgCd5XMkpI+6rSHOeh+UnjsBWw0c0fDvHCi/MdqHGT7yYBPA759qiukVLMtKJ5SAFjdXI68HBxgA+ig9ByaAOZuk/tH4ieFLWRQ5tJLnUSMn5QkXlZ9/nnXk85Az7em1wPgS1+2+MfEWsssAitki0i28sfd2DzJffl5FXk/8s676gAooooAKKKKAOP+KdvJd+GktoVLSTXKIqqcFjg4A9yeK5jxhbSpeaVrMRludGvk8i5it3ZWMEzoV2kcgFhGH/2W443Guu+IV4thY6Vcsjy7NSgCxRrlpGJIVQPUsQOeB1NctrNq3h/wwmkC6a61vUrtngg84skUsj/LFEp+7FGsh5wPljyeSBQBo+MYJoPDAEtxDNd6fc213HbtCAqKssZA54YLwN4xxnPNWPHMEsXiTQ7uG1a6S4WWzeMOFBYYkjJOCQAEl6YPPWpPGt017p39nTRpBc3AWJYi4aQmRxF24AwzN1z8vbBrT8e6fJf+Grg20DXF3akXUMS43SMnJQZBGWXcvI/ioAjsnuVAFxp0CkcKxilkJ/EqSK2raVQxEhgjbqEAKn6849+1cR4f1G1ltkljgJTaGVgqkYK8HgP2P+yOtdda6h5mEALnAxtXjB6H5S2PrgD6UASazFPcW6x26yYYgl4pSjD8iP51554m8W6hosOo6XYeHdb1a4NqXa7tXVzCPmX59z5BBGRjrz6Gu51uK9uIk+zFkU8Ns4K/99Muc1w+pH4j2s9xF4YsdKubKWLiW8vWDRyDcDj7/X5TjIA2n1zQBt29/rseramujaba3aiaVpUmuTCu/wAm2ZAHEbZ+8wwQPXtTfCN1qk+n2F5PokNpqM1spmihlLxoD2XLAAcDjHY8msO50nxBrM9w+n+K30GW0YNcJ5IdZybW0bLgnoCr5YHPzEVreBYNUg02ysZdSOpXUMWZtQkKsRu+YdMjHJAC4GB+NAHYyW9xNbrvlZJFBPysck+nBUVXSK4ywaafG3gqxAz15zkfr+dWbSOeJWb7QlwsjFt7EgJ9Bzn8xUMrxqBNJJAMYIfC+v8AwIn86AMbXb6TTNJu71ZZHkjQRRQNOJPMmdgkS4HT52UZPrVrVvDFre+BT4fnlkSGO1SJJ04eN4wCkg9wyq34VUv7f+0/F2k6eJDLa6ap1O5BJIMhylupySeplf2Ma111AHmPhfwZYar4SB8UxW1zNrdvG12HbkSeWFJhY/MvPTBG0BcDOSdD4ew6hZeItV0zVpLm4lsLC0hiu7hgz3EPm3OxnYY3OMFS2BuwG43YFDw34etbrSTYavAs63siiIzxiTyoBEGMMZYHaBIr/KegPtx03h2G4tfEt9bXkiTTR6daKJFBG5RJcdc9/fvjPHSgDp6KKKACiiigCO4nitreWe4kSKCJS8kjsFVFAySSegAqnpWs6fqzSrp9yszxBS64KsobO04IBwcHB6HBpfEFpHfaJfWk1q15FNC0bQLJsaQEYIDZGD6HI57iuJWx8TArKseqz2Ntc2s0drezWxumwz+aA8bBSm1kIDtkkNz0yAegvcQpcRwPLGs8oZkjLAM4XG4gdSBkZ+oqSvNoPDupz3GjXmo6ZJJLFdaoSrTRs9sJ7oyQuTvwVVQMhSSOAAelQJo/iS80W4tprG8tpV0ezsRuu4w0k0cjGRlZHJHBHzEgn60AeoUV5vfeFL2HxSslvDfPYRvbtZSW0kJNsFYF1ZpWDqGbJbZu3KxB6AVo+AdI1DStS1AXFk0NpIilZ7ny/tM0m9id7RuwkGCPmYK3PfsAa/iXRbfVJY59ZuWfRrRDNJYlf3Urrzvl7uqgZCdM8nPGNy2mjuLeKaBg0MiB0YDqpGQfyryz+y77V9S1drCxmFxFqN4j3zyoFeEwOogHzbiC7IcEBRgtnIGZI/D2v/23pU4sGt5rSS3QXUH2faYBAFcSMW81iGLDauEwAeTzQB6nVfUL2306xnvL2QRW0Kl5HIJCgdTxXmreG9Tfw5p9tHo08F5DJC2qt5sEh1PCOGI3ORJ+8Kv+925Ax7CvqvhTVJ9EuLV9KvNRV9PaGyS6lt99lN50rEkb9oBR4lUoWwseDjuAd14lsbqbUdKu7DVLawuYmkhVbi2M6zb1B24DoQRsz19aRbLxTj5tc0cn20mQf+3FWPEVreXN1obWasUgvxLcYcLiPypBzzz8zLxz+lc78PvD1/ojaU11bGFm0S3hv280MXu1xuLEE7mGWG7kY4zjFAG59j8T/wDQa0n/AMFUn/yRThaeI++saX/4LH/+P1x2qeHNefVtebSLd4TeRXGL25aNZdzFdqRyo5fYQCAHQbOx45dY+E7qU6bbyWepQab/AGn591bySwwKsf2SdPlWB8bTI0WRnkkkjGTQB0+o6Rr9/Zvbya3YR5ZXV49NOVZWDA/NKR1A7VXtvDmtwNCRr1sViCqq/wBn8YCso/5aejYJ/wBkVz7+GtUZ7qP7FewzMb4XN/bXMayXkUhfyUjJfIZQyY3gKuzAODmqs3h3W5tGisJtCgWy864ZVtobZJkykYjco8jRJk+bkoSeEIALNgAseBPAM/gSzi0PTfEwlE8730cdxYqzEgKrn5WHHKnnuR64rpLTw7rNrdrPHr0B2xtGA1hnqVJOd+c/Ko/CsrT9P1bUPDOrPcLMdWj0kaXAGf5jMIcyMHzjLSsFJzj90DnvVe58IXUU93JY2AV0OnTWpEqjbKsubhxk8MUC7m6sOOaAOtFjr3fW7b/wA/8As6RrDXSeNctwPawGf/Q64q20jVr9dftrW4aW10pmsbDbMVM6vIksqFs9VTbAG7YfnrV208M3Vzf2qz6WbbQjqMkx02WSMrDD9l2YZVYrgygtsXI5yeScAHS/2b4gz/yMEWMn/lwXp/31VaTSr5tY0p9T8QxSGC4a4hthbJGZSI3QjqScByePQVyA8I69FolpFZxPBeSaWkV+3nqXnkSeFijNk7mMQlQMcgbsEgVb07wvcQ3ui3Umk3ssFtfTP9nna2Q2yvEgDRrG+wIHQsVBzkk45oA9IkniilhikkVZJiVjUnliASQPwBNSV5l/wiOrJoFjFbJNHqMv2z7XI92WwXgnSIkljwGdMBenHHFTy6Trmqyztc6ddW1vJJpitDNcxkskUjGf7jkY2kZGfmHr0oA9GorgdC8M3em6vp1zFZiERajeiRlkX5bNhIYUHP3M+XhB930HNd9QAUUVheLdYm020ittMSOfW75jDYwOeC3eR8c+WgO5j6YA5ZQQClrWr6nqGrT6H4WaCG5gRWvdSuIzJFaFsFUVAR5kpXnGQFBBbOVVvM3S2+HniEA6vNq2m6/fPM93d7FMF633wCqqhWTC4UY2smP4q9YstGh0fRobGLM+WLzFx895O3LPIf8AaOWPbt0GKtvodhcWM9rqFrBeJcR+VOJowwkXH3cHovovQUAU9OnjKgSFVjZQ3zH5DjuD2Of/AK+DWhqOmxXaRkApJH91gccen+f615zpl5deC7i4g1Nrm48Mqd1nrMwBjiXH+ruMnPy8BZuFYYBIPLeo20y3EEc0ZBR1DAjoRQBlW9pNawW6NFbB03AlUJBJ/i6cHGOc0lu2WaIRE5AO2C42fkofj9Ks6ugxHJ9qit2XOPMAwx46Z6H3Hr9KqRpdzITLtdQcbV81Sw9CDjJ96ALbIQg/0e8JPJH2g/z3VDI53bGVo2UbvLllDkj/AL+c/jUDQzFf3lsxj/uqrbh9PnpJGWC23M5jGcDewUk/X56ACSe1glZ5Jbe2cZU+SU3nPPICkjp61znjLWo9I0Wa9inlkn3BY4I4XMlw5+WNMZLnLEcE4xk44Nal7qmnaJpz6hdSw2+nxDmd2YAnoEUgD5iwwAASSe9cd4XtvEFz4lk8Wa7pclorbk0yxu48raQEcyOyMzRyuvB3J8q/LkZbIA7wV8N7nSdMkn0rxdqLajNcNdXexmjha5YAufKOQpJxwytxjiu/8OatcTTPpmrhU1SGJZSVACzRnjcACQCGBVlBODjsy5s211BqQiuB50NzbjzGiUgsVYdOMh0OOCMgkDHI4w9aEglh1TSSJdzie3IAH7wYWSA8ZHmIMAHpIozzgUAdjRUVrcRXdrDc20iyQTIJI3U5DKRkEfUGpaACiiigDmfHMvkpokm3eU1KNguM5wkh/pXj3hjVoNP8Sre3cdxrCxeeZ7qaXY1l5Um9gC2NyhChAxknOWPG30z4w340vQdMvTIsRh1KFlZm2jftfaCfQtgH2NfPPjbxJqXhiPwvLpdzA02pam73W4RttjhMSrbl1+8h8xmIb5iCpNAH0RoFuPEnidPEPlzLptqGNm8u0m5kdQDIu3jy1XKqedxZjngE9zXLfDCd5vA2mRyTJcNaB7Lz05WYQyNEHB7hgmfxrqaAPLtai/4RnxMtq6wPp2pF5bMMfLaN87pIg446ksu7jBIH3eeq0sWssahppLeQDgOcP26Mev4YrT8S6JaeIdHn0+9X5JBlJB96J/4XX0IP+B4JFea+AtYuzHPo+vj/AInWm3MltMGG1ZSu0+ZGcYZSskbdAw3jJ70AenXOlQXlsIr0CcqSVL5IB+ma5bUvDutvqPl6L4qGmxLBIrRizEzIGKbSCzYH3T1/DvXSW6+bal7O6MSAneFjBAI645zn8TXDa34Ss/EPiWCaHVvENk5EsU01jdJGJQQDtJAPB29Dg0AZ194W0zVLiGHX9WlhOnwJve1uPJkmH2eDLYxlhlBxjqRW54I0G3t9Fh09b+8u7LTwYmuruQuZXDEMc4A4wRyDxjrWB4W8JR6jq2qReLrCRrTS4bLyHmDqj4tEDsrDHKlSD/Kuj8I+F9N8PXU+maZDGtnA8twsRkaVtzvkZLZYYz68nPpQB0qfYtqRxxB4YSY/McgKTwc7vXPuKp6vqdvpGl3t9csIobWMyzeQBuKj+HJ5ZmICgDqSOaljUtI7ALJOmN3lZyO3UjP5g/WuY8PbvGfiD7bAPL8KaVcN5BUgrqd0hx5me8UTBtvUNJ82fkGQDqPBekTaZpss+oKv9rahKbu8w27Y7AARhu4RQqA99ue5roKKKAOavIkstQMTTTqkrmSNFKqG3tyATzuVzkYP/LTGCORPYSCXxnqEkbExvp1qR6f624rU1PT7XU7Rra+iEsLEHGSCCOhBHII9RzWFolmth4y1WJJ7mYNYWr5uJmlK/vLgYBPQUAdPRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFQ3lzFZwNNOxCDAGASWJ6AAcknsBQBDrGo2+k6bcX14zCGFckKNzMScBVHdiSAAOpIFYej6fqAu31vWFgh1C4UBlJDCxtlw3kBu7E8u/Qn2VamsdPutT1GLVdcHlJCd1lYZyICRjzJD0aU5I9FBwMnLHRMT6hNuuEeO0jb5YmGPNI/iYeg7Dv1PagCxbr5z/AGlx7RD0X1+p/lgetSzoJo3iJI3DBx6d/pSzyrDGXYE46ADJJ9BSRbli3TFQ+Msew9voKAKuqOVtxbwsI2lBG7YG2IB8xC9D2A4PJHBHFchB4c1TwzYvL4d1VLOxB3nSrpPNhjHHyxOMujHqQA65PyqM89rGhkYSuuC3OCOgHQf1+tOlijnkQsQwibdt7BscE/TOfyPpQB5NL451bTUJ8Y+F9U0gnlJ45TNDjPG6RA6g9c7yv0pNH+I/hG9kJtL+xdpf+Wf2iFmB47GTJ59hXrs+/wAiTyiBJtO0npnt+tc1PomnS6YYWsbdpJ5Bbxs0KuyoDtyCQf4FLfXmgDktS8e+HrOHzbrUrK0QgKu8K7H/AGQqbiT7UWviHUNahd/BWj3eoLvEbXFzH/Z9sOeeZB5pI/2VxXaW3hPQNOv4rnTtF0uxkQFjNBaRxtkMp5YAH+9+ZrWKGDUg6nEdwNrD1cDg/ioIJ/2VoA88svBp1XU7XU9f1O5vtTjcmOCcFILKQYJWOMMHWTaARLvYkAkcEA9/ZXMcfk2kks7z4bBmTDHHYkDGcfmASM4Jo1S33oZowRIAAWUc4ByD7lTyPxHc1FKN8cWpwIftCJiRF/5aIM5T3wclffOOGOQCtqFqNMWO5sl8uOORnPOEiB+8MY4RiOcfdOGxwalSOKdGIVls73llwAYZfX2JI7dGGeSatR36PCkkioqFvLlJkXEbHGOT1ByMeu4cc1Us1XT7xrRRi0JG1SOEJ+7j/Z6r7FR60AVfD8j6dfzaZdFVErtLCo4CseXVR/dPLr1x86/wV0dZ+saYmoQja3lXEZ3RygcqR0pmj6i84NrfqIdRiHzxnjeAcb09VPt0PFAGnRRRQBy/juyt9RGh2V7Ck9rcah5csTjIZTBNkV4Jd+GND17VY7NnufIi1Ff7JvJJWb7YpilDKEbOELLEuVxuwDwMGvoXxMM3/hwZP/IS7d/3E1a0Njaw3lxdxQRpdXAUSyhfmcKMKCfagCHRLA6bp0ds83nSZZ5JAmwM7MWbC/wjJOBzgY5PWr1FFABXl/xP0aG31GPVHlW2trl1dpwdrQXUakI4btvj3Rtng7Iwc5r1CsHx3b21z4R1Nb6HzrWOPz5E7lYyHOPf5eD64oAyfDWo/aNMa2vn8tnjwbgHKN6HB4U+w+X0A6Vcl0i+iQSWcnmSjGxwy5HHJBI447frXJ+D9Uj0jUP7O11EUq/l2+oxsY4Z1J+U9cIxGPlJ5zlS3RfS91tZWzAyRwxRjDMWAxxnn3xzQBzV0JLua4XVpZTa4XdZrIuN3XDEdBwD94nn25Ys9qtoVjjihh5d47ZDzj12glj9ce4GKaLKJLj/AFUpd8OrC2JLD03eWQT7ZqadZGMauLl3HCK0nlg/zP4DDdKAOa8Yrqmr+A9VitjLp32wf2bb24KpJJLMyxo7MudqjfuKqeQvJAyD6HoGlW2h6HYaVYoEtbKBLeMAY+VQAPx4rhFuJNX+IvhqzgeM6dpqXt1L5Q/dzToI4gR6hPPKgnq27ulelUAFFFFABWHbf8jxqX/YOtf/AEbcVuViWx/4rbURgf8AIOtef+2lxQBt0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABSFQSCQCVORkdDS0UARTQiV495BjU7ihUEEggqefQjIx3qWiigCNGjnVZEKuoJ2t1HpkfrROhlUJxsY/PnuPT8f8akpsasqgO25u5xj8hQAy7nFtbvKwJxgBR1ZicAD6kgUlnE0NuquQZDlnI6FicnHtk0hgMk4eYgiNiY1BOOg5I7kHOPrU9ADXwcAnqePw5/pUEg/wBKtY+yBpM/QBcf+P8A6VZI/Sq6D/iYzEjpEgB/Fs/0oAW/j86xuY8gb42XJOAMii5BFuGOMxkOe/Q5OPwyPxqcjIwelV7VXawhWTIcxANkcg45oAsVTgPk3ckI/wBW3Kj+6cfyODj/AHTVyk2jOcDPrigDHtIFt9Te0cDy2QtGCMq8WfufVCRj/ZYfhJcKJJ/s8m97iMEr5uFE8bfeAI4449wQp6HJ0pY1k2kj5lJKtgEqcEZGe+CaHiSQJ5iq+xgylhnBHf60AYev643h7SzPdxS3BWWKOMxJuabfIqbQP7/zdOhPTuBf0O+j1jS7TUBD5bSKfkbl4mzhkbjhgQQR2II7VLq2m2WsafNY6paxXdnNgSQzLuR8EEZB68gUunafbadC0NlEsMGQVjQAKuFC4A/CgC1RRRQBh+IxnUvDnp/aJz/4Dz1uVh+If+Qt4ZGODqLf+ktwf6VuUAFFFFABXPeINUkkW60/TYo5ZVQrczzIXht9y8AqMGRzkYjUgkHkrlcrqOsreReTo13GFZvLkvlAdIv9lOzyE8BRnB5PZWsWtjFb28UwErQQruhhfO4ueS755Lkk8npknrQB5t4S0e/0GS18O6jezXLxWoW3ublY1kaJeNsiqWBAHYkkrjvmuy1Tw21tZK9jtlkTl/OUMMDkEA+mBxmta101byxaS+DC4nbzt6kq0RxgFTnKkD9ODxXOyW3isX92YLhb23ifYnmuYXZfdR8jH3G3IwfagCsl3qBL7o4JGBBZUhQjn2z+tM1OC7v49ga5jhjId1hKRhyOzNyABxk/LwOverCzeL3vFij0y3id0JDXEwSPIIHO13z1/uj8KSw8K32q3Kr41vW1CNQ3+hwIYrUMCD83JMgwVxkgcNlc9ADn9B0q/ur+31qx1S604fYzY2EcUMQjnjMvmGUCSPYQ7fdQMh8tVOctx3GieIbldQh0vXo41uZgRa3kKlYbsqCWTacmKUAEmMk8AkE4YLfi0230vesbf8S5hlrVwZFXnkqOwyRnt+Qpus6BBqFuUZ5QSwYsrEPwcqysOQ69Vbrxg5BNAG3RXOaPq9zbCO11uRZQTsivxGY1kOQAsq4/dynI4+62eMZ2jo6ACsK2APjnUTg5GnWvP/bW4/wrdrAtc/8ACeanxx/Ztpzj/prcUAb9FFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFGOc96KKACiiigAooooAKKKKACiiigAqjqmrWGkpE+pXcNssrbEMjY3HBOB68An8KvVzPjDSNQ1TUNCfTLmWzNtPK73UQjYxAwSKp2uCGG5gMYzz260Aad9YaT4j0+2N1DbahZlhcQNkOhO0gOpHsx5HY1VHhHQAQRpdvkDHQ/wCNcJeeFdYlstNtprG8W2tbJ7UR2UsDvHOHObhDKwxvBBVgQ6kYwM1YsbLUb3xNqM1jZSG9s9XLHUJpU2CMWqZh4beQzMMgLt53dQKAOvn8MeG7ZBJPp1pGjOsYLDjczBVH1LMB+NPfwf4ecEPo9mwIwQ0eQR6Vwuj+G9fg80x2E9msr6XJLCGt4k8yK8V5yixMePLzyxLMBjJ4Fdr4I0aTStPuJLyORdQubiZ5TJMZMr50hjxyQBtYcDHX1oAfH4K8NRpEiaFp6pDzGogXCdvlHb8KJ/Bnhyc/vdItGHoV46Y6Vydp4fv00SygudBmlvoXjbVZPPiP9rYzvIO/5ssQ+JNvA29OKjuPCeq3WnyxzWblF0/UBZwPOp+zSvMGtkzuxuVeAwOExgHABoA7L/hD9AyT/ZVvz7H/ABqqnhnwrBqC2KaZaLdSRGYR7DkopCk+nBZR+Ncpr2k3Gk3KAWEsmn3V5p4NtFIn+kS4lEwILAEn5NxYgN3zzTbnwr4geyC2cTWw+z3KpF5yboonvYpRbA5IyYVZO6rnbnABoA7OTwx4ZS4hjl06wWeTd5SsAGbAydo6nA64qwPCmhbs/wBk2mf+uYri7PwtdR3GkXP9l3jx217O6wTm2U2okiQBkRH2CMOm4qDnJJxzVPS/CuuW2mFJrbUHutlut8hlt1iv9kyNLhlbc7MocbpNuQ21sZ4AO3tdB8NXzTm20+0kMMjQSYQja69V/WrP/CLaJn/kGwevQ1Q8GabdaVpGqpFp6WDS3k09rbOU2qrAbQdhIAz2HSuN03wvrnk3MZ0+4tIbk6Y08Ae3hQvHdq9wUETdPKzyxLsBjJ4FAHcXnhPwzHa3Mt5pFk0HlHzjJHvDIAc7geoxmpbXw34dntoprfS7JoZFDowiHKkZBrjL/wALaiEurZtI+26Vm/S0skkiCQtIYzDIFZgoAxIBjld3A546jUrDUU8I6PDaQSSXlnJZySwRyKrOsboZFBJC5wD1IB9aALM3hrwyJ4oZtM00TS58tHRdz45OB3x14rS0zSNO0syHTbK2tTJgOYowpYDOASOuMnH1PrXEQaFqM9/o2oanpMsxg1O9mMLTRtJDHK5Mbff24GFyASR2BrHsfCOurp0sFxHqX9oPHFFd3Ec8MUV2wuImeUOjiUttWQgsAQGYelAHrtFef3OjarZ6pNaabY3LadJqVjcxzLcJsihj8sSKQz78/IxwAQQeueKs+CdI1DTNf1F5rF4rKVWb7Tc+X9olkMhOC8bnzFwTguqsBgc84AO3ooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK47xr4lvdPS/t9HgRprOKCaeeR8CMSyFVCrtO8/K2c4AGOSeK7GsfVvDel6tcme+t5HlZFjcpPJGJFViyhwrAMASSM5xk46mgDn7zxwbG6kilt4zGLyaA3NxJ9nhQRlBt34YbzvyA20HaeRirU/i6QXcsQsTHbfa5tPS580FvPSNpASmPuEKRnOc9sc1pXnhTR7xZ0nt5jHO7vNGt1KiTF8bw6hgGBx90gjrxyar6b4RsbbUby9uWlup57qW5QNJIEh8xdp2puKhtpYbwAcMfU0AY2meOXEOgR3cCXL3kVolxNCzFoppkUjeoTYgJYdXBwcgGrL+PI2sWmtdNuZ54bcS3UKnJtnM/k7HwCeGWUkgHCxMcHgVpxeDdDilgeK0lTyWhdEW6lCboQqxsU3bWYBEG4gkhQCTinWHhe0t01jzmZpNUuzdTyQM1uwxtCKGRtwwFXJB5O48biKAHW/iKOTwhca6VgljggmmZbW4EyN5e7IV8DP3e4BHQgEVmJ4xnN0tg2lhdTmlhS2hNz8jiSOWQF32/LhYZMgBugxnNb0Oh6fDo0+lJAfsM6yLKjSOzSeZneWcncSdxySc89ahuvDelXUjyS27iVhEPMjmkR18vdsKsrAqQHYZGCQSDmgDItPGbXl1Db22lTu/lzSXJ85AsHlTNDIOuWw6NjA5HpVMePbgWTXcmjbYEsYdTY/agSLaQkZxt/1g2k7emP4s8V09noGmWZU21tsYQG2z5jEmMsWIOTySxJLHkk9aibwxpDWj2zWmYHsk09l81+YEztTOc8bjz1560AYWq+NTBqF5YQwIf3dykF1CzSKJoo2cq+UCA/K3AdiCOQK1X12W18PaNcND9qv9QEMUUe4Rq8rpuJJwdqgBiSAeBwCcCnt4R0Vrt7hrWUuzyybPtMvlq0oYSFU3bVLb2yQBkknrzV280Wwu9Mh0+eEm1h2eUFkZGjKfdKuCGBGOoOaAMS68WT2c0y3OmBUs/J+3utyD5JlYquwbfnAGGOdvBGATkCvL41m23LR6aFjxqEds7TZ8yW0dkYMoHyqxQ4OSeOQOCdhvCukNPDM8E7yRbOXupW8zY5dPMBbEm1iSN+cE8VKfDekmNU+y/Kr3MgHmPw1wzNMev8AEXb6Z4xQBymh+K9SgWG01FTeanc2tlLDGzIimSc3HV1UYULAT90kAdWJrSg8bxtZ3Es9i8ctvbX9xIiyBhm0mMLqDgZyQSDgcVd1fwpZ3dswskit7vy7eFJpPNfYkDOYwNkiMCPMk+YMD83ORxVa08C6UNGgsdR866dBc+ZKk8sJkFxIZJVO18lCx+6xboMknmgAm8Xss2phNP229gse+5nuFjjLyIjIg6tn5wPu9cYyTiqNh41vtR1PS7a00xFMtzcW14krOhjMaI4ZNyqSCHB+ZQe3vXSTeHdLmt7yCS2Pl3bxyS4lcEtGFEbAg5Vl2IQVwQVB681BB4U0iAxtFBOJY7g3Yl+1zGTzCoUkuW3EFVAIJIOORQBhWnjlm09rn7EZ4LWBbi+m3iMxo0kiDYnO4gRsSMjjGCScVpWHiprrWYrRrAx2013cWUU/nAs0sO4tlMcKQjYOc5GMd6tf8IjogMGLR1EKhAqzyBXUOXVXAbEgDMxAbIG4461ch0PToZoZY7fEkNxLdxne3Esu4O3XvvbjoM8YoA0qKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA//9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (E) Using the lightest possible suture, the third layer approximates the superficial myometrium and serosa. The rough edges should be imbricated as much as possible to prevent adhesions along the suture line.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_47_43770=[""].join("\n");
var outline_f42_47_43770=null;
var title_f42_47_43771="Bact arthritis child PO Rx";
var content_f42_47_43771=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F58533&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F58533&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Doses of oral antibiotics commonly used in the treatment of bacterial arthritis in infants and children &gt;1 month of age*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Oral agent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Amoxicillin",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        100 mg/kg per day divided in 4 doses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cefixime",
"       </td>",
"       <td>",
"        8 mg/kg per day in divided in 1 or 2 doses; maximum dose 400 mg/day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cephalexin",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        150 mg/kg per day in divided in 4 doses; maximum dose 4 g/day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Clindamycin",
"       </td>",
"       <td>",
"        30 mg/kg per day divided in 3 doses; maximum dose 1.8 g/day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cloxacillin",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        125 mg/kg per day divided in 4 doses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dicloxacillin",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        100 mg/kg per day divided in 4 doses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Penicillin V",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        150 mg/kg per day divided in 6 doses",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * See text for details regarding indications for particular drugs; recommended doses are for patients with normal renal function. Antibiotics administered orally for bacterial arthritis are generally given in higher doses than those used for treatment of other infections and recommended in package inserts.",
"     <br>",
"      &bull; To achieve adequate serum levels, doses can be increased to 200 mg/kg per day without serious adverse side effects. Diarrhea can be mitigated by using the doses above and adding probenecid (40 mg/kg per day in 4 divided doses, maximum of 2 grams per day).",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_47_43771=[""].join("\n");
var outline_f42_47_43771=null;
var title_f42_47_43772="Laboratory monitoring during leprosy treatment";
var content_f42_47_43772=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F76797&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F76797&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Laboratory monitoring for multiple drug treatment (MDT) for leprosy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Initial visit",
"       </td>",
"       <td class=\"subtitle1\">",
"        Second visit",
"        <br/>",
"        (1-2 months)",
"       </td>",
"       <td class=\"subtitle1\">",
"        3 months",
"       </td>",
"       <td class=\"subtitle1\">",
"        6 months",
"       </td>",
"       <td class=\"subtitle1\">",
"        12 months",
"       </td>",
"       <td class=\"subtitle1\">",
"        18 months",
"       </td>",
"       <td class=\"subtitle1\">",
"        24 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CBC + platelets",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        X",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        AST",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        X",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        ALT",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        X",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Calcium",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        BUN",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Creatinine",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bilirubin",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        G6PD",
"       </td>",
"       <td>",
"        X",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hepatitis B",
"       </td>",
"       <td colspan=\"7\" rowspan=\"2\">",
"        <br/>",
"        Screen if patient requires prednisone for treatment of immunologic reaction.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hepatitis C",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CBC: complete blood count; AST: aspartate aminotransferase; ALT: alanine aminotransferase; BUN: blood urea nitrogen; G6PD: glucose 6 phosphate dehydrogenase.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_47_43772=[""].join("\n");
var outline_f42_47_43772=null;
var title_f42_47_43773="Duke criteria for IE I";
var content_f42_47_43773=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F73023%7EID%2F53004&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F73023%7EID%2F53004&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Modified Duke criteria for diagnosis of infective endocarditis - table A",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Definite IE",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Pathologic criteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"1\">",
"        Microorganism:",
"demonstrated by culture or histology in a vegetation, or in a",
"vegetation that has embolized, or in an intracardiac abscess",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"1\">",
"        Pathologic lesions: vegetation or intracardiac abscess, confirmed by histology showing active endocarditis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Clinical criteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Using specific definitions listed in",
"        <strong>",
"         Table B:",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        2 major criteria",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        1 major and 3 minor criteria",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        5 minor criteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Possible IE*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1 major criterion and 1 minor criterion",
"        <strong>",
"         OR",
"        </strong>",
"        3 minor criteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Rejected IE",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        Firm alternate diagnosis for manifestations of endocarditis",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        Resolution of manifestations of endocarditis, with antibiotic therapy for four days or less",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        No pathologic evidence of infective endocarditis at surgery or autopsy after antibiotic therapy for four days or less",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        Does not meet criteria for possible infective endocarditis, as above",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * The category of possible IE represents a modification from the previous published Duke criteria.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Li JS, Sexton DJ, Mick N, et al. Clin Infect Dis 2000; 30:633. Copyright &copy; 2000 University of Chicago Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Modified Duke criteria for diagnosis of infective endocarditis - table B",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Major criteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Positive blood cultures for IE",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_single\">",
"        Typical microorganism for infective endocarditis from two separate blood cultures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Viridans streptococci",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Streptococcus gallolyticus (formerly S. bovis), including nutritional variant strains (Granulicatella spp and Abiotrophia defectiva)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        HACEK group - Haemophilus spp, Aggregatibacter (formerly Actinobacillus actinomycete comitants), Cardiobacterium hominis, Eikenella spp, and Kingella kingae.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Staphylococcus aureus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Community-acquired enterococci, in the absence of a primary focus;",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_single\">",
"        Persistently positive blood culture, defined as recovery of a microorganism consistent with IE from:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Blood cultures drawn more than 12 hours apart",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        All of three or a majority of four or more separate blood cultures, with first and last drawn at least one hour apart",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_single\">",
"        Single positive blood culture for Coxiella burnetii or antiphase I IgG antibody titer &gt;1:800*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Evidence of endocardial involvement",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_single\">",
"        Positive echocardiogram for IE",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        TEE recommended in patients with prosthetic valves, rated at least \"possible IE\" by clinical criteria, or complicated IE [paravalvular abscess]; TTE as first test in other patients*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3_start\">",
"        Definition of positive echocardiogram",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Oscillating intracardiac mass, on valve or supporting structures, or in the path of regurgitant jets, or on implanted material, in the absence of an alternative anatomic explanation",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Abscess",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        New partial dehiscence of prosthetic valve",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_single\">",
"        New valvular regurgitation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Increase in or change in preexisting murmur not sufficient",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Minor criteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Predisposition - predisposing heart condition or intravenous drug use",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fever - 38.0&deg;C (100.4&deg;F)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vascular phenomena - major arterial emboli, septic pulmonary infarcts, mycotic aneurysm, intracranial hemorrhage, conjunctival hemorrhages, Janeway lesions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Immunologic phenomena - glomerulonephritis, Osler's nodes, Roth spots, rheumatoid factor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Microbiologic evidence - positive blood culture but not meeting major criterion as noted previously (excluding single positive cultures for coagulase-negative straphylococci and organisms that do not cause endocarditis)",
"        <strong>",
"         OR",
"        </strong>",
"        serologic evidence of active infection with organism consistent with IE",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Echocardiographic minor criteria eliminated*",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Modifications from the previous published Duke criteria are noted by the asterisk.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Li JS, Sexton DJ, Mick N, et al. Clin Infect Dis 2000; 30:633. Copyright &copy; 2000 University of Chicago Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_47_43773=[""].join("\n");
var outline_f42_47_43773=null;
var title_f42_47_43774="Diagnosis of protein losing enteropathy";
var content_f42_47_43774=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F59916&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F59916&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 624px\">",
"   <div class=\"ttl\">",
"    Presentation and evaluation of protein-losing gastroenteropathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 604px; height: 385px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_47_43774=[""].join("\n");
var outline_f42_47_43774=null;
var title_f42_47_43775="Bullous pemphigoid DIF";
var content_f42_47_43775=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F53466&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F53466&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Direct immunofluorescence of bullous pemphigoid",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 380px; height: 396px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Direct immunofluorescence discloses linear deposits of IgG and C3 along the dermoepidermal junction. Ultrastructurally, these antibodies and complement are present in the lamina lucida.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Rubin, E, Farber, JL. Pathology, 3rd ed, Lippincott Williams &amp; Wilkins, Philadelphia 1999. Copyright &copy;1999 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_47_43775=[""].join("\n");
var outline_f42_47_43775=null;
